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A man’s reach should extend his grasp,  
or what’s a heaven for? 
 
Robert Browning, 1855
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General introduction 
 
The blueprint for human postnatal growth is defined by the genetic background of an 
individual, but is fine-tuned by hormonal, environmental, psychosocial and nutritional factors. 
As the result of a process called endochondral ossification taking place in the epiphyseal growth 
plates, long bones elongate and the size of the skeleton increases. Successive phases of growth 
can be distinguished, each characterized by specific hormonal regulation [1). In the intrauterine 
phase and neonatal period, up to the age of approximately 3 year, a high but rapidly declining 
growth velocity is observed. It is assumed that prenatal growth is mainly regulated by insulin-
like growth factors (IGFs), insulin and nutrition. From the second semester onward growth 
hormone secretion plays an important role, and in the first 2-3 years the correlation between 
the child’s length and parental height gradually increases, suggesting a growing influence of 
genetic factors.  
From the age of 3 years to puberty, growth continues at a lower and gradually diminishing rate, 
predominantly under the influence of thyroxin and growth hormone (GH). During pubertal 
development, sex steroid secretion and concomitant upregulation of GH-IGF-I signaling causes 
an increased growth rate, also known as the pubertal growth spurt. In both genders, estrogen-
induced maturation and closure of the epiphyseal growth plates at the end of pubertal 
development is associated with a rapidly declining growth rate and the termination of growth, 
inevitably determining adult height (2). In contrast, it has also been suggested that growth 
deceleration precedes epiphyseal fusion (3). 
Although many scientific research projects have been dedicated to unraveling the regulatory 
pathways underlying growth, there are still many remaining questions. Also, the 
pathophysiological mechanisms underlying the majority of growth disorders are still to be 
elucidated and more effective modes of treatment need to be developed.  
As this thesis touches upon several aspects of growth regulation and modulation, this first 
introductory chapter is subdivided in three parts. Part A reviews the background of idiopathic 
short stature (ISS) and growth hormone (GH) treatment. Part B recapitulates evidence from 
animal studies regarding alternatives for GH treatment. Part C addresses the need for 
development of an appropriate model system for studying growth regulation in humans. 
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A. Idiopathic short stature (ISS) 
 
Definition and subcategories  
 
Short stature is one of the most common reasons for referral of a child and his parents to a 
pediatric endocrinologist for diagnostic evaluation and advice. A large variety of congenital or 
acquired conditions that can be classified as primary, secondary or idiopathic growth disorders 
can cause shortness (4). A primary growth disorder, such as achondroplasia, is due to an 
intrinsic defect in the growth plates of long bones. Secondary growth disorders result from 
conditions that negatively affect growth plate physiology (e.g. endocrine disorders, chronic 
illness, malnutrition). In industrialized countries, celiac disease, Turner syndrome and growth 
hormone deficiency (GHD) are the main causes for short stature. In the majority of cases of 
short stature, however, an elaborate assessment of the child’s medical history, physical 
examination, laboratory tests, and radiological examinations does not reveal any clue for an 
underlying pathological mechanism, leaving the patient with the diagnosis ISS, short stature of 
unknown origin (5).  
ISS is a condition defined by an individual’s height more than 2 standard deviation (SD) below 
the corresponding mean height for a given age, sex, and population group (thus a height 
standard deviation score (SDS) of <-2) without evidence of systemic, endocrine, nutritional, or 
chromosomal abnormalities (4;6-9). Children with ISS have a normal birth size and body 
proportions, are not growth hormone deficient and have no psychiatric disorder associated with 
poor growth. By definition, ISS is a diagnosis of exclusion, as it does not rely on the 
identification of certain features characteristic for ISS, but rather on excluding all currently 
known other causes of short stature. Since approximately 80% of the short children referred to 
a pediatric endocrinologist meets the criteria for ISS (10), the clinical relevance of this entity is 
evident. 
The label ISS presumably unifies a variety of different causes of short stature that are unknown 
at present. Subdivision of this group in broad categories may therefore seem arbitrary, but is 
considered useful from a diagnostic and prognostic point of view (11). The most important 
distinction is between familial and non-familial short stature (FSS and NFSS, respectively), based 
on how the child’s growth pattern relates to his target height. The conditional target height 
(cTH) for short children, that takes into account the effect of assortative mating and parent-
offspring correlations, can be calculated according to the formula of Hermanussen and Cole 
(12): 0.72 × average of parental height SDS. The lower limit of the target height range is 
defined as cTH minus 1.6 SD.  
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A child with FSS grows within the target height range of the family, but is short in comparison 
with the appropriate reference population. In contrast, NFSS is characterized by short stature for 
the normal population as well as for the genetically defined familial growth potential. The 
diagnostic work-up in children with FSS may be limited, since the chance of finding a 
pathological mechanism underlying short stature is small in those cases, given that no 
pathological causes for parental short stature are present. However, the probability of a 
dominant genetic disorder (e.g. hypochondroplasia) is higher in case of one short parent (height 
SDS <-2.0 SDS) and a more elaborate diagnostic evaluation is then warranted. 
A second subdivision can be made according to the tempo of maturation of the child. Girls 
reaching breast development stage 2 later than the age of 13 years and boys with a testicular 
volume smaller than 4 ml at the age of 14 years are considered to have delayed puberty in the 
Netherlands and in many other industrialized countries (11). Information on pubertal onset is 
usually not available at the moment of diagnostic evaluation, as most short children referred to 
a pediatric endocrinologist are prepubertal. Therefore, it is impossible to ascertain pubertal 
delay before the age of 13 years in girls and 14 years in boys. The determination of skeletal age 
may render additional information, as pubertal delay is more likely in the presence of delayed 
bone maturation (bone age minus chronological age < 0 years). However, in some children with 
delayed skeletal age puberty is not delayed, and vice versa. 
Whereas the demarcation line between FSS and NFSS is sharply, though arbitrarily defined 
before puberty, the presence of normal and delayed puberty can only be definitively established 
in retrospect after the onset of puberty. Still, it is valuable to consider the possibility of delayed 
maturation from a prognostic perspective. In a child with NFSS and a positive family history of 
late puberty, the likelihood of delayed pubertal maturation is high and the pediatrician may 
choose to limit the number of diagnostic tests and follow an expectative line of treatment and 
advice. In case of normal pubertal timing and development in the parents, a pathological 
process underlying the clinical presentation of the child is suspected and additional 
investigations should aim at finding this mechanism. 
 
Impact on psychosocial functioning 
 
Children with short stature may experience psychosocial stress attributed to shortness such as 
social immaturity, infantilization, low self-esteem, being bullied or not accepted by their peers, 
and an overprotective parenting style that may hamper development of autonomy (13;14). In 
most clinic-based studies parents indeed report increased psychosocial stress in their short 
children (15-19), whereas peers and teachers do not mention a relevant decrease in social 
competence (15;18). Unfortunately, the experience of the children themselves is usually not 
 General introduction 
 
13 
 
investigated (14). The impression from population-based studies is that children and 
adolescents with ISS may experience varying degrees of stature-related stress, but generally are 
functioning within the normal range (20). 
Studies on psychosocial well-being of short individuals in adulthood are inconclusive, some 
reporting a lower chance of getting married, a higher percentage of unemployment and more 
self-reported problems in social functioning (21-24), whereas others find no difference between 
short and normal-sized adults (25;26). In the absence of conclusive evidence that ISS has a 
persistent negative impact on psychosocial functioning, it is important that the potential 
psychological burden for each patient referred for ISS is individually assessed (13).  
 
Indications for growth-promoting treatment 
 
Once the presence of ISS has been established, various treatment options may be considered 
(13;27). The decision whether or not treatment is indicated in an individual patient is based on 
a careful evaluation of auxological, psychosocial, ethical and financial arguments (13;27). 
Biochemical parameters have not been recognized to justify initiation of pharmacological 
interventions. Ideally, treatment results in alleviation of psychosocial stress, attainment of a 
normal adult height and preferably also a normal height during childhood. It should be stressed 
that a taller stature per se will not necessarily result in an improved quality of life or 
psychosocial functioning (14). For a short child that is not concerned about or hampered by his 
height in any way, treatment is usually not recommended. On the other hand, when a child 
evidently suffers from stress attributed to shortness, treatment can be considered. The patient 
and parents should be provided with a realistic perspective of the results that can be expected 
regarding height gain, the variability of clinical outcome, the risks, benefits, costs and possible 
treatment alternatives. 
 
Growth hormone treatment 
 
Many clinical trials with GH treatment for ISS have been performed since recombinant GH 
became available in 1985. GH on average increases AH of the majority of ISS children with 3-7 
cm after 4-7 years of treatment, compared with historical, placebo-treated or non-treated 
controls or with predicted adult height before the onset of treatment (27). The effectiveness of 
GH treatment has been attributed to the notion that most children with ISS have a certain 
degree of GH insensitivity that cannot be counteracted by endogenous GH secretion, but can 
be overcome by GH replacement. 
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The applied dosage is an important determinant for the response to treatment. It has been 
demonstrated that higher GH dosages result in a more pronounced acceleration of growth 
velocity and a taller adult height than lower dosages (28;29). The currently known most 
effective treatment regimen is 1.4 mg/m2/day (equivalent to 50 µg/kg/day) subcutaneously. This 
is approximately twice as high as the substitution dose, as assessed by studies on spontaneous 
secretion (30), but only slightly higher than the regular GH ’replacement’ dosage prescribed in 
GHD in the United States. The long-term outcome of such a regimen has been reported by 
several authors (reviewed in (27)). The data on the effects of even higher dosages are 
contradictory. In one study, a dosage of 2 mg/m2/day (equivalent to 75 µg/kg/day) appeared to 
accelerate bone maturation and advance pubertal onset (31;32), whereas no such effects were 
observed in other studies that applied up to 2.8 mg/m2/day (equivalent to 100 µg/kg/day) 
(33;34), nor in a recent Swedish study that used a dosage of 1.9 mg/m2/day (equivalent to 67 
µg/kg/day) (35). In the latter three studies the average age at onset of therapy was close to 11 
years, while average age in the first study was 8.7 years. Premature advancement of maturation 
may limit the effectiveness of GH treatment, as the timeframe reserved for growing is limited 
once puberty has commenced.  
Even if corrected for the dosage effect, there is still a large interindividual variation in growth 
response. It is therefore estimated that there are many other predictive factors, the majority of 
which still unknown. Factors with a positive influence on growth response are a younger age, 
larger bone age delay, initial height and midparental height, a higher body weight and a 
relatively large difference between initial height and cTH at start of treatment. Also, a better 
response to treatment in the first year is associated with adult height outcome (27). The 
explained variance of these variables is still rather low (40-60%) (36). 
Several parameters can be used for the evaluation of the success of treatment. For assessing the 
first year’s growth response, the change in height SDS, height velocity, height velocity SDS and 
the change in height velocity may all be useful, provided that these parameters are corrected 
for the age, pubertal stage, and degree of growth retardation of the individual patient (27). 
Whether or not treatment was successful in the long term can be objectified with the 
auxological parameters adult height SDS, adult height SDS minus height SDS at start of GH 
treatment, adult height SDS minus predicted adult height SDS, and adult height minus 
conditional target height (27).  
The absence of a circumscript defect in the GH-IGF-I axis in most children with ISS, the large 
inter-individual variation in response to GH-treatment and the high cost of GH have prompted 
the search for alternatives for GH treatment. An additional reason to do so is that GH treatment 
is not registered for ISS in the Netherlands and other European countries. 
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Gonadotropin releasing hormone agonists (GnRHa) 
 
At pubertal onset, a steep increase in the level of circulating estrogen results in acceleration of 
bone maturation, which preludes epiphyseal fusion and determines a person’s adult height. The 
development of pharmaceutical compounds that can delay or inhibit pubertal development has 
received increasing interest. Postponing pubertal development would hypothetically result in 
prolongation of the timeframe reserved for growth, leading to an increased adult height gain. 
In children with central precocious puberty (CPP), suppression of gonadal sex steroid synthesis 
effectively halts pubertal development and augments adult height (37;38).  
The beneficial effects of GnRHa treatment on height gain in CPP has prompted attempts to 
apply this treatment strategy in children with short stature without precocious puberty as well. 
In general, GnRHa monotherapy in children with ISS results in a marginal increase in adult 
height of 0-4 cm (39-41). The efficacy of GnRHa depends on the duration of treatment. Short 
term GnRHa (2 years) does not improve adult height, due to a balance between decreased 
growth velocity and arrested bone maturation, whereas in long term treatment (3-4 years) the 
decreased but continuous growth in the absence of bone age progression augments adult 
height with approximately 1 cm per treatment year (42). 
The possibility of adding GH to GnRHa can be considered, as the decreased growth velocity 
observed during GnRHa treatment may limit height gain (43;44). In such a scenario, GnRHa 
ideally extends the period available for growth while GH simultaneously preserves growth 
velocity, ultimately leading to a taller adult stature. Combined GH+GnRHa treatment was 
shown to augment adult height by approximately 4-5 cm in two controlled clinical trials (45;46), 
but analysis of large databases of GH-treated children that were also treated with GnRHa has 
revealed no effect (47-49). Combined GH+GnRHa treatment may be considered in children 
with ISS and a pronounced growth retardation at pubertal onset (27). In the absence of 
information on the possible adverse effect of sex steroid deprivation on bone mineralization and 
of postponing puberty on psychosocial well-being, GnRHa treatment, whether or not combined 
with GH, should not be considered routine treatment for children with ISS (27).  
 
Aromatase inhibitors 
 
Bone age advancement and epiphyseal fusion are caused by the surge in estrogen secretion 
during puberty (50) as illustrated by unfused epiphyseal plates, ongoing growth into adulthood 
and extremely tall stature observed in patients with disruptive mutations in the aromatase gene 
(51-55) or estrogen receptor gene (56). Therefore, it has been postulated that blocking 
endogenous estrogen synthesis may result in delayed bone maturation, prolongation of the 
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timeframe reserved for growth and increased adult height (57). Aromatase inhibitors reversibly 
or irreversibly prevent the conversion of androstenedione and testosterone into estrone and 
estradiol, respectively. 
Several studies have been conducted in order to establish whether aromatase inhibitors can be 
used as an alternative for GH treatment in children with short stature by various causes. Some 
studies resulted in no beneficial effects of aromatase inhibitor treatment (58-60), but most 
reported an increased predicted adult height (61-66). Due to differences in trial design, such as 
the presence or absence of a control group, inclusion of various types of short stature (GH 
deficiency, McCune-Albright syndrome, precocious puberty), employment of different classes of 
aromatase inhibitors or co-treatment with other compounds (GH or testosterone), it is difficult 
to draw conclusions on the efficacy of aromatase inhibitors. Moreover, only two trials were 
randomized controlled clinical trials (61;66). Adult height data of most of these studies have not 
yet been reported. In boys with short stature due to constitutional delay of growth and puberty, 
letrozole treatment was shown to increase near-adult height, without apparent detrimental 
effects on bone mineralization (67). However, it was recently reported that aromatase inhibition 
may predispose to vertebral disc deformities (68). 
Estrogen receptors and aromatase activity are ubiquitously present throughout the body, 
illustrating that estrogen signaling is crucial and inhibition of estrogen biosynthesis may result in 
adverse effects in various tissues or organs. The clinical phenotype of estrogen-deficient men 
gives several clues to potential unwanted effects of pharmaceutically induced estrogen 
deficiency. Obesity, insulin resistance, steatohepatosis, and severely decreased bone mineral 
density have been described in these patients (52;54;55;69). In ISS boys anastrozole or letrozole 
treatment did not impair skeletal mineralization (59;61;70), but the bone turnover rate was 
diminished due to treatment (61). Furthermore, a high number of vertebral body deformities 
was described after letrozole treatment raising the concern that aromatase inhibition may 
impair vertebral body strength (68;71). A reduced HDL-cholesterol in the absence of other 
effects on the lipid profile (61;72), and decreased insulin sensitivity have also been described 
(72). Theoretically, estrogen deprivation might result in disturbances of cognitive function and 
fertility, but this has not been documented in human studies so far. A careful exploration of the 
potential side effects of aromatase inhibition is required before such treatment can be applied 
in clinical practice (73). 
Aromatase inhibition has been tested for the treatment of precocious puberty in girls with 
McCune-Albright syndrome (58;60), but not for growth enhancement in girls with ISS. Potential 
adverse effects such as virilization due to hyperandrogenism and the development of ovarian 
cysts warrant a cautious approach.  
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B. Manipulation of growth in animal models 
 
Rodent models  
 
Animal studies have provided valuable insights into the process of postnatal growth regulation 
and modulation. Although growth can be studied in a variety of animals (e.g. goat, rabbit, pig), 
most information has come forward from studies involving rodent models and this segment will 
therefore focus on results from studies in the mouse and rat.  
 
GH-IGF-I signaling and growth 
 
The crucial role of GH and IGF-I signaling in the regulation of postnatal growth has been 
established by studies in various rodent models such as spontaneously mutated mouse models 
characterized by dwarfism, knockout mice for several constituents of the GH-IGF-I axis, mice 
transgenically modified to overexpress components of the GH-IGF-I family, and 
hypophysectomized rats with combined pituitary hormone deficiency. 
 
Dwarf mouse models 
 
Spontaneous mutations in the pituitary-specific transcription factors Pit 1 or Prop-1 result in 
underdevelopment of subsets of pituitary cells and render the mice deficient for GH, thyroid-
stimulating hormone and prolactin (74). This combined pituitary hormone deficiency translates 
into a growth phenotype characterized by normal body size and weight at birth, but severe 
growth retardation afterwards (Snell dwarf, Ames dwarf). Similarly, the GH deficient Little 
mouse (mutation in the GH releasing hormone receptor) shows a progressively impaired growth 
pattern from the age of two weeks onward. The phenotype of the Little mouse was shown to 
be rescued by injection with a recombinant adenovirus containing rat GH and a human 
promoter sequence. This form of gene therapy resulted in elevated levels of GH and IGF-I, and a 
normalization of body weight and body length as compared with wild-type mice (75), 
highlighting the important role of GH signaling in postnatal growth. 
 
Transgenic and knockout mice 
 
Additional insights into growth regulation by the GH-IGF-I axis have been gathered from studies 
in transgenic and knockout mice (76). GH insensitivity due to knockout of the GH 
receptor/binding protein gene (GHR; Laron mouse) or caused by transgenic overexpression of 
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an antagonizing GH analog results in decreased IGF-I levels and dwarfism (77-79). In contrast, 
gigantism is observed in transgenic mice that overexpress GH or hypothalamic GH releasing 
hormone (GHRH) (80;81). 
IGF-I knockout mice have demonstrated that postnatal growth is mainly determined by GH-
dependent IGF-I, whereas both hormones also act independently. This was shown by 
observations of compromised intrauterine and postnatal growth in IGF-I knockouts, but an even 
more pronounced postnatal growth retardation in IGF-I and GHR double knockouts (82). Partial 
reduction in IGF-I signaling in heterozygous IGF-I receptor knockout mice leads to an apparently 
normal phenotype, although there are also clues that a reduced growth potential may be 
present (82;83). Formation of a ternary complex with IGF binding protein 3 (IGFBP-3) and acid-
labile subunit (ALS) normally increases the half-life of IGF-I in the systemic circulation. 
Overexpression of IGFBP-3 results in pre- and postnatal growth retardation, whereas ALS 
overexpression results in a moderate delay of postnatal growth. When both ALS and IGFBP-3 
are overexpressed, growth inhibition is more pronounced (84). On the other side of the 
spectrum, transgenic mice overexpressing IGF-I show somatic overgrowth (85). 
The findings in GH and IGF-I knockout mice are confirmed by observations in 
hypophysectomized rats that serve as a model for GHD. A markedly retarded somatic growth is 
seen in these animals compared with wild-type littermates. Both GH and IGF infusion in these 
rats results in stimulation of longitudinal growth. However, the effect of GH is more 
pronounced than that of IGF-I (86). 
 
Representativeness of models for the influence of GH-IGF-I on growth 
 
In the human, disorders or gene mutations leading to GH or IGF-I deficiency or resistance all 
result in various degrees of shortness, generally similar to the phenotypes observed in rodent 
counterparts (87). Patients with primary IGF-I deficiency or GH deficiency show a strikingly 
similar degree of growth retardation (87). Suppletion of GH or IGF-I in these patients results in 
stimulation of growth, but with GH treatment having a superior effect (88). In summary, both 
an effect of GH-dependent IGF-I and a separate, direct effect of GH have been demonstrated to 
be essential for coordinated postnatal growth in humans, which is in agreement with collective 
conclusions drawn from rodent animal models. Therefore, it can be concluded that rodent 
animal models are suitable for studying the effects of deregulation of the GH-IGF-I axis and 
treatment strategies designed for counteracting its effects on postnatal growth. 
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Sex steroid signaling and growth  
 
In the following paragraphs the results of experiments on steroid signaling and growth will be 
reviewed. After the growth hormone (GH)-IGF-I axis, sex steroid signaling is the second major 
determinant of postnatal growth, especially during pubertal development. Many rodent models 
have been developed and applied to assess the influence of sex steroids on the regulation of 
growth, amongst which knockout mice for the estrogen receptor α and β, androgen receptor, 
and aromatase genes, and the ovariectomized or orchidectomized mouse and rat.  
 
Estrogen receptor knockout mice 
 
The actions of estrogen in the human and rodent are mediated by two receptors, the estrogen 
receptors alpha and beta (ERα and ERβ). Three knockout mouse models have been generated, 
the partially estrogen-resistant αERKO and βERKO mice (89), and the completely estrogen-
resistant double knockout (α/βERKO) mouse (90). The effects of ER inactivation depend on sex 
and age of the mice (91).  
In female mice, axial growth is unaffected in αERKO, βERKO and α/βERKO at all stages of life 
(92), although during the postpubertal phase a tendency towards slightly increased growth is 
observed in βERKO (92). During the period of sexual maturation and in adulthood, appendicular 
growth is decreased in αERKO, but increased in βERKO mice, with a more pronounced effect in 
adulthood. The phenotype of α/βERKO mice is intermediate between those of αERKO and 
βERKO in all stadia (92). A direct correlation between appendicular length and IGF-I levels has 
been noted, with high levels stimulating growth (93). Decreased growth of the axial bones is 
accompanied by a smaller width of the growth plate (94). Knockout of ERβ does not affect 
body weight gain, whereas obliteration of ERα or both receptors results in increased body 
weight (92). In adult αERKO and βERKO mice, a higher BMD is reported than in wild-type 
littermates, with a more prominent effect in αERKO mice. BMD in double knockouts is 
comparable to wild-type BMD (92;93). Apart from the growth effects, αERKO and α/βERKO 
mice also show a distinct ovarian phenotype characterized by enlarged, hemorrhagic and cystic 
follicles and are anovulatory (89). 
Male αERKO and double knockout mice display decreased growth of the axial and appendicular 
skeleton, narrow epiphyseal growth plates, low IGF-I levels, less body weight, and a decreased 
bone mineral density (BMD) compared to wild-type littermates (92-94). Ablation of ERβ has no 
effect on growth parameters in male mice. Male αERKO mice show testicular atrophy, reduced 
sperm count and viability, altered sexual behavior and decreased fertility (89). 
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In conclusion, the influence of estrogen signaling on growth in the mouse shows a prominent 
sexual dimorphism. Signaling through ERα stimulates axial growth in male rats, whereas it has 
no effect in females. Appendicular growth is repressed via αERKO in both genders. ERβ does 
not exert an effect on longitudinal growth in both genders, nor on radial growth in males, but 
it does result in growth retardation in females. As it was demonstrated that estrogen levels are 
markedly raised in female αERKO and α/βERKO, but normal in males, it has been speculated 
that hyperestrogenism may inhibit appendicular growth via ERβ signaling. 
 
Aromatase knockout mice 
 
As an alternative model for assessing the role of estrogen signaling on longitudinal growth, 
estrogen-deficient mice can be considered. Targeted disruption of the aromatase gene has 
resulted in the development of such a model, the ArKO mouse (95). Aromatase synthesizes 
estrogen from androgenic precursors. Male and female ArKO mice appear phenotypically 
normal at birth. Appendicular growth is significantly retarded in adulthood in male, but not in 
female ArKO mice (96). Effects on axial growth have not been reported, and it might therefore 
be concluded that such effects are either absent or marginal at most. Both genders display 
osteoporosis (97). Female ArKO mice have underdeveloped uteri and ovaries, and are sterile 
due to anovulation (95;98). Male mice are fertile, but to a lesser extent than wild-type 
littermates (97). Increased abdominal fat deposition and insulin resistance is present in both 
males and females (99) and it has been postulated that a disturbed androgen to estrogen ratio 
may promote visceral fat accumulation (99). 
The differences between the phenotypes of ERKO and ArKO mice may rely on the fact that 
partial estrogen signaling is still possible in ERKO mice, whereas the influence of estrogen is 
completely abolished in the ArKO model. Additionally, the androgen to estrogen ratio is 
presumably more disturbed in ArKO than in ERKO mice, which may account for phenotypic 
variations due to elevated androgenic signaling. 
 
Androgen receptor knockout mice 
 
Besides the established role of estrogen in the regulation of growth, there is also compelling 
evidence that androgens have a unique function. Part of the effect of androgen on the growth 
plate is probably due to aromatization into estrogens, which is suggested by the presence of 
aromatase in rat and human growth plate cartilage (100;101). However, the androgen receptor 
(AR) has been detected in rat (102) and human growth plate cartilage as well (103;104), 
 General introduction 
 
21 
 
suggesting that direct actions of androgen in growth regulation also occur. The observations 
that androgens accelerate growth in mice, and that a nonspecific ER blocking compound does 
not attenuate this effect are in support of a direct androgenic effect (105). 
The androgen-resistant knockout mouse was generated to study the influence of androgens on 
bone and metabolism. A normal growth phenotype was observed in these mice. Male ARKO 
mice had female secondary sexual characteristics, late onset obesity and a marked loss of BMD 
(106;107). The absence of an impact on growth in ARKO mice suggests that androgen 
signaling is not crucial for the regulation of longitudinal growth. The observed growth-
stimulating effect mentioned before may require supraphysiological levels of androgens. 
 
Gonadectomy and estrogen treatment 
 
Sex steroid deprivation can be effectively induced by gonadectomy. The gonads are the 
exclusive source of synthesis of androgen and estrogen precursors in rodents, therefore 
gonadectomy results in complete ablation of sex steroids (108). Ovariectomy (OVX) in rats 
removes the growth-inhibiting influence of estrogens resulting in augmented longitudinal 
growth and decreased bone quality (109;110). Administration of estrogen to OVX rats 
counteracts the growth stimulation induced by estrogen deficiency (111). Treatment of OVX 
rats with non-aromatizable androgens stimulates longitudinal growth, which demonstrates a 
direct influence of androgen signaling on growth as well (112). In contrast, the growth pattern 
of OVX mice is marginally or not altered (113), illustrating different roles for sex steroid 
signaling in growth regulation in rats and mice.  
Orchidectomy (ORCHX) in male rats results in decreased longitudinal growth, impaired body 
weight gain and osteoporosis (109). The contrasting effects of sex steroid depletion in male and 
female rats points at the existence of gender-specific patterns of growth regulation. 
 
Pharmacological suppression of sex steroid biosynthesis or action 
 
Instead of gonadectomy, gonadal sex steroid synthesis can also be obliterated by chemical 
castration with GnRHa. Triptorelin treatment in female prepubertal rats results in enhancement 
of body weight and length gain, comparable to the observations in the OVX phenotype. In 
male rats, GnRHa treatment stimulates body weight gain and also slightly improves length gain, 
which is in contrast with the observed growth retardation after ORCHX (114). It was speculated 
that GnRHa in rats may interfere with the hormonal regulation of food intake and weight 
control instead of having an effect on growth regulation (114). 
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Selective suppression of estrogen signaling can be established by treatment with an aromatase 
inhibitor. Several studies have analyzed the effects of such treatment on bone health and 
growth in male rats, but not in females. Young male rats treated with the aromatase inhibitor 
vorozole display decreased body weight and BMD, but normal femoral length (115). The 
selective estrogen receptor modulator (SERM) tamoxifen reduces body weight gain, axial and 
radial growth, and BMD in young male rats (62). These observations are in agreement with the 
phenotype of castrated male rats, albeit less prominently. In contrast, treatment with the 
aromatase inhibitor vorozole in male mice was shown to result in augmented body weight and 
tail length gain, an increased width of the epiphyseal growth plates and elevated GH levels 
(116). These results in mice are in contrast with the decreased growth patterns that characterize 
male estrogen receptor or aromatase knockouts that show normal to decreased growth. 
 
Representativeness of models for the influence of sex steroids on growth 
 
Estrogen has been identified as the main regulator of growth during the pubertal phase. Low 
levels of estrogen initiate the growth spurt at the beginning of puberty, whereas high levels at 
the end of this period arrest growth and result in epiphyseal fusion both in males and females 
(2). The growth-inhibiting actions of estrogen have been illustrated by the clinical presentation 
of male and female patients with estrogen deficiency due to inactivating mutations of the 
aromatase gene (52;54;55) and in the estrogen-resistant man with a mutation in the ERα gene 
(56). These patients all share a common phenotype with absence of a pubertal growth spurt, 
ongoing growth into adulthood, unfused epiphyses and a tall stature.  
An in vivo model for studies on the effect of sex steroid signaling on growth would ideally 
recapitulate the hallmarks of human growth regulation. Rodents do not display the typical 
estrogen-driven signs of maturation as observed in humans. However, even though epiphyseal 
fusion never occurs in rodents, growth velocity approximates zero at the end of sexual 
maturation. Female OVX rats show stimulated axial and appendicular growth, and estrogen 
administration to intact male and female rats inhibits longitudinal and radial growth (110), 
pointing at an important role of estrogen signaling in growth regulation in the rat similar as in 
humans.  
ERα, ERαβ, and aromatase gene knock-out as well as gonadectomized mice show either 
retarded or unaffected growth patterns compared with wild-type littermates. The contrast with 
the observed stimulation of growth in estrogen-devoid human patients implies that growth 
regulation in mice is markedly different than in humans, and argues against the use of mice 
models for studying human growth regulation by sex steroids.  
 General introduction 
 
23 
 
C. In vitro models for the analysis of growth regulation 
 
The epiphyseal growth plate, localized at the distal ends of long bones, is a complex structure 
that is crucial for skeletal growth (1;117). At this level, endochondral ossification takes place, 
during which cartilage is first formed and subsequently replaced by osseous tissue, resulting in 
bone elongation. The growth plate is a polarized, multilayered structure, that consists of 
chondrocytes at various stages of differentiation: the resting zone, with relatively quiescent, 
stem-cell like chondrocytes, the proliferative zone and the hypertrophic zone. Upon unknown 
triggers, chondrocytes from the resting zone are recruited to undergo proliferation, 
hypertrophic differentiation and programmed cell death. As a net result of this differentiation 
program, a cartilaginous scaffold is synthesized, that is subsequently invaded by blood vessels 
and bone cell precursors and then replaced by bone. 
The highly complex process of endochondral ossification is regulated by the interplay between 
systemically circulating hormones and growth factors produced locally at the level of the 
epiphyseal growth plate. The exact mechanisms underlying the coordination of growth plate 
physiology remain to be elucidated in detail. Apart from in vivo models as described in part B, 
various animal-derived and human in vitro models have been developed and applied for 
studying growth regulation and physiology at the level of the growth plate. 
 
Whole bone tissue culture  
 
Explanted, cultured rodent bones such as the tibia or metatarsals can be easily manipulated by 
the addition of hormones, growth factors, cytokines, or pharmacological compounds to the 
culture medium. In most studies, the results of metatarsal culture are directly compared with 
those obtained in similarly designed experiments in cultured (human) chondrocytes. Valuable 
insights have emerged from this experimental approach. For example, it has been demonstrated 
that locally produced estrogen increases metatarsal growth by stimulating chondrocyte 
proliferation and inhibition of apoptosis (118). Inhibition of estrogen activity by the SERM 
tamoxifen results in growth inhibition (91). Modulation of the androgen receptor does not have 
an effect on growth (119). Metatarsal cultures have also made clear that glucocorticoids, pro-
inflammatory cytokines and parathyroid hormone related protein (PTHrP) inhibit bone growth, 
possibly by interfering with the phosphoinositide-3-kinase (PI3K) pathway (120-124).  
While there are clear advantages of this model, such as the easy accessibility of the explanted 
whole bone tissue culture, there are also disadvantages. When aiming at the analysis of 
chondrocyte differentiation, it has to be taken into account that other tissues such as bone and 
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hematopoietic tissue are also present in this culture system which may influence the behavior of 
the chondrocytes as well. In addition, species differences may hamper the translation of 
experimental data obtained in rodents to the regulation of growth in humans. 
 
Growth plate studies 
 
Rats and mice do not display epiphyseal fusion after completion of the sexual maturation 
phase. In contrast, rabbit growth plates do undergo fusion at the end of sexual development 
and important knowledge on this phenomenon typically observed in humans has emerged from 
studies in rabbits. It is hypothesized that epiphyseal fusion is a consequence of senescent 
changes within the growth plate, a process that is accelerated by estrogen (125). Catch-up 
growth, that is often seen in children after removal of a growth-inhibiting condition, was also 
demonstrated in rabbits after termination of growth-inhibiting dexamethasone treatment and 
was found to be associated with delayed growth plate senescence (126).  
Theoretically, human growth plate specimens may also be used for analysis of growth plate 
architecture at different ages and phases of development, under the condition that a sufficient 
number of growth plates is available for such studies. However, normal human growth plate 
specimens are difficult to obtain, as they cannot be biopsied or removed from healthy children. 
Moreover, single growth plates have limited value in growth studies, as they only represent a 
specific growth stage corresponding with the donor’s age and gender. 
 
Chondrocyte culture 
 
Various animal-derived and human cellular model systems have been developed to study the 
biomechanics of chondrocyte differentiation. The focus of this paragraph will be on human 
culture models. Amongst the most often used models are the primary chondrocyte culture, 
clonal normal cell lines (e.g. HSC-2/8), and transformed clonal cell lines (e.g. C-28/12, T/C-28a2) 
(127). Although applied for many years, there are many disadvantages to these models. Primary 
chondrocyte cultures have a low proliferative capacity, that is directly correlated with the age of 
the donor. Due to ethical considerations, it is difficult to obtain sufficient chondrocytes. 
Moreover, primary chondrocytes often show a tendency to dedifferentiation.  
Clonal normal cell lines descend from one common ancestor and are non-transformed. Many 
cell-lines are derived from tumors, such as HSC-2/8 that was derived from an aggressive 
chondrosarcoma. The malignant origin of such cell lines may affect their biological 
characteristics. In addition, cell lines may display genomic instability or the frequent occasion of 
random mutations. 
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Transformed clonal cell lines are genetically modified resulting in immortalization of the cell line. 
These cell lines may display continuous proliferation in monolayer culture, but the loss of 
chondrocyte phenotypical characteristics has also been reported, as well as gradual loss of 
proliferative capacity.  
Many of these cell lines have been obtained from articular cartilage, which is not identical to 
growth plate cartilage, and it is therefore unlikely that such models are representative for 
processes taking place in the growth plate during endochondral ossification. Some cell lines 
originate from diseased cartilage, such as osteoarthritic or trauma-damaged cartilage, which 
has been reported to alter the characteristics of the chondrocytes (127).  
 
Stem cells 
 
Alternatively, much effort is currently put into development of a human model for 
chondrogenesis using human mesenchymal stem cells (hMSC). hMSC are multipotent cells that 
can differentiate into a variety of cell types, such as chondrocytes, adipocytes, myocytes, and 
osteocytes, when exposed to the proper stimuli. hMSCs driven towards chondrogenic 
differentiation would provide a model that might facilitate a detailed analysis of molecular and 
biochemical processes underlying growth as it occurs within the human growth plate. It would 
allow a detailed analysis of even the very first stages of chondrogenic development, when the 
stem cells are triggered to undergo chondrogenic differentiation. 
Some studies have addressed the potential use of hMSC-derived chondrocytes as a model for 
chondrogenic development and have characterized this model by means of large-scale 
expression profiling (128-130). Data emerging from these studies are promising, with respect to 
the aspect that cartilage is indeed formed after appropriate stimulation of hMSCs. However, 
before cartilage derived from hMSCs can be used as a model for studying chondrogenesis as it 
occurs in the human growth plate during endochondral ossification, it still remains to be 
determined whether hMSC-derived chondrocytes adopt a phenotype similar to growth plate or 
to articular cartilage. 
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D. Structure and scope of this thesis 
 
In this thesis, we aimed to answer three questions related to the regulation and manipulation of 
growth. After the introductory Chapter 1, the main body of the thesis is divided into three 
parts addressing these questions. 
The first question we aimed to resolve in part A of this thesis was: what are the long-term 
results of two novel treatment modalities of children with ISS? Here we report the results of 
two randomized controlled clinical trials in children with ISS. Chapter 2 describes adult height 
outcome after high dose GH treatment restricted to the prepubertal period. Chapter 3 presents 
the effects of combined GH and GnRHa treatment on growth in adolescents with a relatively 
early pubertal onset. 
In part B, we addressed the question: what is the effect of the administration of aromatase 
inhibitors in the rat? Aromatase inhibitor treatment has been suggested as a possible alternative 
to currently available growth-enhancing therapeutic regimens for children with ISS, but their 
efficacy and potential adverse effects have not been studied in a growing and developing 
model system. The answers to these questions would enable a better estimation of the 
potential efficacy and adverse effects of aromatase inhibition when considering to apply this 
type of medication to children. In Chapter 4 the effects are shown of 3 weeks treatment with 
the steroidal aromatase inhibitor exemestane on longitudinal growth parameters, bone quality 
and gonadal morphology in female prepubertal rats. Chapter 5 summarizes the results of 6 
weeks of exemestane treatment on growth and bone quality in male prepubertal rats. 
Part C provides an answer to the question: can mesenchymal stem cells differentiate into 
chondrocytes with a phenotype resembling the epiphyseal growth plate? Chapter 6 illustrates 
how human fetal mesenchymal stem cells can be stimulated to undergo chondrogenic 
differentiation and may serve in future studies as a model for investigating processes taking 
place in the epiphyseal plate during growth.  
Finally, Chapter 7 provides a general discussion on the various elements of this thesis and is 
followed by a summary in Chapter 8. 
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Abstract 
 
Objective: to assess the long-term effect of prepubertal high-dose growth hormone treatment 
on growth in children with idiopathic short stature (ISS). 
Design and methods: 40 children with no signs of puberty, age at start 4-8 years (girls) or 4-
10 (boys) years, height SDS<−2.0 SDS and birth length>-2.0 SDS, were randomly allocated to 
receive GH at a dose of 2 mg/m2/day (equivalent to 75 µg/kg/day at start and 64 µg/kg/day at 
stop) until the onset of puberty for at least 2 years (preceded by two 3-month periods of 
treatment with low or intermediate doses of GH separated by two washout periods of 3 
months) or no treatment. In 28 cases adult height (AH) was assessed at a mean (SD) age of 
20.4 (2.3) years. 
Results: GH-treated children (mean treatment period on high dose GH 2.3 yr (range 1.2-5.0 
yr)) showed an increased mean height SDS at discontinuation of treatment compared with 
controls (-1.3 (0.8) SDS versus -2.6 (0.8) SDS, respectively). However, bone maturation was 
significantly accelerated in the GH-group compared with controls (1.6 (0.4) versus 1.0 (0.2) yr, 
respectively) and pubertal onset tended to advance. After an untreated interval of 3-12 yr, AH 
was -2.1 (0.7) and -1.9 (0.6) in the GH-treated and control group, respectively. Age was a 
positive predictor of adult height gain. 
Conclusion: High dose GH treatment restricted to the prepubertal period in young ISS children 
augments height gain during treatment, but accelerates bone maturation, resulting in a similar 
adult height compared to untreated controls. 
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Introduction 
 
Growth hormone (GH) treatment in children with idiopathic short stature (ISS) has been the 
subject of many clinical trials. There are essentially four outcome parameters of GH treatment 
that can be considered: short term growth response (1st year’s height velocity), bone age 
advance, onset and progress of puberty, and increase in adult height (AH). As recently reviewed 
(1;2), almost all children with ISS respond to GH treatment with an increase in height velocity, 
even on a relatively low dose. The dose-response curve for the first year’s height velocity 
appears to reach a plateau after a dose of 50 µg /kg/d. No acceleration of bone age advance 
and pubertal onset and progress has been observed in the dose range of 30-53 µg /kg/d and 
the most effective dose regimen (50 µg /kg/d) leads to approximately 7 cm adult height gain 
(1;2).  
At the time this study was designed, there were three important issues with respect to GH 
treatment of children with ISS that awaited resolving. First, it was unknown what the effect 
would be of a further increase of the GH dosage on growth velocity, bone maturation, puberty 
and AH. Second, the relative contribution of GH treatment before and during puberty was 
unclear. Third, there was a need to gain more insight into the factors affecting the growth 
response, as only a modest part of the inter-individual variation can be explained (3). 
In order to address these issues, we started a controlled clinical trial in children with ISS in 1993. 
We hypothesized that a high GH dose before puberty might be able to bring height within the 
population’s range, as shown for a dose of 0.1 mg/kg/day (4), without undue bone maturation 
and advance in puberty, and without adverse effects. We limited the period of GH therapy to 
the years before pubertal onset, primarily to improve the cost-benefit ratio, but also based on 
studies showing that HSDS at the onset of puberty is a strong predictor of AH in GH deficient 
children (5;6) and that pubertal height gain on GH treatment was not different between GH 
treated children and untreated controls (7). In order to improve the predictive power of clinical 
and biochemical variables we included an elaborate assessment of GH sensitivity. 
In three previous papers on this study we reported that high dose GH limited to the prepubertal 
period increased growth, but also advanced bone age maturation and pubertal development, 
so that the predicted adult height (PAH) did not change (8), and that biochemical (9) and in 
vitro (10) indices of GH sensitivity had little predictive power for the short-term growth 
response. In the present paper we report the results on adult height. 
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Subjects and methods 
 
Patients 
 
This report includes AH data on 28 out of 40 children with ISS who originally enrolled in a 
multicenter study in The Netherlands from December 1993 to December 1996. Inclusion criteria 
were: no signs of puberty (G1 in boys and B1 in girls); height at baseline (HstartSDS) <-2.0 SDS for 
Dutch references available at that time (11), age at baseline 4-8 years for girls and 4-10 years 
for boys; birth length >-2.0 SDS (12); maximum serum GH level more than 10 µg/liter (1 mg = 2 
IU, using World Health Organization (WHO) International Reference Preparation 66/217 as 
standard) after provocation (exercise, arginine, clonidine, L-dopa or glucagon), and a normal 
sitting height/subischial leg length ratio (between P3 and P97) (13). Screening blood tests and 
urinalysis were normal. No organic causes of growth failure, primary bone disease, chronic 
illness, or dysmorphic syndrome were present. Further details of the subjects and data obtained 
after discontinuation of treatment have been reported previously (8;9). 
Three children of Turkish origin were included in the trial, 1 girl and 1 boy in the GH-group, and 
1 boy in the control group. HstartSDS was calculated using Dutch references (-2.50, -2.73, -3.23, 
respectively), and their height was also <-2 SDS for references for Turkish children that became 
available in 1997 (14). For further analyses, SDS values of these and all other children were 
calculated using references for Dutch children. 
The protocol was approved by the medical ethical review boards at the three participating 
centers (Amsterdam, Rotterdam, and Eindhoven). Before conducting any study-related 
procedure, written informed consent was obtained from parents and, when appropriate, also 
from the participants. For AH analysis, written informed consent was obtained from the 
participants. This clinical trial was registered in the metaRegister of Controlled Trials 
(ISRCTN52337368) of the Current Controlled Trials Ltd. 
 
Study design 
 
Forty patients were randomly allocated to receive GH treatment or no treatment (figure 1). 
Details have been reported previously (8). In short, in the GH treatment group GH 
responsiveness was assessed during the first year of the study by administering GH in an on/off 
scheme at a dose of 0.5 or 1.0 mg/m2/d (equivalent to 19 or 38 µg/kg/day, respectively) during 
two periods of 3 months, separated by two wash-out periods of 3 months without GH 
treatment (figure 2). In the second year, long-term GH treatment with 2.0 mg/m2/d (75 µg/kg/d) 
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was started and was intended to be given for at least two years. Treatment was discontinued at 
the first full year visit after the onset of puberty (G2 for boys and B2 for girls), which resulted in 
a treatment period of 2-5 years on high dose GH (mean 2.3 yr). At discontinuation of GH 
treatment, the dose was equivalent to 64 µg/kg/d. The GH dose per kg body weight was lower 
at discontinuation of treatment than at start of the high dose treatment phase due to the fact 
that body weight shows a larger increase with age than body surface. GH (Genotropin; 
Pharmacia & Upjohn, Uppsala, Sweden; now Pfizer, New York, USA) was administered 
subcutaneously, 7 days per week between 6.00 and 8.00 p.m. The measurements at 
discontinuation of treatment in the GH-group were compared with measurements after 
attaining Tanner stage 2 (B2 for girls, G2 for boys) in the control group. 
Directly after randomization, four patients (two from each group) refused to start the treatment 
they were randomly allocated to receive and dropped-out (fig 1). In addition, one boy from the 
GH treatment group was found to have neurofibromatosis and was excluded from the study.  
At adult height analysis, 6 patients from the control group could not be motivated to 
participate. One patient from the GH-group could not be traced and was lost to follow-up. One 
boy stopped using high dose GH after 1.2 years and could not be motivated to continue 
according to protocol. However, his growth data are included in this report. Pubertal onset and 
development were not registered for 1 girl from the control group and her last  
 
 
Figure 1 
Trial design. 
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Figure 2 
Time-scheme for GH-treatment and control groups. GH doses: 0.5 mg/m2/d = 19 µg/kg/d; 1.0 mg/m2/d = 
38 µg/kg/d; 2.0 mg/m2/d = 75 µg/kg/d. 
 
 
 
 
 
 
 
 
known auxological information at the age of 9.7 yr was used for the analysis at stop.  
At follow-up, we took a short medical history, performed a physical examination, assessed bone 
age (15) and measured height, weight, and sitting height (SH). Leg length (LL) was obtained by 
subtracting SH from height. Blood was collected for DNA extraction and single-nucleotide 
polymorphism genotyping (SNP-array) as described before (16) using the Affymetrix Genechip 
Human Mapping 250K array set. We also assessed the psychosocial status, which will be 
reported separately.  
 
Outcome parameters 
 
Four outcome parameters were used to evaluate the response to treatment: 1) Adult height 
SDS (AH SDS); 2) AH minus height at start SDS (AH–Hstart SDS); 3) AH minus height for bone age 
at start (AH–H for BAstart SDS); and 4) AH minus conditional target height SDS (AH–cTH SDS). 
Because of the young bone age of most patients at start of the intervention, the predicted adult 
height (PAH) according to Bayley and Pinneau (17) could not be calculated at start.  
To assess the degree of change of growth potential after discontinuation of treatment, we 
analyzed AH SDS minus predicted adult height at discontinuation of therapy (AH-PAHstop SDS). 
For both groups, pubertal development at Tanner stage 2 was expressed as SDS for age and 
gender according to a recent technique (18).  
Height and BMI SDS were based on recent Dutch references (19). For calculation of AH SDS, 
the age of each patient was set at 21 yr, enabling comparison of AH with the height 
distribution in the normal adult population. For 4 patients, a BA radiograph at discontinuation 
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of treatment was not available, but bone age was extrapolated from a BA determination closest 
to this time point (at visit x) using the formula: BAstop = (BAvisit x/CAvisit x) × agestop.  
A total of 24 out of 28 patients consented to undergo an X-ray of the left hand for automatic 
determination of the pediatric bone index (PBI), an index for the amount of cortical bone 
specifically developed for the pediatric population (20). PBI was expressed as SDS based on a 
Dutch reference cohort. For patients older than 19 yr, SDS values were calculated using 
references for 19-yr old adolescents. 
Parental height SDS was calculated and corrected for the secular trend (in the Netherlands 
estimated at 4.5 cm/30 yr) as follows: Heightfather SDS = [(AHfather + 4.5) – 184] / 7.1 and 
Heightmother SDS = [(AHmother + 4.5) – 170.6] / 6.5 (19). Conditional target height (cTH), which is 
the target height corrected for the effect of assortative mating and parent-offspring 
correlations, was calculated using the formula: cHT SDS = 0.72 × the average of father’s and 
mother’s height SDS (21). 
The SH, leg length (LL) and SH/H ratio were expressed in SDS based on Dutch references (22). 
For calculation of adult SH SDS, LL SDS, and SH/H SDS, the age of each patient was set at 21 yr.  
 
Statistical analysis 
 
The study was designed to compare the effects of high dose GH treatment with those of no 
treatment on AH. Statistical analyses were performed using the statistical package SPSS version 
14.0 (SPSS, Chicago, IL). Results are expressed as mean (SD). Comparisons among treatment 
and control groups were made using Student’s unpaired t tests. Possible interactions between 
the effect of GH treatment on the outcome parameters and the baseline parameters gender, 
age (agestart), height (Hstart SDS), and bone age delay were analyzed by means of linear regression 
analysis using ANOVA applied to the whole group of subjects. Possible associations between 
IGF-I SDS after 3 months or 1 year of treatment with 2.0 mg/m2 GH and the changes from IGF-I 
SDS at start of high dose GH were also tested by means of linear regression. The significance 
level was set at 0.05.  
 
Results 
 
A complete analysis was carried out for the remaining 28 of 40 originally included patients 
(70%). One female (bone age 13) and one male (bone age 15.5) from the control group had 
not reached AH, and their predicted AH (17) was used for further analysis. Patient 
characteristics at start, at stop, and at follow-up are listed in table 1. Age and BMI SDS at 
Chapter 2 
 
50 
 
baseline were higher in the GH-treated subjects compared to controls (in the original cohort of 
40 patients this was not significant). GH-treated children tended to have more bone age delay 
than controls. The mean GH treatment period was 3.3 yr (including the first year’s on/off 
scheme), resulting in a mean high dose GH treatment duration of 2.3 yr (range 2.0-5.0 yr, with 
the exception of 1 boy who stopped after 1.2 years). Children in the control group were seen 
for a period of 4.9 (1.9) years. AH data were collected at a mean age of 20.4 (2.3) years. The 
mean period elapsed between treatment discontinuation and AH analysis was 8.5 (1.7) yr 
(range 3.2-11.7 yr). 
 
Effect on growth, bone maturation and puberty 
 
At discontinuation of treatment, height SDS significantly increased in GH treated children 
compared to controls (table 1, figure 3), as reported previously (8). Bone maturation in the first 
two years of treatment was faster in GH treated children compared to controls, both in the 
original cohort (3.6 yr/2 yrs versus 2.0 yr/2 yrs) and in the cohort available for adult height 
evaluation (3.1 yr/2 yrs vs. 2.1 yr/2yrs). Over the full trial period bone maturation was also 
significantly advanced in GH-treated subjects compared with controls (1.6 (0.4) yr/yr versus 1.0 
(0.2) yr/yr, respectively, p<0.001). PBI SDS was not different between the GH- and control 
groups (table 1). Madelung deformities or other apparent anatomical anomalies were not 
detected on the hand X-rays. 
AH SDS, AH–Hstart SDS, AH–H for BAstart, and AH-cTH were not significantly different between the 
GH-treated and control group (table 1), and in both groups 50% of the participants attained an 
adult height >-2.0 SDS. The percentage of individuals with a height below the target range 
(cTH SDS – 1.6) decreased from 75% at start to 44% at follow up in the GH-group and from 
67% to 27% in controls. The loss of growth potential after discontinuation of therapy (AH–
PAHstop SDS) tended to be greater in the treated group compared with controls, but the 
difference did not reach statistical significance (p=0.1).  
BMI was significantly higher in the GH group compared with the control group at all stages of 
the trial. At follow up, BMI in GH-treated subjects was 1.0 SD higher than BMIstart, while there 
was only an increment of 0.1 SD in controls (p<0.05). 
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Table 1. Summary of initial and outcome variables (mean (SD) 
 Parameter GH Control Treatment 
  (n=16) (n=12) vs. control 
        
Boys/girls 12/4 8/4   
Start treatment       
   Age (yr)a 8.7 (1.4) 7.0 (1.7) p=0.009 
   Bone age delay (yr) 3.0 (1.1) 2.2 (1.3) p=0.07 
   H (cm) 118.4 (8.5) 111.5 (10.6) p=0.06 
   H SDS  -2.9 (0.6) -2.5 (0.3) p=0.09 
   H for BA SDS 0.4 (1.2) 0.7 (2.2) p=0.7 
   cTH SDS -0.7 (0.5) -0.8 (0.6) p=0.8 
   BMI SDS -0.6 (0.8) -1.1 (0.4) p=0.04 
   SH SDS -1.8 (1.0) -1.9 (0.5) p=0.1 
   Leg length SDS -2.9 (0.7) -2.3 (0.3) p=0.007 
   SH/H SDS 1.7 (2.1) 0.8 (0.9) p=0.2 
Discontinuation of treatment (stopb)      
   Age (yr) 12.0 (1.0) 11.9 (2.0) p=0.9 
   Age at T2 (yr) 11.6 (1.2) 12.1 (2.0) p=0.5 
            age at B2 (girls) 10.7 (1.2) 11.5 (1.3) p=0.5 
            age at G2 (boys)c 12.0 (1.0) 12.3 (2.2) p=0.7 
   T2 SDS 0.3 (0.7) -0.2 (1.2) p=0.2 
   H (cm) 144.5 (5.6) 135.8 (6.4) p=0.001 
   H SDS -1.3 (0.8) -2.6 (0.8) p=0.001 
   H for BA SDS -0.5 (0.6) -0.7 (1.3) p=0.7 
   H for BA SDS (stop-start) -1.2 (0.8) -1.3 (1.5) p=0.04 
   Bone maturationd 1.6 (0.4) 1.0 (0.2) p=0.000 
   PAH SDS -1.3 (0.9) -1.7 (1.1) p=0.2 
   BMI SDS -0.2 (1.0) -1.4 (0.7) p=0.003 
   SH SDS -0.6 (1.0) -1.7 (0.6) p=0.02 
   Leg length SDS -1.8 (0.8) -2.2 (0.6) p=0.3 
   SH/H SDS 1.4 (1.0) 1.1 (1.4) p=0.6 
   Years from start to stope 3.3 (0.9) 4.9 (1.9) p=0.02 
At adult height       
   Age (yr) 21.0 (2.1) 19.6 (2.4) p=0.1 
   AH in males (cm) 169.7 (4.2) 168.8 (3.8) p=0.6 
   AH in females (cm) 154.6 (5.0) 160.8 (4.5) p=0.1 
   AH SDS -2.1 (0.7) -1.9 (0.6) p=0.6 
   [AH-H at start] SDS 0.7 (0.6) 0.7 (0.6) p=0.8 
   [AH-H for BA at start] SDS -1.6 (1.0) -1.3 (1.1) p=0.5 
   [AH-cTH] SDS -1.4 (0.8) -1.1 (0.4) p=0.4 
   [AH-PAH at stop] SDS -0.8 (0.9) -0.1 (1.3) p=0.1 
   BMISDS 0.6 (1.0) -1.0 (1.2) p=0.001 
   PBI SDS 0.5 (0.9) 0.2 (0.7) p=0.4 
   SH SDS -1.2 (1.2) -1.7 (1.0) p=0.2 
   Leg length SDS -2.1 (0.6) -1.4 (1.1) p=0.05 
   SH/H SDS 1.5 (0.9) 0.4 (1.7) p=0.04 
   Untreated interval (yr) 9.0 (1.5) 7.8 (2.1) p=0.07 
    
Results are presented as mean (SD). (A)H, (adult) height; BA, bone age; PBI, pediatric bone index; BMI, 
body mass index; cTH, conditional target height; GH, growth hormone; LL, leg length; PAH, predicted 
adult height; SDS, standard deviation score; SH, sitting height; SH/H, sitting height/height ratio; T2, 
tanner stadium 2; TH, target height. aStart signifies the start of the on-off scheme. bStop is defined as 
the moment of discontinuation of GH treatment in the GH-group and the moment of attainment of T2 
in the control group. cTwo boys from the control group had late pubertal onset at the age of 14.2 and 
16.0 yr, respectively. dBone maturation calculated for the full trial period. eIncludes the first year’s on-off 
scheme.  
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Figure 3 
Height SDS, height for bone age SDS, and height gain SDS at start and discontinuation of the intervention, 
and after reaching adult height (AH). 
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At baseline, treatment and control groups were found to be slightly disproportionate, with 
relatively short legs in comparison to sitting height, resulting in a positive SH/H SDS in both 
groups. At the end of the trial phase, SH/H SDS was similar, but at follow up it was significantly 
higher in the GH-group compared with controls (p=0.04). Figure 4 shows SH SDS, LL SDS, and 
SH/H SDS at start and at follow up. GH-treated patients displayed an increased growth of trunk 
and legs compared with controls during the 4 years after start of the trial phase, whereas 
controls had more or less stable SH SDS and LL SDS which increased after (more than) 4 years. 
The GH-treated group had a longer trunk, but shorter legs than controls at follow up.  
Our analysis 5 years after inclusion demonstrated significantly earlier pubertal onset in GH-
treated subjects (8). However, in our present analysis on 26 out of 28 subjects (missing data on 
pubertal onset for 1 patient from each group) the difference did not reach statistical 
significance (p=0.5) (table 1). In boys in the treatment and control groups pubertal onset 
ranged from 10.3 to 13.6 yr and 9.2 to 16.0 yr, respectively. In girls these ranges were 9.2-12.1 
yr and 10.0-12.4 yr, respectively. At the attainment of Tanner stage 2, mean pubertal stage SDS 
for age (in boys and girls) was 0.3 (0.7) and -0.2 (1.2) in the treatment and control groups, 
respectively (p=0.2). None of the 12 GH-treated subjects and two boys out of 8 controls had 
delayed puberty (at 14.2 and 16.0 yrs), while in both groups 50% of patients had at least one 
parent (most often the father) with a reported late onset of puberty.  
 
Linear regression analysis of predictors for growth response 
 
Possible interactions between the effect of GH treatment on the 4 AH outcome parameters and 
on AH-PAHstop and the baseline parameters gender, agestart, Hstart, bone age delay were analyzed. 
Age at baseline was a predictor for the treatment effect (GH x agestart) expressed as AH (B=0.4, 
CI=0.03-0.7, p=0.04) and AH–Hstart (B=0.4, CI=0.06-0.7, p=0.02), but not for the other 
outcome parameters, thus older children had a better response to treatment. Gender showed a 
negative interaction with treatment effect (GH × gender) for AH (B=-1.1, CI=-2.3-0.01, 
p=0.052), with boys showing a larger increase in AH SDS than girls. Height and bone age delay 
at start were no significant predictors for treatment effect in any of the outcome parameters.  
IGF-I SDS after three months of treatment with 2.0 mg/m2 GH was associated with growth 
potential loss, with higher IGF-I levels resulting in a higher loss of growth potential expressed as 
AH-PAHstart (B=-0.6, CI=-1.2 – (-0.02), p=0.045). The change in IGF-I SDS between start and 3 
months of high dose GH treatment showed a trend towards negative interactions with 
treatment effect expressed as AH SDS (B=-0.5, CI=-1.0-(-0.1), p=0.09) and [AH-HforBAstart] SDS 
(B=-1.0, CI=-2.0-(-0.1), p=0.07), with higher changes in IGF-I SDS over 3 months of high dose 
GH treatment showing lower increases in AH SDS and [AH-HforBAstart] SDS. 
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Figure 4 
Development of SH SDS, LL SDS, and SH/H SDS during four years after onset of the trial phase and during 
follow-up until AH. At start and on AH, data of 100% of patients are represented. After 1, 2, 3, or 4 whole 
years after start of the trial phase, data of 96%, 89%, 89%, and 61% of patients are shown.  
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Genetic analysis 
 
Informed consent for genetic analysis was obtained from 18 out of 28 patients (11 GH-treated, 
8 controls). SNP-array did not detect insertions, deletions or duplications explaining short 
stature. Mutational analysis was not performed. 
 
Discussion 
 
The long-term results of this first randomized controlled study on the effect of high dose GH 
treatment restricted to the prepubertal period show that this regimen does not lead to an 
increased adult height. This confirms our earlier findings after discontinuation of treatment, 
where we showed that the positive growth response significantly accelerated skeletal 
maturation and advanced the onset of pubertal development, and did not improve predicted 
adult height (8). In contrast to retrospective studies (3), where the growth response was 
inversely associated with age at start of treatment, in our study a younger age at start was 
associated with a lower adult height.  
The lack of effect of this therapeutic regimen can be explained in at least three ways. The most 
likely explanation is that a high GH dose (approximately 3 times higher than substitution) (23) 
administered to young children not only leads to faster growth but also results in faster bone 
maturation. There are only few data on GH treatment of young children with ISS, as in virtually 
all studies the average age was approximately 11 years. It seems unlikely that the high dose per 
se causes the lack of effect, because children treated with a high GH dosage (67 µg/kg.day) 
starting at a mean age of 11 years achieve an adult height gain of 1.3 SD, which is slightly 
more than on 33 µg/kg/day (24). We speculate that the epiphyseal plates of young children 
may be more sensitive to high doses of GH and/or IGF-I than at later ages. The finding that a 
higher IGF-I SDS after 3 months of high dose GH treatment was associated with less adult 
height gain would suggest that circulating IGF-I plays a role in advancing epiphyseal maturation. 
The report by Cohen et al (2007) that even on a high GH dose (median 98, range 20-346 
µg/kg/d) titrated on circulating IGF-I levels of +2SDS, administered to young children (age range 
2.9-13.5, mean 7.53), no bone age advance was observed is not necessarily in contradiction 
with our findings, as the dose range in that study was large, and the children who needed high 
GH doses to reach the aimed IGF-I level may have been more resistant to GH. The trend 
towards a worse response to treatment in females may reflect the relatively strong influence of 
estrogens on bone maturation. 
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A second explanation is that the effect on bone maturation may be caused by the on-off GH 
treatment scheme employed during the first year of the trial, that may have primed the 
epiphyseal growth plate. We cannot exclude this possibility, but consider it less likely than the 
first explanation. The third possibility, that also cannot be ruled out with certainty, is that the 
poor result may be due to discontinuation of GH in puberty. The discontinuation of GH may 
have led to a ‘catch-down’ phenomenon, as was previously shown in children with SGA, who 
showed attenuation of growth after discontinuation of GH while puberty (and thus skeletal 
maturation) was progressing (25). However, the equal predicted adult height in the GH-treated 
and control groups at discontinuation of the trial phase argues against this hypothesis.  
There are two noteworthy limitations of our study. First, the long diagnostic phase that may 
have been a confounder of the effect of long-term GH therapy. Second, the small size of the 
cohort. With respect to the latter limitation, we believe that even in this small study group the 
absence of any effect of treatment makes it very unlikely that this is a false negative result.   
Our results imply that there may be an inverse U-shaped relationship between GH dose and 
adult height gain, if treatment is started at a young age. Dose is positively associated with adult 
height gain in the range of 25-50 µg/kg/d (2), but in young children higher doses may decrease 
adult height gain due to accelerated maturation of the epiphyseal plates and possibly also of 
the GnRH regulatory center, while the effect on growth has reached a plateau. This observation 
appears in contradiction to the overgrowth and tall adult height of children with pituitary 
gigantism, but in that condition plasma GH levels are characterized by an elevated baseline 
without high peaks, while the GH profile on a high GH dose shows one very high peak per day, 
followed by approximately 12 hours of suppression. During the peak plasma free GH must be 
considerably higher than in children with pituitary gigantism. Furthermore, the different GH 
profiles may also have different biological effects, similarly to observations in rodents (26). 
The effect of a high GH dosage on pubertal onset in young children is less clear. In the final 
analysis on 26 children using a novel technique for expressing pubertal stage in SDS (correcting 
for age and gender) (18), we found a trend (p=0.2), but no statistically significant difference 
between the groups at Tanner stage 2. While this technique enables appropriate correction for 
the (statistically significant) age difference at start of the trial between the groups, the inability 
to reach statistical significance may well be related to the limited number of subjects that could 
be studied at follow up. In the larger group of 35 subjects studied 5 years after inclusion, the 
age difference at start did not reach significance, some patients had not yet entered puberty at 
the moment of analysis, and another method (cumulative proportions of patients having 
entered puberty, and calculation of relative risk) was used. In that analysis the relative risk for 
early puberty, adjusted for age and sex, was 4.7 (1.4-15.8, p=0.012) (8). There are two other 
observations that can serve as indirect evidence for an effect on puberty onset. First, the 
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observation that none of the 12 males in the GH treatment group entered puberty late, 
compared to 2 of the 8 controls. Second, at follow-up the GH-treated subjects had a 
significantly shorter leg length than controls and a higher SH/H SDS, suggesting earlier exposure 
to sex steroids. The higher SH/H ratio may also explain the increase in BMI SDS observed in the 
GH-treated children (27). Unfortunately, the study design during follow-up did not allow for the 
collection of sufficient data on the progression of puberty.  
The untreated controls do not only serve as comparison with the GH treated children, but also 
to illustrate the natural history of ISS. Up to early adolescence, height SDS remained stable at -
2.6, but adult height was 0.7 SD higher than height SDS at start, presumably due to a rather 
delayed and possibly protracted puberty. A similar pattern was seen for SH and LL SDS. This 
result confirms our and others’ earlier findings (28;29). It also shows that HSDS for BA in young 
children severely over-predicts adult height. However, the average predicted adult height 
according to Bayley and Pinneau at discontinuation of the trial was almost identical with the 
attained adult height, consistent with our previous report (30). 
In conclusion, high-dose GH treatment limited to the prepubertal period in young children with 
ISS has no effect on adult height, probably caused by concomitant advance of bone 
maturation, and may advance pubertal onset.  
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Abstract  
 
Objective: To assess final height (FH) and adverse effects of combined growth hormone (GH) 
and gonadotropin releasing hormone agonist (GnRHa) treatment in short adolescents born 
small for gestational age or with normal birth size (idiopathic short stature, ISS).  
Design and patients: 32 adolescents with Tanner stage 2-3, age and bone age (BA) <12 (girls) 
or <13 (boys) years, height SDS<−2.0 SDS or between –1.0 and –2.0 SDS plus a predicted adult 
height (PAH0) <−2.0 SDS, were randomly allocated to receive GH+GnRHa (n=17) or no 
treatment (n=15) for 3 years. FH was assessed at the age of ≥18 (girls) or ≥19 years (boys). 
Results: FH was not different between treatment and control groups. Treated children had a 
higher height gain (FH−PAH0) than controls: 4.4 (4.9) and −0.5 (6.4) cm, respectively (p<0.05). 
FH was higher than PAH0 in 76% and 60% of treated and control subjects, respectively. During 
follow-up, 50% of the predicted height gain at treatment withdrawal was lost, resulting in a 
mean gain of 4.9 cm (range −4.0 to 12.3 cm) compared to controls. Treatment did not affect 
body mass index (BMI) or hip bone mineral density (BMD). Mean lumbar spine BMD and bone 
mineral apparent density (BMAD) tended to be lower in treated boys, albeit statistically not 
significant.  
Conclusion: Given the expensive and intensive treatment regimen, its modest height gain 
results and the possible adverse effect on peak bone mineralization in males, GH+GnRHa can 
not be considered routine treatment for children with ISS or SGA. 
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Introduction 
 
Short children with a relatively early onset of puberty often attain a poor final height (FH), due 
to premature growth acceleration and epiphyseal fusion induced by the pubertal rise in sex 
steroid levels (1). Growth hormone (GH) treatment increases FH in children with idiopathic short 
stature (ISS) or a persistent short stature after being born small for gestational age (SGA), 
particularly when initiated in early childhood (2). The effect of GH therapy is dose-dependent, 
with lower dosages being less efficacious (3;4), whereas too high doses may accelerate growth 
velocity and stimulate a rapid progression through puberty, possibly limiting FH gain (5). Once 
puberty has started, GH treatment may limit FH gain, because by that time the process of 
epiphyseal maturation has already been set in motion (6). 
An alternative for GH treatment is to delay or halt pubertal onset with gonadotropin releasing 
hormone agonists (GnRHa). However, in many children, GnRHa therapy concomitantly 
decreases growth velocity to values below the normal prepubertal pace, which may at least in 
part result from accelerated growth plate senescence induced by prior estrogen exposure (7).  
Combined GH and GnRHa treatment in adolescents with short stature has been analyzed in a 
few studies with limited numbers of patients and conflicting results. None of these were 
randomized controlled trials (RCT) and final height results are scarce. Height gain defined as the 
difference between FH and baseline height prediction (PAH0) was 1.0-10.0 cm (8-13). 
Treatment response was usually analyzed by comparison with a GH-treated group (12;14), or a 
not randomly assigned, untreated control group (9;9;15) or no control group at all (8). 
Moreover, most of the trials focused on girls only and excluded children with a persistent short 
stature after being born SGA. 
In 2001, we reported three years’ results of the first RCT investigating GH+GnRHa treatment in 
short, early pubertal adolescents with ISS or SGA. We concluded that three years of GnRHa 
treatment was effective in suppressing puberty, while growth velocity was preserved due to 
addition of GH, resulting in a significant gain in PAH without demonstrable side effects (16). 
Assessment of the motives of adolescents and their parents to participate in this trial and 
psychosocial functioning of the participants during treatment were described recently (17;18). 
Psychosocial functioning in young adulthood will be described elsewhere (Visser-van Balen, 
submitted for publication). Here we report FH data and analyze possible adverse effects of 
treatment on bone mineral (apparent) density (BM(A)D) and body mass index (BMI). 
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Material and methods 
 
Patients 
 
This report includes FH results from 32 out of 40 adolescents with short stature that originally 
enrolled in a multicenter study in the Netherlands in 1993-96. Inclusion criteria were: 
chronological age (CA) and bone age (BA) <12 (girls) or <13 years (boys); pubertal stage of G2-
3 (boys) or B2-3 (girls); height at baseline H0<–2.0 SDS for Dutch references (19) or between –
1.0 and –2.0 SDS with PAH0 <–2.0 SDS (according to Bailey & Pinneau, (20)); maximum serum 
GH level >10 µg/l (1 mg = 2IU, using The first International Reference Population of hGH, MRC 
London, code 66/217 as standard) after provocation (exercise, arginine, clonidine, L-dopa, or 
glucagon), and a normal sitting height/subischial leg length ratio (between P3 and P97 (21)). 
Screening blood tests and urinalysis were normal. No organic cause of growth failure, primary 
bone disease, chronic illness, or dysmorphic syndrome were present. During the trial phase, 
fasting glucose and insulin levels remained within the normal range in all children. Markers for 
bone formation (osteocalcin, alkaline phosphatase, PICP and PIIINP) were not different between 
treatment and control groups. Details of the subjects and data obtained after withdrawal of 
treatment were reported previously (16). 
The protocol was approved by medical ethical review boards at the four participating centers 
(Amsterdam, Utrecht, Eindhoven, Rotterdam). Before conducting any study-related procedure, 
written informed consent was obtained from parents, and, when appropriate, also from the 
participants. This clinical trial was registered in the metaRegister of Controlled Trials 
(ISRCTN82161629) of the Current Controlled Trials Ltd. 
 
Study design 
 
Forty patients were randomly allocated to receive combined treatment with GH+GnRHa or no 
treatment for a period of three years (see fig.1). GH (Genotropin®, Pharmacia, Sweden; now 
Pfizer, New York, USA) was given in a dose of 1.33 mg (4 IU)/m2/day subcutaneously, 
equivalent to 0.05 mg/kg body weight/day. A 3.75 mg 1-month depot preparation of GnRHa 
was intramuscularly administered (Triptorelin (Decapeptyl®) Ferring, Malmö, Sweden; after 
withdrawal by Ferring in 1998, triptorelin from Ipsen, Paris, France was used). This 
corresponded with a mean Triptorelin dose of 125 µg/kg at start of treatment and 67 µg/kg at 
discontinuation of treatment.  
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Randomization was performed separately in children born SGA, defined as birth length <−2.0 
SDS (22). Directly after randomization, 4 patients (two from each group) refused to start the 
intervention they were randomly allocated to receive and dropped out. Additionally, 2 patients 
dropped out from the control group due to a lack of motivation for visiting the outpatient clinic 
during the trial phase and another 2 (one in each group) could not be traced and were lost to 
follow-up.  
Adolescents were considered to have attained final height if treatment withdrawal was at least 
3 years prior to evaluation and chronological age was greater than or equal to 18 (girls) or 19 
years (boys). FH, being the average of four measurements made by a single observer using a 
Harpenden stadiometer, was determined at an outpatient clinic visit or at a house visit.  
 
Bone mineral density 
 
BMD of the lumbar vertebrae and hip were measured by dual-energy X-ray absorptiometry 
(DXA) at the moment of FH analysis. DXA-scans were performed at the Department of 
Radiology of the VU University Medical Center in Amsterdam or at the Diagnostic Center 
Eindhoven using a Hologic Delphi 4500A or a Hologic Delphi W-type 70991 (Hologic, Waltham, 
MA, USA), respectively. Cross-calibration with phantoms demonstrated that the DXA machines 
were comparable, and data from both centers were pooled. Each machine was calibrated using 
the manufacturer’s ‘daily quality control’ protocol. Z-scores were calculated, using hip reference 
values based on the National Health and Nutrition Examination Survey from 1988-1991 
(NHANES) (23) and Hologic reference values for lumbar spine (L1-L4). To correct for bone size, 
DXA-derived data were used to calculate lumbar spine BMAD (24). BMAD Z-scores could not be 
calculated due to the lack of appropriate reference values.  
 
Outcome parameters 
 
Four outcome parameters were used to evaluate response to treatment: 1) FH (SDS); 2) FH 
minus baseline height (H0) (SDS); 3) FH minus PAH0 according to Bayley and Pinneau (20) (cm); 
and 4) FH minus target height (TH; cm). FH minus PAH3 (PAH at discontinuation of treatment) 
was also calculated, to show the difference between final outcome and height prediction at 
discontinuation of treatment. All SD scores were based on Dutch references (19). For calculation 
of FH SDS, the age of each patient was set at 21 years, enabling comparison of FH with height 
distribution in the normal adult population. For 3 patients, a bone age radiograph at baseline 
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 was not available, and BA determination closest to this time point was used and transformed 
to BAbaseline as follows: BAbaseline = (BAvisit/ Chronological age visit) x Agebaseline. 
TH was calculated as midparental height plus or minus 6 cm (for boys and girls, respectively), 
plus 3 cm to correct for the average secular trend in the Netherlands (25). One patient’s TH 
could not be calculated, because of adoption from a foreign country and absence of height 
data of his biological parents.  
The following outcome parameters were used to analyze possible effects of GH+GnRHa 
treatment on bone mineralization and body weight: 1) Lumbar spine BMD (SDS) and BMAD 
(g/cm3); 2) Hip BMD (SDS); and 3) BMI (SDS).  
 
 
Figure 1  
Trial design. 
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Statistical analysis 
 
The study was designed to compare the effects of GH+GnRHa treatment with those of no 
treatment on final height. Statistical analyses were performed using the statistical package 
SPSS, version 11.0.1 (26). Results are expressed as mean and SD. Comparisons among 
treatment and control groups were made using Student’s unpaired t-tests. Possible interactions 
between GH+GnRHa treatment and the baseline predictors gender, diagnostic subgroup, age 
at baseline (age0), height at baseline (H0SDS), and bone age delay (CA−BA) were analyzed by 
means of linear regression analysis using ANOVA. The significance level was set at 0.05.  
 
Results 
 
A complete case analysis was carried out for the remaining 32 out of 40 originally included 
patients (80%). One patient from the GH+GnRHa group discontinued treatment after 2 years 
due to a lack of motivation, but her near-final height two years after termination of treatment 
was included in the evaluation. Anthropometric data were not statistically different between 
treatment and control groups at baseline, but predicted adult height and target height 
happened to be about 3 cm lower in the treatment group. During the trial phase, clinical 
(Tanner stage) and biochemical (serum estradiol and testosterone levels) evaluation 
demonstrated that pubertal development was effectively arrested in the GH+GnRHa group, 
while puberty progressed in the control group (16). After withdrawal of therapy, pubertal 
development immediately resumed, with most children from the GH+GnRHa group reaching 
Tanner V development within 1-2 years and most girls reaching menarche within 1 year. All 
participants were sexually mature at final analysis.  
There was a significant gain in PAH of 9.3 cm after three years of GH+GnRHa treatment, 
compared with 1.2 cm gain in the control group (fig. 2a). There was no significantly different 
pattern between the two diagnostic subgroups and genders in changes in height parameters.  
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Figure 2 
Height gain compared with predicted adult height at baseline (FH-PAH0) and after discontinuation of 
treatment (FH-PAH3); in cm. *p<0.1; **p<0.05; ***p<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect on growth 
 
Patient characteristics at start, after treatment discontinuation, and at the moment of FH 
analysis are listed in table 1. FH data were collected at a mean age of 19.9 (1.8) and 20.9 (1.0) 
years in girls and boys, respectively. The mean treatment period was 3.0 yr (range 2.8-3.3 yr). 
The mean period elapsed  
between treatment discontinuation and final analysis was 5.7 yr (range 3.6-8.7 yr).  
FH SDS [−2.0 (1.0) vs. –2.3 (0.6)] and height gain compared with H0SDS [0.5 (0.9) vs. 0.3 (0.6)] 
were not significantly different between treated and control subjects. In the GH+GnRHa group, 
53% reached a FH>−2.0 SDS, compared with 33% of control patients (difference not 
statistically significant). The treated subjects attained a FH closer to TH than controls [−6.0 (7.2) 
vs. −11.2 (5.7) cm; p<0.05], but mean FH of treated subjects was still significantly lower than 
TH (p<0.01).  
Height gain (FH−PAH0) was 4.4 (4.9) in the treatment and –0.5 (6.4) cm in the control group 
(fig. 2b). Of the predicted 9.3 cm gain in PAH (PAH3−PAH0) approximately 50% was lost during 
follow up (fig. 2), resulting in a net gain of 4.9 cm in the treatment group, compared to 
controls. Seventy-six percent of the GH+GnRHa treated children and 60% of the controls had a 
FH greater than predicted at baseline. 
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Height gain was similar in both genders, but there was a difference in the accuracy of the 
height prediction method between genders. Untreated boys attained a FH 5.5 (4.1) cm lower 
than predicted at baseline, whereas untreated girls became 1.9 (6.0) cm taller. Treated girls had 
a FH significantly closer to TH than controls (p<0.05), whereas no significant difference existed 
between treated and untreated boys. 
 
Linear regression analysis of predictors for growth response 
 
Gender was a predictor for the treatment effect (GH+GnRHa∗gender) expressed in FH–TH, with 
girls showing a better response than boys (regression coefficient B=10.7, CI=1.3−20.2, p<0.05; 
graph not shown). Age at baseline showed a trend towards a positive interaction with 
treatment effect (GH+GnRHa∗Age0) in the outcome parameters FH SDS minus H0SDS (B=0.7, 
CI= −0.01−1.5, p<0.1), and FH SDS minus PAH0 SDS (B=0.8, CI= −0.1−1.7; p<0.1). Baseline 
height and diagnostic subgroup were no significant predictors for treatment effect in any of the 
outcome parameters. 
 
Side effects 
 
Lumbar spine and hip BMD were determined in 21 patients (69%), 15 treated and 6 control 
subjects; the others could not be motivated. There was no apparent difference in lumbar spine 
and hip BMD SDS between treated and untreated children (fig. 3a, c). Lumbar spine BMD SDS 
was markedly lower in the six treated boys (−2.5 (1.0) SDS), than in the two controls (−1.1 (0.3) 
SDS) who consented to undergo this diagnostic procedure (p=0.1; CI=−0.5-3.3). This difference 
was statistically not significant due to the small sample size of the control group (n=2). Lumbar 
spine BMAD showed a similar, albeit less prominent pattern (fig. 3b). BMI SDS remained 
unchanged during and after GH+GnRHa treatment in boys and girls.  
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Figure 3  
Effect of GH+GnRHa treatment on (a) lumbar spine BMD expressed as Z-score, (b) lumbar spine BMAD 
expressed in g/cm3, and (c) total hip expressed as Z-score. Error bars represent standard deviations.  
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Discussion 
 
We report final height results of the first RCT of combined GH+GnRHa treatment in short boys 
and girls, that includes a non-treated control group. Treatment resulted in a modest increase of 
approximately 5 cm compared to controls, as documented by difference between obtained 
adult height and initial predicted adult height and target height. The reason that the differences 
in final height SDS as such and the change in height SDS were not statistically significant is 
probably that the predicted adult height at start, as well as the target height, of the children 
randomly allocated to the treatment group happened to be approximately 3 cm lower than in 
controls. 
Two previously published studies employed untreated controls as reference group. Saggese et 
al. found an increase in PAH of 6.1 cm after two years of GH+GnRHa in 7 ISS girls compared 
with controls (27). In contrast, Lanes and Gunczler (9) found no improvement in PAH or FH 
after 2.5 years of treatment in 10 short boys and girls. Other studies with different experimental 
designs showed similarly contrasting results on growth, varying from no effect on FH or PAH 
gain in girls with familial short stature (8) and in ISS boys and girls (14), to 10.5 cm gain in PAH 
and 10 cm height gain (FH−PAH0) in ISS girls (12). These studies and ours cannot easily be 
compared due to differences in experimental design. GH+GnRHa trials in short adopted girls 
showed an increased PAH, FH−PAH0 and FH compared with GnRHa-treated controls (10;13). 
Mul et al. suggested that the relevance of their results in adopted girls might be extrapolated to 
girls born SGA and those with ISS (10). Indeed, in our trial we found significantly increased 
PAH, height gain and FH compared with TH in the treated girls.  
Approximately 50% of the apparent gain in PAH during treatment was lost during follow up. 
Initial height prediction overestimated FH in untreated boys, which has also been described by 
others (28). Height gain in terms of FH−PAH0 is similar in both genders, although the accuracy 
of height prediction depends on gender. Untreated boys attain a FH considerably lower than 
predicted at baseline, whereas girls become slightly taller. Prediction at discontinuation of 
treatment overestimated final height, regardless of gender. A longer duration of combined 
therapy might further increase height gain, but would delay puberty even longer, up to an age 
that would far exceed the normal range. This might cause adverse effects on psychological and 
bone parameters. However, prolonging GH treatment after discontinuation of combined 
treatment until FH may be a way to fulfil part of the height gain predicted in PAH3. 
Gender did not influence the response to GH+GnRHa in three out of four outcome parameters. 
Only for FH−TH a better response to treatment was seen in girls. Previously published reports on 
GH+GnRHa treatment were usually conducted in short girls only, except a few small trials 
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 including both genders (9;14). The inclusion of boys in our trial, might explain a somewhat 
lower overall response to treatment compared to other studies on GH+GnRHa treatment in 
short girls. The predictive value of gender on height outcome is limited in this study, since an 
effect was found in only one outcome measure (FH-TH).  
We included an SGA subgroup, even though this category of patients was excluded from the 
1996 consensus definition of ISS (29) and from most of the previously published studies. In our 
opinion the distinction between ISS and idiopathic SGA is arbitrary, due to varying definitions 
and reference values for length and weight for gestational age. In the ISS consensus, SGA was 
defined as a birth weight and/or length <−2.0 SDS for gestational age. This definition implies 
that a child with a birth weight in the lower normal range, may be categorized as ISS in case of 
an unknown birth length, and as SGA if birth length would be recorded as <−2.0 SDS. 
Moreover, the Gaussian distribution of birth weight and length in ISS is shifted to the left by 1 
SDS (30), suggesting that persistent short stature born SGA and ISS are not separate entities. 
SGA and ISS children in our study had a similar response to treatment, demonstrating that 
diagnostic subgroup did not interact with the treatment effect. Similarly, Crowe et al. found no 
difference in response to GH treatment between SGA or ISS groups (31). However, patient 
numbers in our subgroups were small and larger sample numbers are required to analyze 
response to definitely confirm or reject our hypothesis that SGA and ISS children respond 
similarly to combined GH+GnRHa treatment. 
Apart from beneficial effects on height gain, GH+GnRHa treatment may also have adverse 
effects. Palmert et al. found an elevated BMI in GnRHa-treated girls with central precocious 
puberty (CPP) (32). We did not find an increased BMI, neither directly after discontinuation of 
treatment (16) nor at final height analysis. The stimulatory effect of GnRHa on fat mass 
induction may have been counterbalanced by an adverse effect of GH in the treated children. 
The elevated BMI in GnRHa-treated girls from the American trial was possibly associated with 
precocious puberty itself rather than with the treatment. 
A more relevant possible side-effect of GnRHa treatment was described by Yanovski et al. (33), 
who found a significantly decreased lumbar spine BMD after 4 years GnRHa treatment, with or 
without GH, of children with short stature based on various etiologies. A similar result was 
reported after 3.4 years of GnRHa treatment in girls with ISS (34). In GnRHa-treated children 
with CPP, lumbar spine BMD was significantly decreased during treatment (35), but restored to 
normal values several years after withdrawal of treatment (34;35), suggesting that GnRHa-
therapy did not impair peak bone mass in this subcategory of patients. In contrast, Finkelstein et 
al. demonstrated that adult men with a history of delayed puberty had a decreased radial and 
spinal BMD (36), suggesting that the timing of puberty is an important determinant of peak 
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bone density in men. BMD achieved during young adulthood might be a major determinant of 
bone density and a predictor for the risk of osteoporotic fractures in later life.  
In our study, there was no apparent difference between treatment and control groups in 
lumbar spine and hip BMD measured at least 3.5 years after termination of treatment. 
However, the six treated boys had a lower lumbar spine BMD and BMAD than the 2 untreated 
boys, albeit statistically not significant. A meta-analysis by Marshall et al. demonstrated that 
with each 1 SDS decrease in lumbar spine BMD, fracture risk increased 2.3 fold (37). Therefore, 
we believe that there is sufficient reason to be cautious when considering GH+GnRHa 
treatment in boys. On the other hand, it has been shown that after interruption of skeletal 
development in childhood, there is still potential for catch-up in BMD, even ongoing into the 
third decade of life (38;39). Taking this into account, it remains to be seen whether the low 
lumbar spine BMD in treated boys has clinical repercussions and whether it will restore to 
normal values.  
In girls, there was no difference in lumbar spine and hip BMD between treated and control 
groups. This may be explained by an immediate rise in estrogen to high levels after treatment 
withdrawal in girls, favoring bone mineralization. In boys, the post-treatment rise in estrogen 
levels may be slower and reach a lower maximum, resulting in a later and possibly lesser 
stimulation of bone mineralization. 
Apart from these clinical issues, psychosocial issues should also be taken into account. Analyses 
of psychosocial functioning during treatment tentatively suggested adverse psychological 
consequences for the treated adolescents on self-perceived competence of scholastic and 
athletic ability, and trait anxiety (17). Parents reported some behavioral problems in their 
children before treatment (18), but did not report changes during treatment. Psychosocial 
outcome after attaining final adult height was one of the final evaluation criteria of this trial 
and so far no differences have been observed between treatment and control groups in social 
circumstances, height-related psychosocial stressors, perceived competence, and psychological 
distress in young adulthood (Visser-van Balen, submitted for publication). 
We conclude that 3 years of GH+GnRHa treatment has a positive, but modest effect of 4.9 cm 
on final height in short, early pubertal children with ISS or a persistent short stature born SGA, 
compared with non-treated controls. The costs of long term treatment with GH+GnRHa of 
short, but otherwise healthy patients, with extremely expensive drugs that require parenteral 
administration and regular clinic visits, and may have an adverse effect on peak bone 
mineralization, particularly in males, overshadows the modest benefit of 4.9 cm height gain. 
We therefore do not recommended this treatment regimen in general. However, treatment may 
be felt justified in individual patients, particularly girls, with an extremely low adult height 
prediction, an early pubertal onset and considerable psychosocial problems. 
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Abstract  
 
Background: Aromatase inhibition has been proposed as a potential approach for growth 
enhancement in children with short stature, but detailed animal studies are lacking.  
Aim: to assess the effect and potential adverse effects of aromatase inhibition on growth in 
female rats.  
Methods: Prepubertal Wistar rats received intramuscular injections with placebo (PLC) or the 
aromatase inhibitor exemestane at a dose of 10, 30 or 100 mg/kg/week (E10, E30, E100) for 3 
weeks. A control group was ovariectomized (OVX). Weight and length gain, tibia and femur 
length, growth plate width, organ weights, insulin-like growth factor I (IGF-I) levels, and 
histology of the ovaries, uterus, and brain were analyzed. X-ray microtomography of femora 
was performed.  
Results: E100 significantly increased weight gain and growth plate width, but less prominently 
than OVX. Trabecular number and thickness were decreased in E100 and OVX in the 
metaphysis and epiphysis. E100 significantly decreased ovarian weight and multiple cysts were 
seen upon histological evaluation. No significant effects were found on IGF-I levels and brain 
morphology in E100. E10 and E30 had no effects on growth. 
Conclusion: a high dose of exemestane marginally increases axial and appendicular growth in 
female rats, at the expense of osteopenia and polycystic ovaries.  
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Introduction 
 
Estrogens play a pivotal role in the regulation of normal skeletal growth and maturation in both 
boys and girls (1-5). In both genders, estrogen deficiency due to mutations in the aromatase 
gene (6) leads to the absence of a pubertal growth spurt, ongoing growth into adulthood and 
potentially tall stature. Based on these clinical observations, it was postulated that estrogen 
deficiency induced by aromatase inhibition, could be valuable in clinical practice because of its 
potential growth-enhancing effect (7;8).  
Treatment with the nonsteroidal aromatase inhibitor letrozole resulted in an increased predicted 
adult height in boys with idiopathic short stature (ISS) (9;10) in two clinical trials performed by 
the group of Dunkel et al. In one of those trials, treatment with a combination of letrozole and 
testosterone increased near-final height in boys with a constitutional delay of puberty (11). 
There is limited experience with the use of aromatase inhibitors in female patients with short 
stature, since therapy-induced hyperandrogenism and consequent virilization may be expected, 
as observed in female aromatase-deficient patients. However, it is uncertain whether treatment 
with aromatase inhibition limited to the prepubertal period, with the objective to increase 
longitudinal growth and adult height, would cause persistent virilization and disturbance of 
reproductive function after cessation of treatment.  
In girls with McCune-Albright syndrome (MAS) (12;13) or congenital adrenal hyperplasia (CAH) 
(14), treatment with the aromatase inhibitor testolactone or letrozole resulted in attenuated 
height velocity and bone maturation rates, resulting in a poor adult height prediction. These 
results are in conflict with the potentially growth-enhancing effect of aromatase inhibition in 
boys with ISS, but may also be the reflection of the complex endocrine deregulation in MAS 
and CAH patients. The reported clinical trials in girls were uncontrolled, and usually did not 
include an evaluation of bone mineral density (8).  
The broad tissue distribution of aromatase expression in humans underscores the importance of 
locally produced estrogens (15). Therefore, aromatase inhibition for the purpose of growth 
enhancement may have side effects on several organ systems. Aromatase-deficient females are 
diagnosed with 46,XX DSD (disorder of sex development) at birth and show progressive bone 
age delay, eunuchoid proportions, and reproductive dysfunction based on primary amenorrhea 
and enlarged, polycystic ovaries in adolescence (6). Bone mineral density has not been studied 
in these patients, but one could hypothesize that they would develop osteoporosis, as it occurs 
in adult men with congenital estrogen deficiency (2). Treatment of adolescents girls with a 
gonadotropin releasing hormone agonist (GnRHa), an alternative way to diminish circulating 
estrogen levels, indeed resulted in a decreased bone mineral density (16). Moreover, aromatase 
expression plays an important role in the brain under both physiological and pathological 
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conditions (17). Aromatase inhibition may also have an impact on the brain, since aromatase 
expression was found to have a neuroprotective role both under physiological and pathological 
conditions (17). 
In the present article, we report the results of a study in which female sexually immature rats 
were treated with the steroidal, irreversible aromatase inhibitor exemestane (E) in a slow-release 
preparation in order to test the hypothesis that aromatase inhibitors can increase longitudinal 
growth and to evaluate potential side-effects. Treatment was short-term and confined to the 
period of sexual immaturity in order to mimic the potential treatment strategy in girls with ISS. 
We chose to work with exemestane in our experiments, because it can be administered once a 
week as a slow release preparation to ensure long-lasting aromatase inhibition, in contrast to 
the other available aromatase inhibitors that have to be administered daily. This facilitates its 
use in experimental animal models, and it presumably would also increase compliance in clinical 
practice. A second advantage of exemestane over the other aromatase inhibitors is that it 
irreversibly inactivates aromatase and completely abolishes estrogen biosynthesis, which can 
only be overcome by de novo synthesis of aromatase. We applied a slow release depot of 
exemestane to continuously counteract de novo synthesis of aromatase. Finally, exemestane 
may exhibit androgenic effects on bone, potentially preventing the loss of bone mineral density 
(BMD) induced by estrogen deficiency (18), which may be an advantage when treatment with 
aromatase inhibitors is considered in clinical practice. 
In addition to the effects of aromatase inhibition on growth, we also studied possible adverse 
effects of aromatase inhibition on bone physiology, brain morphology, and morphology of the 
ovaries and uterus. This study is the first detailed analysis of the impact on growth and potential 
side effects of aromatase inhibition in a female animal model.  
 
Experimental design 
 
Animals 
 
Weight-matched female Wistar rats (n=30) were purchased from Harlan (Horst, The 
Netherlands). At the start of the experiments, all rats were 26 days old, and sexually immature, 
since rats usually enter sexual maturation at the age of 30 days. Animals were kept in a light 
and temperature controlled room (12 hours light, 20-22°C) with water and food (Hope Farms, 
Woerden, The Netherlands) ad libitum and a maximum of 3 animals per cage. Experiments 
were approved by the Committee for the ethical care and use of laboratory animals of the 
Leiden University. 
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Five groups consisting of 6 rats were formed. One group was ovariectomized at baseline by the 
dorsal approach under isoflurane anaesthesia in order to obtain an estrogen-deficient control 
group (OVX). In previous experiments, no difference in growth phenotype was found between 
sham-operated and placebo-treated control-group rats (19). Therefore, no sham-group was 
included in this study. Three groups were treated with the slow-release preparation exemestane 
(Aromasin® provided by Pfizer, New York, U.S.A) at a dose of 10, 30 or 100 mg/kg body 
weight/week (coded as E10, E30, E100, respectively). Exemestane was administered by 
intramuscular injections in alternated hind paws. A control group was treated with vehicle 
(placebo, PLC). After three weeks of treatment, all rats were sacrificed.  
Weekly measurements of nose-anus length, tail length and body weight were performed. At 
the end of the experimental period, animals were anaesthetized by intraperitoneal Nembutal 
injection and blood samples were collected by means of cardiac puncture. Serum was separated 
for insulin-like growth factor I (IGF-I) measurements. Femora were collected for X-ray 
microtomography (micro-CT). Subsequent in vivo fixation was performed by means of 
transcardiac perfusion with 4% paraformaldehyde and 0.2% glutaraldehyde in 0.1 M 
phosphate buffer supplemented with 75 mM lysine monohydrochloride and 10 mM Na-
periodate. After fixation, the rats were decapitated, and the brains were stored in the same 
fixative for at least 12 weeks. Tibiae of the right hind legs were measured, postfixated for 24 
hours, decalcified in 12.5 % EDTA, pH 7.4 for 4 weeks, cut in halves in a sagittal orientation 
and subsequently processed for paraffin embedding. Ovaries and uterus were weighed and 
processed for paraffin embedding. The organ weight/total body weight (TBW) ratio was 
calculated.  
 
Growth plate histomorphometry 
 
For histomorphometrical analysis of the growth plate, paraffin sections (5 µm) perpendicular to 
the growth plate axis were mounted on APES/glutaraldehyde-coated slides, and deparaffinized 
in Paraclear® and graded ethanols. They were stained with Haematoxylin/Eosin (H&E) and 
mounted in Histomount (National Diagnostics, Atlanta, USA). Representative pictures of the 
proximal tibial growth plate were taken (Nikon DXM 1200 digital camera). Widths of the total 
growth plate, proliferative zone and hypertrophic zone were measured in ImagePro Plus. The 
ratio between proliferative and hypertrophic zone widths (P/H ratio) was calculated. 
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X-ray microtomography (micro-CT) 
 
To examine the effects of exemestane treatment on whole bone parameters and on trabecular 
bone in particular, right femora were analyzed by high resolution X-ray microtomography. 
Micro-CT has been shown to be well suited for the non-destructive visualization and 
quantitative analysis of bone and calcified tissue (20;21). 
 
a. ‘Whole bone’ parameters 
Isolated whole femora were scanned with a high resolution desktop micro-CT scanner (Skyscan 
1076, Kontich, Belgium). In this X-ray micro-CT system, both the X-ray source (focal spot size 5 
µm, energy range 20-100 keV) and the detector (CCD camera 2.3kx4k) rotate around the 
bone. Scans were isotropic and a voxel size of 35×35×35 µm was chosen with 1.0 mm A1 
filter. Virtual cross-sections were reconstructed by Feldkamp cone-beam algorithm (22). Further 
technical details about the scanner have been published elsewhere (23). 
The same threshold and reconstruction parameters were used for the reconstruction of all 
cross-sections. Frequency distribution of the grey levels was analyzed. 3D models were created 
using Skyscan software packages ANT and CT Analyzer. From the virtual cross-sections the 
volumes taken by bone as well as the anatomical volume (Archimedean volume) were 
calculated. Distinction between bone and other tissues was based on thresholding of the grey 
values in the reconstruction. Analysis of the grey values in the individual slices also resulted in a 
relative value for total calcium and overall calcium density. Details of these calculations have 
been reported previously (20). In addition, the length of the femora was measured manually 
with a caliper. 
 
b. Trabecular bone 
For analysis of the trabecular bone, the distal end of the femur was scanned, but for this 
purpose at a higher resolution than required for the ‘whole bone’ scans. Therefore, an in vitro 
desktop micro-CT system (Skyscan 1072, Kontich, Belgium) with a rotating stage was used (24). 
Polychromatic X-rays, with peak energy of 80 kV, were generated by a microfocus X-ray source 
with a focal spot size of 8 microns. A (1024×1024) 12 bit CCD camera was used as detector. In 
all experiments the rotation step was 0.9°, acquisition time 6 sec/projection, and total 
acquisition time about 2 hours. Scanning was isotropic with a voxel size of 13 µm3.  
The growth plate was chosen as a reference for selecting comparable and reproducible regions 
of interest for analysis of trabecular bone parameters such as trabecular number, trabecular 
thickness, bone volume and distribution of trabecular thickness. Trabecular bone parameters 
were studied in two different regions of the femur: the metaphysis (primary ossification center) 
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and the epiphysis (secondary ossification center). For analysis of the primary ossification center 
at the proximal side of the growth plate, a transverse reference slice of the growth plate was 
selected and used to reconstruct a cylinder with fixed dimensions as from 50 slices above the 
reference slice; the height of the cylinder was 150 slices. 
 
Gonadal histology 
 
Midsagittal sections of the ovaries (5 µm) were stained with Haematoxylin and Eosin (H&E). A 
minimum of three sections was analyzed per ovary. In H&E stained longitudinal sections (5 µm) 
of the uterus, endometrial thickness was measured using ImagePro Plus and the 
endometrium/total wall thickness ratio (E/T-ratio) was calculated.  
 
Brain histology 
 
Brains were removed from the skulls, rinsed with PBS and cut in coronal sections (30 µm) in a 
Vibratome. Sections were Nissl-stained with toluidine blue for screening morphometrical 
analysis of all brain areas. Immunohistochemical staining of astrocytes (anti-GFAP, Glial Fibrillary 
Acidic Protein, DAKO, Barcelona, Spain; diluted 1:1000), microglia (OX-42, Serotec, Bicister, 
United Kingdom; diluted 1:300) and reactive astrocytes (anti-vimentin, clone V9, DAKO, 
Barcelona, Spain; diluted 1:500) was performed. For the morphometric analysis of GFAP 
immunoreactive astroglia, a quantitative evaluation of the surface density of GFAP 
immunoreactive cell bodies and cell processes in the hippocampus was performed using a 
stereological grid, according to the point-counting method of Weibel (25). For each animal, a 
minimum of two slides was evaluated.  
 
Insulin-like Growth Factor I (IGF-I) assay 
 
Total serum IGF-I levels were measured by specific radioimmunoassay (RIA) after acid Sep-Pak 
C18 (Waters Associates Ltd., Milford, MA) extraction of 250 µl aliquots, following procedures 
as described previously (26). 
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Statistical analysis  
 
The study was designed to analyze the effect of aromatase inhibition on growth and to analyze 
potential adverse effects on bone, brain and organ development. Comparisons of growth 
among treatment and control groups were made using one-way analysis of variance (ANOVA). 
Results are expressed as mean and SD. The significance level was set at 0.05. 
 
Results 
 
Effects on growth and organs 
 
At baseline, there were no significant differences between groups in auxological parameters. 
Body weight gain, nose-anus length gain and tail length gain, tibia length, growth plate 
characteristics, and IGF-I levels are summarized in table 1. The effects of aromatase inhibition 
on organ weights are summarized in table 2. Figure 1 illustrates nose-anus length gain in OVX, 
PLC and E100. Figure 2 shows growth plate samples from these groups. Results in the E10 and 
E30 groups were not significantly different from the placebo-group and are therefore not 
presented. 
Body weight gain was significantly increased in both E100 and OVX (p=0.000 and p=0.001, 
respectively) compared with PLC. Nose-anus length gain was significantly higher (p=0.000) in 
OVX compared with PLC. Figure 1 illustrates that the increased length gain in OVX was already 
prominent one week after ovariectomy. A less pronounced increasing nose-anus length gain 
with a trend towards statistical significance (p=0.054) was seen in the E100 group. The 
difference in nose-anus length gain between OVX and E100 was statistically significant 
(p=0.021). When compared to the rats that received placebo-treatment, for both E100 and 
OVX no effect on tail length gain was found. Total growth plate width in the E100 group was 
increased (p=0.000), based on equal thickening of both the proliferative and hypertrophic 
zones compared with PLC. The P/H ratio was not significantly different from controls. Similar 
effects were found in OVX. The serum IGF-I level was raised in OVX (p=0.000), but not 
significantly in E100, compared to PLC. 
In the OVX group, a significant decrease of 15% of the liver/TBW ratio was found (p=0.042). 
The increased thymus/TBW ratio found in OVX (p=0.000), was not seen in the E100 group.  
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Table 1: Effect of aromatase inhibition on growth parameters and epiphyseal morphology 
Parameter   PLC E100 OVX 
Tail length gain (cm) 7.2 (0.7) 7.3 (0.4) 7.9 (0.5) 
Nose-anus length gain (cm) 5.0 (0.7) 5.7 (0.8)# ^ 6.5 (0.4)*** 
Body weight gain (g) 96.7 (10.2) 120.6 (7.3)*** 115.0 (7.6)** 
Tibia length (mm) 30.7 (0.4) 31.2 (0.7)# ^ 31.7 (0.3)**  
Femur length (mm) 26.6 (0.4) 27.6 (0.4) * 27.0 (0.2)  
Growth plate width (mm) 0.34 (0.02) 0.42 (0.02)*** 0.44 (0.02)*** 
     proliferative zone (mm) 0.14 (0.01) 0.18 (0.01)*** 0.18 (0.01)** 
     hypertrophic zone (mm) 0.20 (0.02) 0.24 (0.02)* 0.26 (0.02)** 
     P/H-ratio 0.70 (0.05) 0.77 (0.1)§ 0.67 (0.05) 
Serum IGF-I (ng/ml) 0.9 (0.04) 1.1 (0.16)^ 1.4 (0.25)* 
  Means (SD). E100 or OVX versus PLC: *p<0.05; **p<0.01; ***p<0.001; #p<0.1. 
  E100 versus OVX: ^p<0.05; §p<0.1. 
 
 
 
Table 2. Effect of aromatase inhibition on organ weights  
Parameter   PLC E100 OVX  
liver  70.9 (10.8) 70.3 (6.3)§ 59.7 (11.1)* 
thymus  2.9 (0.4) 3.3 (0.5)^^ 4.0 (0.5)*** 
kidney  5.5 (0.3) 5.8 (1.1)§ 5.1 (0.6)  
adrenal gland 0.23 (0.04) 0.19 (0.05)#^ 0.23 (0.03)  
ovary  0.2 (0.03) 0.1 (0.02)***  
uterus  2.6 (0.8) 2.1 (0.9)^^^ 0.2 (0.04)*** 
     endometrium thickness (µm) 0.43 (0.10) 0.31 (0.10)* ^^ 0.14 (0.05)*** 
     total wall thickness (µm) 0.75 (0.06) 0.57 (0.12)** ^^ 0.26 (0.09)*** 
     E/T-ratio 0.57 (0.11) 0.54 (0.11) 0.57 (0.09)  
Organ weights as permillage of total body weight. Means (SD). E/T-ratio, ratio between endometrium 
thickness and thickness of the total uterus wall. 
E100 or OVX versus PLC: *p<0.05; **p<0.01; ***p<0.001; #p<0.1. 
E100 versus OVX: ^p<0.05; ^^p<0.01; ^^^p<0.001; §p<0.1. 
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Figure 1 
Changes in nose-anus length gain in PLC, E100 and OVX during the experimental period. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
Growth plate samples from PLC, E100 and OVX. Notice the increase in total growth plate width in E100 
and OVX. 
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Effects on bone  
 
a. ‘Whole bone’ parameters 
Femur length was significantly increased in E100, but not in OVX, whereas tibia length was 
significantly higher in OVX only. Observed changes between groups in calcium density, total 
calcium, bone volume and anatomical volume did not reach statistical significance (table 3). 
 
b. Trabecular bone analysis 
As illustrated in table 4, a clear reduction of trabecular number and trabecular thickness was 
apparent in both the epiphysis and the metaphysis of OVX and E100 as compared to PLC 
(p<0.05). Figure 3A shows the trabecular volume distribution of trabeculae with a given 
thickness, corrected for the bone volume that was studied in the epiphysis. Notice that the 
percentage of thin trabeculae (<5.0 pixels) was increased whereas the percentage of thick 
trabeculae (>5.0 pixels) was decreased in OVX and E100. A similar, but more pronounced effect 
on the distribution of trabecular thickness was observed in the metaphysis or primary 
ossification center (fig. 3B). As expected, the trabeculae in the metaphysis were thinner than in 
the epiphysis. 
 
Effect on ovaries and uterus 
 
E100 caused a statistically significant decrease of 50% of the ovary/TBW ratio (p=0.000). No 
statistically significant difference in the uterus/TBW-ratio was found, but the ratio was 
significantly decreased in OVX with 92% (p=0.000). Both endometrial thickness and the total 
thickness of the uterus wall were significantly decreased in E100 and OVX, resulting in normal 
endometrium thickness/total wall thickness ratios compared with PLC. 
Ovaries from placebo-treated controls contained follicles in various stages of development 
(fig.4A), including secondary follicles, mature Graafian follicles and corpora lutea, the latter 
confirming the occurrence of ovulation. Similar histological characteristics were seen in the 
ovaries of E10- and E30-treated rats (data not shown). The ovaries from the E100-treated group 
also showed different developmental stages of the follicle, but corpora lutea were absent  
and there were less mature follicles, demonstrating the absence of ovulation (fig. 4B). Instead, 
large cystic follicles, surrounded by a thin granulosa cell layer or no granulosa at all, were 
abundantly present.  
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Table 3. Whole bone parameters 
Parameter   PLC E100 OVX 
Va: anatomical volume (mm3) 277.8 (8.3) 287.3 (7.4) 279.2 (14.5) 
Vb: bone volume (mm3) 95.5 (4.4) 97.1 (5.1) 90.8 (5.1) 
Vb/Va-ratio (%) 34 34 33 
Total calcium 1.00 0.97 0.85 
Calcium density 1.00 0.89 0.85 
Means (SD). PLC was taken as a reference for calculating relative total calcium and relative calcium density. 
 
 
 
Table 4. Trabecular bone analysis 
Parameter     PLC E100 OVX 
Epiphysis      
   Trabecular bone volume mm3 25.6 (1.4) 22.4 (1.6)*^ 20.2 (1.8)* 
   Trabecular thickness µm 143.1 (1.0) 139.4 (2.3)* 139.6 (3.2)* 
   Trabecular number 1/mm 1.8 (0.0) 1.6 (0.2)* ^ 1.4 (0.1)* 
Metaphysis     
   Trabecular bone volume mm3 2.5 (0.4) 1.9 (0.3)* 1.8 (0.3)* 
   Trabecular thickness µm 85.1 (3.3) 75.9 (2.9)* 78.5 (3.1)* 
   Trabecular number 1/mm 3.6 (0.5) 3.0 (0.3)* 2.9 (0.4)* 
Trabecular bone volume is the volume taken by trabecular bone in the selected region of interest.  
Means (SD); *p<0.05 as compared to PLC; ^p<0.05 E100 versus OVX. 
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Figure 3 
(A) Normalized trabecular volume distribution in the secondary ossification center (epiphysis). Only the 
volume taken by bone tissue in the epiphysis is taken into account. Notice the increase of trabeculae <5.0 
pixels (pixel size = 27.64 µm). (B) Normalized trabecular volume distribution in the primary ossification 
center (metaphysis). Only the volume taken by bone tissue in the selected cylinder is taken into account. 
Notice the increase of trabeculae <5.0 pixels (pixel size = 13.82 µm). *p <0.05. 
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Figure 4 
Ovaries of PLC (A) and E100 (B); GF, mature Graafian follicle; CL, corpus luteum; C, cyst; OD, ovarian duct. 
Magnification 40×. Notice the presence of cysts and the absence of corpora lutea in E100. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Brain histology 
 
Histological examination of the brain was performed on slides of the hilus of the hippocampus 
area on E100 and placebo-treated animals to assess for possible neurodegenerative effects of 
the treatments. Since neurodegeneration is associated with gliosis, immunohistochemical 
staining for several glial markers was performed. There was no statistically significant difference 
in the surface area of GFAP immunoreactive astrocytes between groups. No reactive astrocytes 
or reactive microglia were detected after vimentin and OX-42 immunostaining, respectively. In 
addition, there was no qualitative evidence of neuronal loss or degeneration (data not shown). 
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Discussion 
 
The aims of this study were to investigate the effect of aromatase inhibition on growth 
parameters and to study potential side-effects of this treatment on organ weight development, 
bone, and brain morphology in sexually immature female rats. The main conclusion from this 
study is that the currently highest available dose of exemestane (100 mg/kg/week) partially 
inhibits aromatase activity, which causes only a marginal stimulation of length gain and 
appendicular growth, but also results in the appearance of multiple ovarian cysts and changes 
in bone architecture consistent with early stage osteopenia. 
All the currently available animal models for studying longitudinal growth are in some way 
flawed since they do not fully represent the hallmarks of human growth, such as an obvious 
growth spurt at the beginning and epiphyseal fusion with growth arrest at the end of puberty. 
These processes are both mediated by the exclusive action of estrogen, as illustrated by the 
clinical phenotype of estrogen resistant or deficient patients (6). Although rodents do not clearly 
demonstrate these maturational phenomena, growth diminishes after sexual maturation with 
growth rates approximating zero. Rats tend to respond in a similar fashion as humans to 
estrogen, with estrogen deficiency stimulating growth and estrogen treatment causing growth 
arrest (27). In contrast, estrogen receptor (α/β/αβ) and aromatase knockout mice show a 
normal adult length (28-32), indicating that hormonal regulation of growth in mice is distinctly 
different than in humans and rats. We therefore feel that the rat is the most appropriate of the 
available animal models for in vivo studies on the impact of chemically induced aromatase 
deficiency. 
To correlate the effects seen in our study to the degree of aromatase inhibition, it would have 
been valuable to assess serum levels of estradiol, testosterone, dihydrotestosterone (DHT), and 
exemestane. However, accurate methods for measurement of estradiol in rat serum are lacking 
(33). Available estradiol assays that are developed for analyzing human serum samples, are 
insufficiently sensitive for quantification of low estradiol levels (34). Treatment with exemestane 
even further complicates estradiol detection due to the fact that metabolites of the compound 
interfere with the available assays for measurement of gonadal steroids (35). To our knowledge, 
there is currently no laboratory experienced with estradiol serological measurements in 
exemestane-treated rats.  
Alternatively, we used the ovary, a highly estrogen-dependent organ, as a biological readout 
system for the effect of exemestane. The observed ovarian phenotype characterized by the 
absence of corpora lutea and the presence of multiple cysts is similar to the ovarian phenotypes 
of the aromatase knockout mouse (ArKO) (36) and female estrogen receptor alpha and beta 
knockout mice (αERKO and βERKO) (28). Moreover, aromatase deficient female patients also 
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have reproductive dysfunction based on primary amenorrhea and enlarged, polycystic ovaries in 
adolescence (6). The observed changes in ovarian morphology convincingly demonstrate that a 
reduction in estradiol levels was achieved by the administration of exemestane in our model 
system. 
Hyperandrogenism is likely to occur during treatment with aromatase inhibitors and may 
eventually lead to virilization, as reported in female patients with aromatase deficiency. In our 
study, exemestane treatment was applied short-term and was not expected to cause signs of 
hyperandrogenism. However, when considering a longer treatment period covering the period 
of sexual maturity, possible signs of virilization, such as masculine sexual behavior and 
disturbance of reproductive function, should be monitored during and after termination of 
treatment 
The growth phenotype of E100-treated female rats shows similarities with other described 
animal models for estrogen deficiency. An increased body weight gain was also observed in 
female αERKO and αβERKO mice, and female ArKO mice (29-31;37), corresponding with an 
increased deposition of intra-abdominal adipose tissue, high leptin and cholesterol levels, and 
hyperinsulinism (38). An elevated body mass index has not been described in female patients 
with aromatase deficiency, but this is probably due to the fact that they have received estrogen 
treatment. In the present study, fat deposition, food intake and energy expenditure were not 
measured. 
Nose-anus length gain in E100-treated rats was normal, but showed a trend towards a 
significant increase compared with non-treated controls. In female αERKO, βERKO, αβERKO 
and ArKO mice, adult length was found to be normal compared to wild-type mice (28-32). 
However, the βERKO mouse but has a tendency to slightly increased growth during the post-
pubertal phase (31), whereas female ArKO mice show an increased length gain peripubertally 
(29;30). E100 treatment resulted in a marginal increase of the length of the tibia (not 
significant). Surprisingly, femur length was found to be significantly higher in E100 compared 
with PLC, in the absence of a similar and more pronounced effect after OVX. All other 
parameters were more dramatically influenced by OVX than by E100, and we have no 
explanation for the contrasting effects of OVX and E100 on femur length. However, our 
knowledge of the timing and regulation of growth in various bones is limited, and has not been 
studied in detail. Regional differences may exist, and aromatase inhibition may therefore result 
in various degrees of growth stimulation in different bones. 
Increased appendicular growth was found in βERKO mice (31). In contrast, the other knockout 
mouse models either have normal or decreased growth of the femur and/or tibia (29-31). One 
must bear in mind that in our study exemestane was administered during a short timeframe, 
whereas inborn genetic mutations in knockout mice and human patients with estrogen 
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deficiency or resistance can influence growth during all stages of life, which may explain the 
differences in growth characteristics. 
The OVX group was included as a control group, to be able to compare the results of 
exemestane-induced and ovariectomy-induced estrogen deficiency. Ideally, there would be a 
complete absence of circulating estrogen in both E100 and OVX. However, the differences in 
several parameters between the groups suggest that E100 did not completely abrogate 
estrogen biosynthesis. OVX induced increased levels of IGF-I, as reported before in 
ovariectomized rats and mice in other studies (39;40). A raised IGF-I level was also found after 
E100-treatment, but this effect did not reach statistical significance. Estrogen normally causes 
thymus atrophy (41), which in our experiments was strongly prevented by OVX and to a lesser 
extent by E100 (not significant). Similarly, a reduced weight of the liver was found in OVX 
females, whereas no reduced liver weight was found in E100. Circulating high levels of 
androgen may have had protective effects on these tissues, either by direct effects on target 
organs or maybe in part by aromatization to estrogen by residual aromatase activity. Since the 
gonads are the only organs capable of synthesizing androgen precursors in the rat, ovariectomy 
results in a combined estrogen and androgen deficiency, ruling out protective effects by 
circulating androgen in the OVX group.  
E100 treatment had a similar, but less prominent effect on growth than OVX. The increase in 
nose-anus length gain in E100 was delayed compared with OVX, suggesting that at least one 
week is necessary to establish a steady-state plasma level of exemestane that is able to 
influence growth. The growth plate and the long bones of the appendicular skeleton seemed 
most sensitive to aromatase inhibition, resulting in effects similar to those seen after OVX. Axial 
skeletal growth was less stimulated by E100, compared with OVX. Differences in sensitivity for 
aromatase inhibition may reflect variability in local estrogen biosynthesis in various tissues 
resulting in different levels of aromatase inhibition. Second, some organs may be more 
accessible for exemestane penetration than others. Another possible explanation for the modest 
effect of E100 on longitudinal growth may be that the dosage was too low to achieve complete 
inhibition of aromatase activity at the systemic level or at the tissue level. However, preclinical 
studies have shown that a single subcutaneous dose of 30 mg/kg exemestane reduced ovarian 
aromatase activity in adult female rats with approximately 80% (E. di Salle, unpublished results). 
The absence of significant growth effects in E10 and E30 was presumably due to sub-
pharmacological serum levels of exemestane.  
Studies in mature, female rats have demonstrated that the steroidal aromatase inhibitor 
exemestane and its principal metabolite 17-hydroxyexemestane significantly prevent bone loss 
induced by OVX, based on androgenic actions of these compounds on bone. In contrast, the 
non-steroidal aromatase inhibitor letrozole, that has no structural relationship to androgens, 
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does not have such protective effects on bone in mature female rats (18;42). Analysis of the 
trabecular bone in both the epiphysis and metaphysis demonstrated a significant reduction in 
the number and thickness of trabeculae in E100 and OVX, associated with a non-significantly 
decreased calcium density in both groups. Loss of bone tissue is a sign of osteopenia, generally 
considered as the stadium preceding osteoporosis. Similarly, ArKO mice were found to have a 
decreased peak BMD, prominent osteopenia on plain film radiographs and decreased trabecular 
volume and thickness (29;30). A low BMD was also found in βERKO and αβERKO mice (31).  
In our study, the bone phenotypes of E100 and OVX were very similar. This suggests that there 
is no apparent bone-protecting androgenic effect of exemestane and its principal metabolite 
17-hydroxyexemestane in prepubertal rats treated for 3 weeks, in contrast to what was 
reported previously about mature rats treated for a period of 16 weeks (18;42). Exemestane 
was reported to have a very low binding affinity (0.22%) for the androgen receptor in vitro and 
a marginal androgenic activity (only 1% of that of testosterone propionate) in vivo in male 
castrated rats. Since androgen receptor expression is lower in the tibial epiphysis and 
metaphyseal bone in female rats compared to males, we expect the androgenic potency of 
exemestane in our model system to be even lower than 1% which makes pronounced 
androgenic effects of exemestane on growth unlikely. In line with this hypothesis is the fact that 
no protective androgenic effect of exemestane on bone quality was observed. The discrepancy 
between our study and the report by Goss et al. may be explained by the fact that during bone 
modeling that occurs in immature rats different regulatory pathways involving androgen 
signaling may play a role than during maintenance of bone quality in mature rats. 
It is not clear whether the osteoporotic changes observed would lead to a permanently worse 
bone quality. As the growing skeleton is in a constant process of bone modeling, it remains to 
be seen whether osteoporotic changes induced in this period would render the mature skeleton 
more vulnerable to osteoporotic fractures. Patients with P-450 aromatase deficiency or estrogen 
receptor mutation have a low bone mass, which may result from not having achieved a normal 
peak bone mass during childhood growth and development of the skeleton (43). Estradiol 
treatment in those patients induced an increase in BMD (6). 
The uterus/TBW ratio was decreased after OVX, but not significantly different after E100 
treatment, probably due to incomplete aromatase inhibition at the tissue level. Studies in 
mature cycling rats treated with letrozole also revealed a decreased uterine weight (44). In 
female patients, aromatase deficiency results in reproductive dysfunction based on primary 
amenorrhea and enlarged polycystic ovaries in adolescence (45), emphasizing the pivotal role of 
estrogen in ovarian development (46). Similarly, E100 reduced ovary weight and caused 
histological changes similar to those seen in polycystic ovary syndrome. It is unknown whether 
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the effects of temporary estrogen deficiency on the female gonadal tract are reversible and, if 
not, whether these changes have an impact on fertility or sexual behavior. 
In the mammalian nervous system, aromatase expression plays an important role in neural 
differentiation and plasticity, neuroendocrine functions, and (sexual) behavior (17), both under 
physiological and pathological conditions. We therefore have assessed whether aromatase 
inhibition affects morphology of the hippocampus, a brain area that is sensitive to estradiol 
levels (47). E100 did not result in reactive gliosis, one of the most prominent cellular responses 
of the central nervous system to neurodegeneration (48). This finding is in agreement with 
previous studies showing that adult ArKO mice have normal hippocampus morphology, 
although they are more susceptible to neurodegeneration than their wild-type littermates (49). 
Thus, although aromatase exerts a protective effect against neurodegenerative stimuli (50-52), 
its inhibition does not compromise neuronal survival under normal circumstances. However, we 
cannot exclude that aromatase inhibition may affect other brain regions, especially brain nuclei 
that develop during sexual maturation (e.g. the medial amygdala) (53).  
In summary, partial inhibition of aromatase activity by E100 resulted in marginal stimulation of 
axial and appendicular growth in female prepubertal rats. Although aromatase inhibition was 
probably incomplete, pronounced adverse effects were found on ovarian histology and bone 
architecture, and it remains unclear whether these would have long-term, permanent 
consequences for reproduction and fracture risk, respectively. Our finding that E100 stimulates 
growth, albeit marginally, mimics to a certain extent the clinical phenotype in aromatase 
deficient female patients who exhibit tall stature if untreated (54). Species differences in 
dependency on estrogen signaling probably underlie the discrepancies found in growth 
phenotype between the aromatase inhibitor treated rats and mice, and estrogen-deficient 
patients described in literature. However, considering the potential side-effects on bone 
physiology and morphology of the ovaries, treatment with aromatase inhibitors in girls in 
clinical practice should not be advised. 
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Abstract  
 
Background: Estrogen deficiency induced by aromatase inhibitors may be a novel treatment 
modality for growth enhancement in short children, but may have adverse effects on bone, 
brain and reproduction.  
Aim: To assess growth effects and potential adverse effects of aromatase inhibition in male 
rats.  
Methods: 26 days old prepubertal rats received intramuscular injections with placebo (PLC) or 
the aromatase inhibitor exemestane at a dose of 10, 30 or 100 mg/kg/week [E10, E30, E100(6)] 
for 6 weeks completely covering the sexual maturation phase, or with 3 weeks E100 followed 
by 3 weeks PLC [E100(3)]. Growth parameters and histology of the testis, seminal vesicle and 
brain were analyzed. Bone architecture was studied with X-ray microtomography.  
Results: Exemestane dose-dependently decreased body weight and tail length gain, and liver 
and seminal vesicle weights, but did not affect nose-anus length gain, growth plate width or 
radial growth. E100(6) decreased trabecular thickness (epiphysis and metaphysis) and number 
(metaphysis). Normal IGF-I levels and brain, testis and seminal vesicle morphology were 
observed. E100(3) resulted in decreased tail length gain only. 
Conclusion: Exemestane treatment during sexual maturation did not augment linear growth in 
male rats, but caused impaired body weight and tail length gain and osteopenia. 
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Introduction 
 
The phenotypes of estrogen resistance (1) and estrogen deficiency (1-4) are characterized by a 
lacking pubertal growth spurt, ongoing growth into adulthood and tall stature, demonstrating 
the crucial role of estrogens in skeletal growth and maturation in both genders (5-8). These 
clinical observations have led to the hypothesis that estrogen deficiency pharmaceutically 
induced by aromatase inhibitors may be a novel treatment modality for growth enhancement in 
children with idiopathic short stature (9;10).  
Our limited knowledge on the effects of aromatase inhibition on growth in boys is derived from 
one clinical trial in patients with idiopathic short stature (ISS) (11) and two trials in boys with 
constitutional delay of growth and puberty (CDGP) (12;13). Treatment with the nonsteroidal 
aromatase inhibitor letrozole (either or not combined with testosterone) resulted in an increased 
predicted adult height and near-final height, without apparent detrimental effects on bone 
mineralization (11-14). In growth hormone-deficient (GHD) patients treated with growth 
hormone (GH), co-treatment with the nonsteroidal aromatase inhibitor anastrozole led to an 
increased predicted adult height, but adult height results have not yet been published (15).  
The ubiquitous expression of aromatase in humans underscores the importance of locally 
produced estrogens (16) and implies that aromatase inhibition may have adverse effects as well. 
Male patients with congenital estrogen deficiency have been found to suffer from osteoporosis 
in adulthood (5). Since aromatase has an established neuroprotective function both under 
physiological and pathological conditions, aromatase inhibition may result in unwanted side-
effects on the brain and, as a result, on behavior (17). Finally, estrogen deficiency may result in 
disorders of the reproductive system.  
In this study, the effects of treatment with the steroidal, irreversible aromatase inhibitor 
exemestane (E) were analyzed in male rats during the phase of sexual maturation in order to 
test the hypothesis that aromatase inhibitors can increase growth and to evaluate potential 
side-effects. To mimic the potential treatment strategy in boys with ISS, exemestane treatment 
was initiated 4 days before the start of sexual maturation and lasted 6 weeks. This treatment 
regime covered the whole period of sexual maturation in rats 
We applied exemestane instead of other aromatase inhibitors. An important advantage of 
exemestane is that it is available as a slow release preparation that can be administered once a 
week, in contrast to other inhibitors that require daily dosing. Exemestane completely abolishes 
estrogen biosynthesis by irreversibly blocking aromatase, which can only be overcome by de 
novo aromatase synthesis. The continuous slow release of exemestane from the injected depot 
ensures that de novo aromatase synthesis is counteracted. In addition, exemestane may exert 
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androgenic effects on bone that may prevent the loss of bone mineral density (BMD) resulting 
from estrogen deficiency. We have previously established that exemestane effectively inhibited 
aromatase activity in female rats, resulting in a marginal growth increase, polycystic ovaries and 
a decreased bone quality (Van Gool et al., Horm Res, in press). The present study is the first 
detailed analysis of the impact and side effects of aromatase inhibition on growth in male rats. 
 
Experimental design 
 
Animals 
 
Weight-matched male Wistar rats (n=30), 26 days old and sexually immature, were purchased 
from Harlan. Animals were kept in a light and temperature controlled room (12 hours light, 20-
22°C) with water and food (Hope Farms) ad libitum and a maximum of 3 animals per cage. Rats 
enter sexual maturation at day 30 and the whole process is completed in 6 weeks. Experiments 
were approved by the Committee for the ethical care and use of laboratory animals of the 
Leiden University. 
Five groups of 6 rats were treated with placebo (PLC) or with the slow-release preparation 
exemestane (E) at three different doses: 10, 30 or 100 mg/kg body weight/week (coded as E10, 
E30, E100, respectively). E100(6) was treated for 6 weeks with E100, covering the complete 
period in which young male rats usually exhibit fast growth. E100(3) received E100 for 3 weeks, 
followed by 3 weeks of placebo. This treatment regimen covers only the first half of the period 
of sexual maturation in male rats. The two groups were included in order to determine whether 
short- or long-term aromatase inhibition would have the most profound effect on growth. 
Exemestane (Aromasin®, provided by Pfizer) was administered once per week by intramuscular 
injections in alternated hind paws.  
Nose-anus length, tail length and body weight were measured weekly. At the end of the 
experimental period, animals were anaesthetized by intraperitoneal Nembutal injection and 
blood samples were collected by cardiac puncture. Serum was separated for insulin-like growth 
factor I (IGF-I) measurements. Femora were collected for X-ray microtomography (micro-CT). 
Subsequent in vivo fixation was performed by transcardiac perfusion with 4% 
paraformaldehyde and 0.2% glutaraldehyde in 0.1 M phosphate buffer with 75 mM lysine 
monohydrochloride and 10 mM Na-periodate. After fixation, rats were decapitated, and brains 
were stored in the same fixative for at least 12 weeks. Tibiae of the right hind legs were 
measured, postfixated for 24 hours, decalcified in 12.5 % EDTA, pH 7.4 for 4 weeks, cut in 
Aromatase inhibition in male rats 
 
115 
 
halves in a sagittal orientation and processed for paraffin embedding. Testis and seminal vesicle 
were weighed and processed for paraffin embedding.  
 
Growth plate histomorphometry 
 
Paraffin sections (5 µm) perpendicular to the growth plate axis were mounted on 
APES/glutaraldehyde-coated slides, deparaffinized in Paraclear® and graded ethanols, stained 
with Hematoxylin/Eosin and mounted in Histomount (National Diagnostics). A Nikon DXM 1200 
digital camera was used for photographing the proximal tibial growth plate. Widths of the total 
growth plate, proliferative zone and hypertrophic zone were measured in ImagePro Plus.  
 
X-ray microtomography (micro-CT) 
 
To examine the effects of exemestane treatment on whole bone parameters and on trabecular 
bone in particular, right femora of PLC, E100(3) and E100(6) were analyzed by high resolution 
X-ray microtomography. Micro-CT has been shown to be well suited for the non-destructive 
visualization and quantitative analysis of bone and calcified tissue (18;19). 
 
a. ‘Whole bone’ parameters 
Isolated whole femora were scanned with a high resolution desktop micro-CT scanner ((7); 
Skyscan 1076). In this X-ray micro-CT system, both the X-ray source (focal spot size 5 µm, 
energy range 40-100 keV) and the detector (CCD camera 2.3kx4k) rotate around the bone. 
Scans were isotropic and a voxel size of 35×35×35 µm was chosen with 1.0 mm A1 filter. 
Virtual cross-sections were reconstructed by Feldkamp cone beam algorithm (20). Further 
technical details about the scanner have been published elsewhere (21). 
The same threshold and reconstruction parameters were used for the reconstruction of all 
cross-sections. Frequency distribution of the grey levels was analyzed. 3D models were created 
using Skyscan software packages ANT and CT Analyzer. From the virtual cross-sections the 
volumes taken by bone as well as the anatomical volume (Archimedean volume) were 
calculated. Distinction between bone and other tissues was based on thresholding of the grey 
values in the reconstruction. Analysis of the grey values according to previously reported 
calculations (35) resulted in a relative value for total calcium and overall calcium density. Details 
of these calculations have been reported previously (18). In addition, the length of the femora 
was measured. 
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b. Trabecular bone 
For analysis of the trabecular bone, the distal end of the femur was scanned, but for this 
purpose at a higher resolution than required for the ‘whole bone’ scans. Therefore, an in vitro 
desktop micro-CT system (Skyscan 1072) with a rotating stage was used (22). Polychromatic X-
rays with peak energy of 80 kV were generated by a microfocus X-ray source with a focal spot 
size of 8 microns. A (1024×1024) 12 bit CCD camera was used as detector. The rotation step 
was 0.9°, acquisition time 6 s/projection, and total acquisition time about 2 hours. Scanning 
was isotropic with a voxel size of 13.28 µm3.  
The growth plate was chosen as a reference for selecting comparable and reproducible regions 
of interest for analysis of trabecular number, trabecular thickness, bone volume and distribution 
of trabecular thickness. Two different regions of the femur were analyzed: the metaphysis 
(primary ossification center) and the epiphysis (secondary ossification center). For analysis of the 
primary ossification center at the proximal side of the growth plate, a transverse reference slice 
of the growth plate was selected and used to reconstruct a cylinder with fixed dimensions as 
from 50 slices above the reference slice. The base of the cylinder was a circle and the height 
was 150 slices. 
 
Gonadal histology 
 
Midsagittal sections of the testis and seminal vesicle (5 µm) were stained with 
Haematoxylin/Eosin. A minimum of three sections was analyzed per organ.  
 
Brain histology 
 
Brains were rinsed with PBS, cut in coronal sections (30 µm) in a Vibratome and Nissl-stained 
with toluidine blue for morphometric analysis. Immunohistochemical staining of astrocytes 
(anti-GFAP, Glial Fibrillary Acidic Protein, DAKO, dilution 1:1000), microglia (OX-42, Serotec, 
dilution 1:300) and reactive astrocytes (anti-vimentin, clone V9, DAKO, dilution 1:500) was 
performed. For morphometric analysis of GFAP immunoreactive astroglia, quantitative 
evaluation of the surface density of GFAP immunoreactive cell bodies and cell processes in the 
hippocampus was performed using a stereological grid, according to the point-counting 
method of Weibel (23). A minimum of two slides was evaluated per animal.  
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Insulin-like Growth Factor I (IGF-I) assay 
 
Total serum IGF-I levels were measured by specific radioimmunoassay (RIA) after acid Sep-Pak 
C18 (Waters Associates) extraction of 250 µl aliquots, as described previously (24). 
 
Statistical analysis  
 
The study was designed to analyze the effect of exemestane on growth and to assess potential 
adverse effects on bone, brain and organ development. Comparisons between treatment and 
control groups were made using one-way analysis of variance (ANOVA). Results are expressed 
as mean and SD. The significance level was set at 0.05. 
 
Results 
 
Effects on growth and organs 
 
At baseline, there were no significant differences between groups in growth parameters. Body 
weight gain, nose-anus and tail length gain, tibia length, growth plate characteristics, and IGF-I 
levels are summarized in table 1. The effects of exemestane on organ weights are summarized 
in table 2. Figure 1 shows body weight, nose-anus length, and tail length gain for all groups. 
Previous experiments in female rats demonstrated that 3 weeks treatment with E100 effectively 
inhibited aromatase activity, using ovarian development as a bioassay. Treatment with E100 
induced polycystic polycystic ovarian syndrome-like features generally known to be due to 
estrogen-deficiency (chapter 4). In male rats, exemestane treatment did not influence nose-anus 
length gain. When compared to PLC, the animals that received exemestane showed decreased 
gains of tail length and body weight in a dose-dependent manner, with E10 having a modest 
and E100(6) the most pronounced effect. At termination of the experimental period, body 
weight gain of E100(3) was similar as that of PLC. Exemestane treatment did not affect the 
lengths of tibia and femur, growth plate width or serum IGF-I levels. 
Both E100(3) and E100(6) caused a dose-dependent decrease of the liver/total body weight 
(TBW) ratio compared to PLC. A normal aspect of the livers was found during macroscopic 
evaluation. Only E100(6) resulted in a significantly reduced seminal vesicle/TBW ratio, but no 
apparent morphometrical anomalies were found in the testes or seminal vesicle as revealed by 
histological examination (data not shown). 
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Effects on bone  
 
a. ‘Whole bone’ parameters 
No differences were found in femur length, anatomical volume, bone volume, total calcium and 
calcium density between the groups (data not shown). 
 
 
 
 Table 1. Effect of aromatase inhibition on growth parameters and epiphyseal morphology 
Parameter   PLC E10 E30 E100(6) E100(3) 
Tail length gain (cm) 12.1 (0.9) 11.1 (0.2) ** 10.7 (0.5) *** 10.8 (0.5) *** 10.9 (0.3) ** 
Nose-anus length gain (cm) 9.7 (1.1) 9.7 (0.7) 9.6 (0.4) 9.2 (0.5) 9.7 (0.5) 
Body weight gain (g) 280.5 (17.9) 268.1 (5.8) 247.9 (14.6)** 236.5 (18.0) *** 268.8 (19.1) 
Tibia length (mm) 38.3 (0.9) 38.2 (0.3) 37.9 (0.5) 37.8 (0.7) 37.9 (0.7) 
Femur length (mm) 33.2 (0.4) ND ND 32.9 (0.3) 33.6 (0.4) 
Growth plate width (mm) 0.32 (0.02) ND ND 0.29 (0.03) 0.33 (0.02)^ 
     proliferative zone (mm) 0.18 (0.00) ND ND 0.16 (0.02)# 0.19 (0.01)§ 
     hypertrophic zone (mm) 0.14 (0.02) ND ND 0.13 (0.02) 0.14 (0.01) 
     P/H-ratio 1.29 (0.14) ND ND 1.23 (0.13) 1.33 (0.10) 
Serum IGF-I (ng/ml) 1.5 (0.1) 1.3 (0.3) 1.4 (0.2) 1.5 (0.6) 1.1 (0.1)# § 
Means (SD). ND, not determined; P/H-ratio, ratio between proliferative zone and hypertrophic 
zone.**p<0.01; ***p<0.001; #p<0.1 (compared to PLC). E100(3) versus E100(6): ^p<0.05; §p<0.1. 
 
 
 Table 2. Effect of aromatase inhibition on organ weights  
Parameter   PLC E10 E30 E100(6) E100(3) 
liver  48.2 (6.5) 41.7 (2.6)# 41.5 (7.4) # 38.8 (6.1)* 37.8 (6.2) ** 
thymus  1.5 (0.2) 1.8 (0.3) # 1.6 (0.4) 1.4 (0.2) 1.7 (0.2)§ 
kidney  4.0 (0.2) 3.6 (0.7) 4.0 (0.3) 3.8 (0.3) * 3.5 (0.6) 
testis  4.0 (0.9) 4.5 (0.1) 4.5 (0.2) # 3.7 (0.6) 4.1 (0.4) 
seminal vesicle 2.4 (0.4) 2.4 (0.3) 2.2 (0.2) 1.6 (0.2) *** 2.4 (0.3)^^^ 
Organ weights as permillage of total body weight. Means (SD). *p<0.05; **p<0.01; ***p<0.001; #p<0.1 
(compared to PLC). E100(3) versus E100(6): ^^^p<0.001; §p<0.1. 
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Figure 1 
Growth parameters (A) body weight gain, (B) nose-anus length gain, (C) tail length gain.  
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b. Trabecular bone analysis 
E100(6) caused a decline in trabecular thickness in the epiphysis and metaphysis (table 3). In the 
metaphysis, the number of trabeculae was also decreased. The percentage of small trabeculae 
was increased after three or six weeks of E100 treatment in both the epiphysis and metaphysis 
(<5.0 pixel and <7.0 pixel, respectively; figure 2). E100(3) exhibited a normal trabecular 
number, and a trabecular bone volume intermediate between those of PLC and E100(6) 
animals. 
 
Brain histology 
 
Gliosis, a hallmark sign of neurodegeneration, was not found in E100(6). The surface area of 
GFAP immunoreactive astrocytes was not different between groups and reactive astrocytes or 
reactive microglia were not detected. There was no qualitative evidence of neuronal loss or 
degeneration (data not shown) caused by exemestane treatment. 
 
 
 
Table 3. Trabecular bone analysis  
Parameter     PLC E100(6) E100(3) 
Epiphysis      
   Trabecular bone volume  mm3 48.4 (4.8) 41.0 (3.5)* 43.9 (2.3)  
   Trabecular thickness µm 189.1 (9.1) 178.3 (4.0) * 182.1 (5.0)  
   Trabecular number 1/mm 1.6 (0.3) 1.6 (0.3) 1.7 (0.2)  
Metaphysis      
   Trabecular bone volume  mm3 1.8 (0.2) 1.4 (0.2) * 1.8 (0.3)^  
   Trabecular thickness µm 84.9 (3.1) 81.9 (2.9) 80.6 (3.0) *  
   Trabecular number 1/mm 2.6 (0.2) 2.1 (0.2) * 2.6 (0.3)  
Volume of objects is the volume taken by bone tissue in the selected region of interest. Means (SD);  
* p<0.05 as compared to PLC; ^ p<0.05 E100(3) versus E100(6). 
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Figure 2  
(A) Normalized trabecular volume distribution in the secondary ossification center (epiphysis). Only the 
volume taken by bone tissue in the epiphysis is taken into account. Notice the increase of trabeculae <5.0 
pixels (pixel size= 27.64 µm) in E100(3) and E100(6). (B) Normalized trabecular volume distribution in the 
primary ossification center (metaphysis). Only the volume taken by bone tissue in the selected cylinder is 
taken into account. Notice the increase in trabeculae <7.0 pixels in E100(3) and E100(6) (pixel size= 13.82 
µm). *p <0.05.  
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Discussion 
 
The aims of this study were to analyze the effect of aromatase inhibition on growth parameters 
during the phase of sexual maturation in male rats and to assess potential side-effects of this 
treatment on organ weight development, bone, and brain morphology. The main conclusion 
from this study is that exemestane treatment decreased tail length and body weight gain, but 
also caused alterations in bone architecture that usually occur in early stage osteopenia. 
Human growth is characterized by an evident pubertal growth spurt and growth plate fusion at 
the end of puberty. The clinical phenotype of estrogen-resistant or -deficient patients illustrates 
that these characteristic features are mediated by the exclusive action of estrogen (25). In 
contrast, the adult length of estrogen receptor knockout mice is normal, demonstrating a clear 
difference in hormonal regulation of growth between humans and mice (26-30). For this study, 
the rat was chosen as an animal model. Although rats do not show a clear growth spurt and 
lack epiphyseal fusion, their response to estrogen is similar as in humans, with estrogen 
deficiency stimulating growth and estrogen treatment causing growth arrest (31). We therefore 
feel that the rat is the most valid of all available animal models for in vivo studies on the impact 
of chemically induced aromatase deficiency. 
Serological determination of estradiol levels would have contributed to the interpretation of the 
effects of exemestane on growth. However, estradiol levels in male rats are very low, and 
expected to be even lower during treatment with an aromatase inhibitor. The available estradiol 
assays have been developed for analyzing human serum and are not sufficiently sensitive for 
quantification of such low levels of estradiol (32). Exemestane treatment further complicates 
estradiol detection, because the compound and its metabolites interfere with the available 
assays (33). To our knowledge, there is currently no laboratory experienced with estradiol 
serological measurements in exemestane-treated rats.  
As an alternative to serological evidence, we have demonstrated the effectiveness of 
exemestane to inhibit aromatase activity in a previous study in female rats (chapter 4) which 
normally have high serum levels of estrogen during the sexual maturation phase. In this model 
we used ovarian development as a bioassay for aromatase inhibition. Exemestane at a dose of 
100 mg/kg/week resulted in a pronounced decrease of ovarian weight and histological evidence 
of anovulation and polycystic ovarian syndrome-like features commonly seen in estrogen 
deficiency. The effects on ovarian development were comparable to ovariectomy letting us 
conclude that E100 resulted in a near complete inhibition of the aromatization of androgens. 
Since estrogen biosynthesis is significantly lower in male than in female rats, exemestane is 
expected to inhibit aromatase activity even more effectively in males. 
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In contrast with our hypothesis, exemestane treatment did not result in increased linear growth. 
Instead, although the decreases in nose-anus length gain and appendicular growth did not 
reach statistical significance, a smaller increment in body weight and tail length gain was found 
in exemestane-treated rats compared with PLC. Our results are in line with previous reports. 
Treatment of 6 weeks old male rats with the nonsteroidal aromatase inhibitor vorozole resulted 
in a decreased body weight gain and bone mineral density (BMD) but had no effect on femoral 
length (34). Four weeks old male rats treated with the selective estrogen receptor modulator 
(SERM) tamoxifen led to a declined body weight, nose-anus length, tibial and femoral length, 
and trabecular BMD (35). Similarly, the growth phenotype of male aromatase knockout (ArKO) 
mice and estrogen receptor alpha (ERα) and ERαβ knockout mice are characterized by a lower 
body weight and retarded axial and radial growth (29;30;36). In contrast with our results and 
the other animal models of estrogen deficiency or resistance, peripubertal letrozole-treated 
mice were found to display increased growth (37), which may be attributed to species 
differences and differences between the aromatase inhibitors employed.  
Exemestane has a very low binding affinity for the androgen receptor in vitro (0.22%) and a 
marginal androgenic activity in vivo as demonstrated in castrated male rats (1% of the activity 
of testosterone propionate) (38). It is unlikely that such marginal effects may explain the growth 
inhibition observed. The serum levels of IGF-I were normal during exemestane treatment, 
suggesting that the observed effects on growth were not mediated systemically through the 
GH/IGF-I axis. This observation is in line with the normal IGF-I level reported in a male 
aromatase-deficient patient (2). 
The effects of exemestane treatment appeared to be dose-dependent, E100(6) having the most 
pronounced impact on growth. E100(3) rats showed a growth phenotype intermediate 
between those of E100(6) and PLC animals. This could mean that the treatment period of 3 
weeks was too short to cause significant effects on growth or that potential exemestane-
induced changes already had been undone during the 3 weeks follow-up phase without 
treatment. Likewise, Karimian et al. described a complete catch-up growth of body weight 
when the rats were allowed to recover after cessation of tamoxifen treatment, whereas the 
femora and tibia remained shorter than in untreated controls (35). The smaller body weight 
increment of exemestane-treated rats compared to PLC in our study is consistent with findings 
in male rats treated with other aromatase inhibitors or with Tamoxifen (34;35;39). A lower food 
intake or a decreased visceral fat mass have been suggested as possible explanations for the 
lower weight gain in those studies, but these aspects were not analyzed in our study. 
Analysis of the trabecular bone of E100(6) rats demonstrated a significant loss of bone tissue 
that is generally considered as an early stage of osteoporosis. Impaired skeletal development 
 Chapter 5 
 
124 
 
and a decreased bone mineral density were also reported in male letrozole-treated rats (34;40) 
and in tamoxifen-treated rats (35). Similarly, male patients with P-450 aromatase deficiency or 
estrogen receptor mutations have a low bone mass, probably because they do not achieve a 
normal peak bone mass during childhood. Moreover, Coleman et al. reported on the skeletal 
effects of exemestane treatment in bone quality in postmenopausal women with a status after 
complete resection of unilateral breast carcinoma, who were disease-free after 2-3 years of 
tamoxifen treatment and who were randomly assigned to continue tamoxifen treatment or to 
receive additional exemestane treatment to complete a total of 5 years of adjuvant endocrine 
treatment. Two years of exemestane treatment was found to result in a 4% lower lumbar spine 
BMD and higher levels of bone turnover markers (41). It is unknown whether the observed 
osteoporotic changes in our study would render the mature skeleton vulnerable to osteoporotic 
fractures later in life, or whether these changes are reversible. 
Impaired liver function has been described in aromatase-deficient males (25), with a wide range 
of symptoms including variable degrees of impaired glucose tolerance, hyperinsulinemia, 
dyslipidemia and nonalcoholic hepatosteatosis. Those symptoms can be reversed by estradiol 
treatment (42;43). In our study, estrogen deprivation by exemestane treatment resulted in a 
dose-dependent decrease of the liver/TBW ratio, which confirms literature reports showing that 
the liver is a target organ for estrogen signaling (44;45). This effect seems to be rather 
persistent since in the E100(3) rats the liver/TBW ratio did not normalize, but 3 weeks may have 
been too short to allow for a complete recovery of liver weight. Karimian et al. also reported a 
reduced liver weight, without signs of hepatotoxicity in tamoxifen-treated rats (35). The 
physiological consequences of liver weight reduction in exemestane-treated rats remain 
unknown, as liver function was not assessed in this study.  
Exemestane caused a dose-dependent decrease of the seminal vesicle/TBW ratio, but had no 
effect on the testis/TBW ratio. E100(3) did not influence seminal vesicle weights. ERα and ERβ 
expression and aromatase activity have been demonstrated in the reproductive tract of the male 
rat, implying that estrogen bioactivity is regulated, at least in part, locally (46;47). Our results 
are not compatible with the increased testis/TBW ratio and normal to increased seminal 
vesicle/TBW ratio described in adult male anastrozole-treated rats (44). Differences in age of the 
animals, type and pharmacokinetic properties of the applied aromatase inhibitor, and route of 
administration may explain the discrepancies. Our results are also in contrast with the normal 
reproductive tract in male ERβ knockout mice (48) and in aromatase knockout (ArKO) mice 
(49). There may be species differences in dependency of the reproductive tract on estrogen. The 
reproductive function was not analyzed in this study and therefore, the consequence of a 
reduced seminal vesicle weight remains unclear.  
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Male patients with aromatase deficiency show a variable degree of decreased fertility (25). 
Testis biopsies of an aromatase-deficient patient have revealed a normal aspect of testicular 
morphology, with signs of impaired spermatogenesis (43). Semen analysis in another 
aromatase-deficient patient also identified mild impairment of spermatogenesis (42), which may 
explain subfertility in these patients. In our rats, a normal testicular morphology was found, but 
semen analysis was not performed and reproductive disorders based on abnormal 
spermatogenesis cannot be excluded. Whether discontinuation of treatment reverses such 
abnormalities remains uncertain. Estrogen replacement in an aromatase-deficient patient did 
not result in normalization of spermatogenesis (42). Since obesity was very prominent in this 
patient both before and during estrogen replacement (BMI 29.3 and 32.0, respectively), 
reproductive disorders may also be secondary to overweight. 
Aromatase expression plays an important role in the mammalian nervous system in neural 
differentiation and plasticity, neuroendocrine functions and sexual behavior (17). It was found 
to be upregulated and neuroprotective after a neurotoxic or mechanical lesion in the rat and 
mouse brain (50-52). In our study, no signs of neurodegeneration were observed in the 
hippocampus, a brain area that is sensitive to estradiol levels throughout the brain (53). This is 
in agreement with the normal hippocampal morphology in young, adult ArKO mice. We cannot 
exclude that aromatase inhibition may affect brain nuclei that develop during sexual maturation 
(e.g. the medial amygdala) (54). Moreover, aromatase inhibitor-treated rats may be more 
susceptible to neurodegeneration, as was reported for adult ArKO mice (55). Those mice also 
showed aberrant sexual behavior, which could be reversed by estrogen supplementation (56). 
In our study, sexual behavior was not studied. 
The results of our study contrast with the increased predicted adult height after aromatase 
inhibitor treatment of boys with ISS, CDGP or GHD (11;13;15). Moreover, male patients with 
aromatase deficiency or estrogen resistance show a growth phenotype characterized by 
absence of a pubertal growth spurt, ongoing growth into adulthood, and absence of 
epiphyseal fusion, resulting in tall stature (25). Presumably, there are marked species differences 
in the influence of estrogens on longitudinal growth regulation. 
The effects of aromatase inhibition by exemestane in the male rats in this study are distinctly 
different from those observed previously in female rats. The phenotype of the female 
exemestane-treated rats mimicked the clinical phenotype of aromatase-deficient female 
patients characterized by augmented growth. In contrast, the male rats in this study showed 
growth stagnation, whereas male aromatase-deficient patients exhibit a tall adult stature. 
Although the experimental designs applied in both studies were not completely identical, the 
distinct discrepancies allow us to conclude that marked gender differences in growth response 
to aromatase inhibition occur. The osteoporotic changes observed in both male and female rats 
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demonstrate that estrogen is important in the maintenance of bone quality in both genders. 
We conclude that six weeks of aromatase inhibition by the steroidal aromatase inhibitor 
exemestane in male rats causes retardation of tail growth and body weight gain, but has no 
significant effect on nose-anus length gain or appendicular growth. The adverse effect of 
treatment on bone quality was prominent, but long-term consequences for bone health and 
fracture risk remain unclear. The contrasting growth phenotypes of male exemestane-treated 
rats and human patients with estrogen deficiency or resistance indicate that a species difference 
in the role of estrogen signaling in growth regulation exists. Therefore, extrapolation of our 
results to clinical practice does not seem justified.  
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Abstract 
  
Background: Most studies on growth plate (GP) maturation and fusion have been carried out 
in animal models not fully representing the human epiphyseal GP.  
Aims and methods: We used human fetal bone marrow-derived mesenchymal stem cells 
(hfMSCs) differentiating towards chondrocytes as an alternative model for the human GP. Our 
aims were to assess whether chondrocytes derived from hfMSCs are a suitable model for the 
GP and to study gene expression patterns associated with chondrogenic differentiation. 
Results: hfMSCs efficiently formed hyaline cartilage in a pellet culture in the presence of TGFβ3 
and BMP6. Microarray and principal component analysis were applied to study gene expression 
profiles during chondrogenic differentiation. A set of 315 genes was found to correlate with in 
vitro cartilage formation. Several identified genes are known to be involved in cartilage 
formation and validate the robustness of the differentiating hfMSC model. Other genes like 
Bradykinin and IFN-γ signaling, CCL20, and KIT were not described in association with 
chondrogenesis before. KEGG pathway analysis using the 315 genes revealed 9 significant 
signaling pathways correlated with cartilage formation. 
To determine which type of hyaline cartilage was formed, we compared the gene expression 
profile of differentiating hfMSCs with previously established expression profiles of human 
articular (AC) and epiphyseal GP cartilage. As differentiation towards chondrocytes proceeds, 
hfMSCs gradually obtain a gene expression profile resembling epiphyseal GP cartilage, but not 
AC.  
Conclusion: This study validates differentiating bone marrow-derived hfMSCs as an alternative 
model for the human epiphyseal GP.  
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 Introduction 
 
Growth of the long bones is the result of a tightly orchestrated proliferation and differentiation 
program called endochondral ossification. In the epiphyseal growth plate of long bones, 
chondrocytes originating from mesenchymal stem cells subsequently undergo proliferation, 
hypertrophic differentiation, and programmed cell death before being replaced by bone. At the 
time of sexual maturation, growth first increases but at the end of puberty epiphyseal fusion 
and termination of growth occur. Our knowledge on the molecular mechanisms underlying 
human growth regulation during puberty is limited, although estrogen has been identified as a 
key regulator of growth plate maturation and fusion (1). Gaining a detailed understanding of 
growth regulatory processes is essential to facilitate the development of novel strategies for the 
treatment of various growth disorders. 
Commonly used animal models for studying growth plate regulation do not fully represent the 
human epiphyseal growth plate. For example, rodent growth plates do not fuse at the end of 
sexual maturation (2), and therefore do not display an important hallmark of human growth 
plate development. The shortcoming of the mouse model is furthermore demonstrated by the 
contrast between the marginally affected growth phenotype of the estrogen receptor alpha 
(ERα) knock out mouse (αERKO) (3) and the prominent growth phenotype of a male patient 
lacking functional ERα (4), which is characterized by the absence of epiphyseal fusion and 
continuation of growth into adulthood. 
The lack of representative animal models has led to the realization that alternative human 
models are essential to elucidate the mechanisms involved in growth plate regulation and 
fusion. However, human growth plate specimens are difficult to obtain, whereas in vitro models 
such as chondrosarcoma cell lines or articular cartilage-derived chondrocyte cultures have 
limited differentiation capacity, are often difficult to maintain under laboratory conditions or 
tend to dedifferentiate. Furthermore, articular cartilage and growth plate cartilage have distinct 
functions and it is therefore questionable whether articular cartilage-derived chondrocytes are 
representative for epiphyseal growth plate chondrocytes.  
Multipotent human mesenchymal stem cells (hMSCs) are a promising in vitro model to study 
chondrogenesis. They have been postulated as an alternative cell source for articular cartilage 
reconstruction and for studying endochondral ossification as it occurs in the epiphyseal growth 
plate (5). In this study, we explored the cartilage forming capacity of human fetal (hf)MSCs 
aiming at the development of an in vitro model for the human growth plate. We have chosen 
human fetal bone marrow-derived MSC for their superior differentiation characteristics 
compared to adult bone marrow-derived MSCs (6). Efficient cartilage formation was 
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demonstrated by immunohistochemical analysis and gene expression profiling was applied to 
identify genetic pathways involved in the differentiation process. In addition, the gene 
expression profiles of the differentiating hfMSCs were compared with global gene expression 
patterns of human articular and growth plate cartilage to assess whether differentiating 
hfMSCs represent either articular or growth plate chondrocytes.  
 
Experimental Procedures 
 
Cell culture 
 
The use of human fetal material was approved by the medical ethical committee of the Leiden 
University Medical Center and an informed consent was obtained from the women undergoing 
elective abortion. Cell suspensions of fetal bone marrow were obtained by flushing the long 
bones of fetuses with M199 washing medium. For the chondrogenic differentiation and 
microarray analysis, cells derived from a single 22 weeks old fetus were used. MSCs derived 
from other fetuses were also stimulated to undergo chondrogenic differentiation. Red cells 
were depleted by incubation for 10 minutes in NH4Cl (8.4 g/L)/KHCO3 (1g /L) buffer at 4°C. 
Mononuclear cells were plated at a density of 16×104 cells/cm² in M199 culture medium 
(Gibco) supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptavidin (P/S), 
fungizone, endothelial cell growth factor (ECGF) 20 µg/ml (Roche Diagnostics) and heparin 8 
U/ml in culture flasks coated with 1% gelatin according to previously established culture 
conditions for human fetal MSCs (7). Cultures were kept in a humidified atmosphere at 37°C 
with 5% CO2. The culture medium was changed twice per week. After reaching near-
confluence at passage 4 to 5 (15 population doublings), hfMSCs were harvested by treatment 
with 0.5 % trypsin and 0.5% ethylene diamine tetra acetic acid (EDTA; Gibco) for 5 minutes at 
37°C and replated for chondrogenic differentiation.  
In vitro chondrogenic differentiation 
 
hfMSCs (2×105 cells/well) were cultured in cell pellets. Pellets were formed by centrifugation of 
the cells at 1200 rpm for 4 minutes in U-shaped 96-well suspension culture plates (Greiner). To 
induce chondrogenesis the pellets were cultured at 37°C with 5% CO2 in 200 µl of serum-free 
chondrogenic medium consisting of high-glucose (25 mM) Dulbecco’s modified Eagle’s medium 
(DMEM; Gibco) supplemented with 40 µg/ml proline (Sigma), 100 µg/ml sodium pyruvate 
(Sigma, USA), 50 mg/ml ITS (insulin-transferrin-selenic acid) with Premix (BD Biosciences), 1% 
Glutamax (Gibco), 1% penicillin/streptavidin, 50 µg/ml ascorbate-2-phosphate (Sigma), 10-7 M 
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dexamethasone (Sigma), 10 ng/ml transforming growth factor-β3 (TGF-β3; R&D Systems), 500 
ng/ml bone morphogenetic protein 6 (BMP6) and antibiotic and antimycotic mix (0.06% 
polymixin, 0.2% kanamycin, 0.2% penicillin, 0.2% streptavidin, 0.02% nystatin and 0.5% 
amfotericin essentially as described by Sekiya et al., 2001. The medium was changed twice per 
week for 5 weeks.  
 
Histological analysis 
 
Two pellets per time point (after 1, 2, 3, 4, or 5 weeks of chondrogenesis) were used for 
histological evaluation. Pellets were fixed in 10% formalin, dehydrated by treatment with 
graded ethanols and processed for paraffin embedding. 5 µm sections were cut using a 
Reichert Jung 2055 microtome (Leica). For each pellet, only the sections from exactly the center 
of the pellets were mounted on glass slides. Before histological (toluidine blue) or 
immunohistochemical staining, sections were deparaffinized in xylene, treated with graded 
ethanols followed by three washing steps with phosphate buffered saline (PBS).  
For immunofluorescence of collagen type II, sections were pre-treated with 10mM citric acid 
buffer (pH=6) for antigen retrieval. Sections were incubated with a collagen type II monoclonal 
antibody (clone 3HH1-F9, Abnova) at 1:100 dilution in 1% bovine serum albumine (BSA) /PBS 
buffer overnight at 4oC. After washing, sections were incubated with Alexa Fluor 488-Goat 
anti-Mouse IgG1 (Invitrogen, Molecular Probes, diluted 1:1000 in PBS/1% BSA) for 1 hour and 
protected from light. Sections were counterstained with DAPI and mounted with vectashield. 
For collagen type X immunohistochemistry, sections were preincubated with blocking buffer 
(1% H2O2 in 40% methanol, 60% tris buffered saline) twice for 15 minutes at room 
temperature, followed by overnight incubation at 4ºC with mouse monoclonal antibody against 
collagen type X in a 1:100 dilution (Quartett). Next, sections were incubated with the secondary 
antibody biotinylated rabbit-anti-mouse IgG (DAKO) in a 1:300 dilution, followed by incubation 
with horseradish-peroxidase-conjugated-streptavidine (Amersham Biosciences). Staining was 
visualized with 3-amino-9-ethylcarbazole substrate in 0.2 mg/ml acetate buffer (pH 5.2) with 
0.04% H2O2. After counterstaining with hematoxylin, the sections were mounted in Histomount 
(National Diagnostics). Pictures of the stained pellets were taken with a Nikon DXM 1200 digital 
camera using standardized settings. 
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RNA isolation  
 
Total RNA from 2·106 undifferentiated hfMSCs derived from the 22-weeks old fetus was 
extracted with Trizol (Invitrogen). After 1, 2, 3, 4, or 5 weeks of chondrogenesis, 60 pellets (per 
time point) were pooled and homogenized in 1ml 4M guanidine isothiocyanate solution 
(Sigma) and RNA was extracted according to the optimized method for RNA extraction from 
cartilage as described by Heinrichs et al. (8). The extracted total RNA was purified using the 
RNeasy kit according to recommendations of the manufacturer (Qiagen). 
 
Gene expression profiling 
 
High RNA quality was confirmed by capillary electrophoresis on an Agilent 2100 bioanalyzer 
(Agilent). Total RNA (100 ng) was amplified and labeled using the GeneChip Two-Cycle cDNA 
Synthesis Kit (Affymetrix) and the MEGAscript T7 Kit (Ambion). For gene expression profiling, 
labeled cRNA was hybridized in duplicate to Affymetrix Human Genome U133 PLUS 2.0 Array 
Genechips. All procedures were carried out according to the manufacturer’s recommendations. 
Raw data from Affymetrix CEL files were analyzed using SAS software package Microarray 
Solution version 1.3 (SAS Institute). Custom CDF version 10 with Entrez based gene definitions 
(9) was applied to map the probes to genes. Gene annotation was obtained using the 
Affymetrix NetAffx website (http://www.affymetrix.com/analysis/index.affx). Quality control, 
normalization and statistical modeling were performed by array group correlation, mixed model 
normalization and mixed model analysis respectively. The normalized expression values for each 
gene were standardized by linearly scaling the values across all samples of the time course to a 
mean of 0 with an SD of 1. Analysis of differential gene expression was based on log-linear 
mixed model of perfect matches (10). A false discovery rate of a=0.05 with Bonferroni-
correction for multiple testing was used to set the level of significance. The raw and normalized 
data are deposited in the Gene Expression Omnibus database (available at  
http://www.ncbi.nlm.nih.gov/geo). 
 
Microarray data analysis 
 
The statistical analysis of the microarray data was based on the normalized mean expression 
values per probe at 6 time points with 2 replications at each time point (12 observations per 
probe). In order to identify subgroups of probes with similar expression profiles over time, a 
principal component analysis (PCA) of the covariance matrix was carried out on the mean 
expression value for each probe at each time point. For each probe, factor scores for principal 
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components 1, 2 and 3 were obtained by regression analysis of the 12 array results (6 time 
points in duplicate) for that specific probe to those components. The first principal component 
corresponded with the general expression level during the whole experiment, whereas the 
second and third component corresponded with changes over time. Since our interest was to 
identify genes associated with the changes that occur during differentiation from stem cells 
towards chondrocytes, we focused our analysis on the second and third component. By 
construction, these factor scores had a mean of 0 with an SD of 1. Generally, the distribution 
over the factor scores showed a normal distribution with outliers. We used a cut-off of ±3.29 to 
select outlying probes. This cut-off would select 0.1% of the probes, if the factors scores would 
follow a pure normal distribution that could be expected if the data were pure noise. The 
presence of replications allowed us to assess the statistical significance of the factor scores and 
to remove probes that were not significant at the α=5% level.  
In a separate study we compared the gene expression profiles of human articular cartilage (AC) 
and epiphyseal growth plate (GP) cartilage. A set of 1818 significant differentially expressed 
genes was identified, that can be used to discriminate between the two hyaline cartilage 
subtypes (Leijten et al., manuscript in preparation). All AC (n=5) and GP (n=5) samples were 
derived from 9 to 17 year old female donors with no history of growth disorders. The gene 
expression profiles of the stem cells differentiating towards chondrocytes were compared with 
this list. Principal component analysis (PCA) with Pearson product-moment correlation was 
performed to compute correlations between the expression profiles. 
 
Pathway analysis 
 
Using sets of probes emerging from PCA, a search for relevant KEGG pathways was performed 
using the DAVID® Knowledgebase, a publicly available bioinformatics tool for functional 
annotation (http://david.abcc.ncifcrf.gov). 
 
Quantitative real-time polymerase chain reaction (qPCR) 
 
RNA was transcribed into cDNA using the First Strand cDNA Synthesis kit for qPCR (Roche 
Diagnostics) according to the manufacturer’s protocol. Specific primer sets (available on 
request) were designed to amplify aggrecan (ACAN), pannexin 3 (PANX3), epiphycan (EPYC), 
collagen type II (COL2), and type X (COL10), SRY-box 9 (SOX9), WNT11, lymphoid enhancer-
binding factor 1 (LEF1), Gremlin 1 (GREM1). β2-Microglobulin, and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) were used as housekeeping genes. Based on the microarray data, the 
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expression of these housekeeping genes was stable during differentiation of hfMSCs. In order 
to test donor inter-variation, differentiated MSCs isolated from other fetal donors were used for 
qPCR analysis as well.  
All PCR reactions were performed in triplicate with 5 ng cDNA and according to the 
manufacturer's protocol of the iQ™ SYBR® Green Kit (Biorad) in a final volume of 25 µl. The 
cDNA was amplified using the following thermal cycling conditions: one cycle at 50°C for 2 min 
and 95°C for 10 min, followed by 40 cycles of 15 s at 95°C and 1 min at 56°C using the mIQ 
Single-Color—Real-Time PCR System (BioRad Laboratories, Hercules, California, USA). 
Fluorescence spectra were recorded and the threshold cycle number (Ct) was calculated using 
the accompanying mIQ-software. For each time point mean Ct was calculated and from this 
value the fold difference in expression between undifferentiated hfMSCs and differentiating 
cells using the 2-∆∆Ct method was calculated essentially as described by Schmittgen and Livak, 
2008 using β2-Microglobulin as a reference. For visualization, this value was log-transformed. 
 
Results 
 
Chondrogenic differentiation by hfMSCs 
 
Evaluation of protein and mRNA expression 
 
Pellet cultures were used to induce chondrogenic differentiation of hfMSCs and samples were 
collected at 1, 2, 3, 4 and 5 weeks of culture. Immunohistological evaluation showed an 
increasing expression of cartilage markers with time and a gradual morphological change from 
stem cells to mature and hypertrophic chondrocytes (figure 1). The mean diameter of the pellets 
increased with time, as well as the amount of glycosaminoglycans, a major constituent of the 
cartilaginous extracellular matrix. Immunofluorescent staining for collagen type II demonstrated 
the presence of chondrocytes after 1 week of pellet culture. The expression of collagen type II 
increased over time. Hypertrophic chondrocytes were first detected after 3 weeks, as evidenced 
by immunohistochemical staining for collagen type X. These collagen type 10 positive cells were 
located in a discrete ring-like zone surrounded by collagen type 2 positive chondrocytes. In all 
stages of differentiation, the chondrogenic core of the pellets was surrounded by a thin layer of 
two to three undifferentiated cells (figure 1). 
From each time point RNA was isolated and subjected to microarray analysis. Changes in gene 
expression of a subset of genes consisting of both established marker genes for chondrogenesis 
and differentially expressed genes identified by microarray analysis were validated using qPCR 
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(figure 2). In concordance with the observations of immunohistological markers of 
chondrogenesis, microarray data and qPCR showed time-dependent increases in the expression 
of the cartilage markers collagen type II, and type X, SOX9, and aggrecan mRNA. To further 
extend this analysis, we randomly selected 7 genes (pannexin 3, epiphycan, WNT11, LEF1, 
gremlin 1, Dickkopf 1, matrilin) that showed marked regulation over time based on microarray 
analysis. Again, qPCR demonstrated a strong correlation between the expression patterns 
revealed by both techniques (results for 5 of these genes are shown in figure 2E-I), providing 
further support for the robustness of our dataset. Repeating the qPCR analysis using RNA 
isolated from other fetal donors of MSCs that were stimulated to undergo chondrogenic 
differentiation rendered similar gene expression patterns as observed in this study (data not 
shown). 
 
Principal component analysis and KEGG pathway analysis 
 
The sequential changes that occur during chondrogenic differentiation in the hfMSC model 
were studied with bioinformatics analysis of the microarray data. Using principal component 
analysis, three components were found to explain 99.6% of the variance within our dataset 
(figure 3.A). The factor loadings in figure 3.B show that component 1 describes a general level 
of gene expression, as expected. Component 2 shows to what extent gene expression changed 
with time during chondrogenic differentiation and  
Chapter 6 
 
144 
 
Figure 1 
Expression of (A) glycosaminoglycans visualized by toluidine blue staining, (B) collagen type II fluorescence, 
and (C) collagen type X immunohistochemistry (brown) during 5 weeks of chondrogenic differentiation of 
hfMSCs to chondrocytes. The top panel shows a magnification of the pellet cultures at week 1 and week 5 
stained by toluidin blue demonstrating the change in cell morphology and the deposition of the 
extracellular matrix. The insets in panel B show higher magnifications of collagen type II positive 
chondrocytes. 
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Figure 2 
Correlation between qPCR and microarray expression data for (A) aggrecan, (B) collagen II, (C) collagen X, 
(D) SOX9, (E) pannexin 3, (F) epiphycan, (G) WNT11, (H) LEF1, and (I) gremlin 1 during 5 weeks of 
chondrogenic differentiation of hfMSCs. qPCR data are expressed as delta delta CT values corrected for the 
housekeeping gene β2-microglobulin. The primary y-axis (left) indicates the qPCR results as normalized fold 
expression on a log-scale. The secondary y-axis (right) indicates the microarray analysis results as least 
square means (lsm). 
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Figure 3 
Gene selection based on principal component analysis. A) variance explained by components 1-6 from 
principal component analysis. B) principal components 1, 2, and 3 as expression profiles. C) selection of 
probes based on their factor 2 and 3 scores. D) scatterplot view of gene data in respect to their correlation 
(factor score) to prinicpal components 2 and 3. Subgroups 1, 2, 3, and 4 are represented by blue, green, 
yellow, and pink dots, respectively. Side-placed graphs depict the gene expression profiles for genes found 
in the four subgroups. 
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component 3 signifies whether there was an additional, short term elevation or dip in 
expression around 2 to 3 weeks of differentiation. Since components 2 and 3 were most likely 
to contain genes associated with the loss of stem cell characteristics or the gain of a 
chondrocyte phenotype, we focused on those components.  
Using the ±3.29 cut-off in combination with a 5% significance test, we distinguished four 
subgroups of probes. The precise definitions and the resulting numbers of these subgroups are 
given in figure 3.C. The scatter plot in figure 3.D illustrates that the numbers of probes in 
subgroups 1 and 2 are much larger than the 9 probes (0.05%) that would have been expected 
under purely random selection. Moreover, in these two subgroups nearly all probes in the first 
selection are significant at the 5% level, suggesting that the number of false discoveries in 
these two groups is quite small. More noise is presumably present in the smaller subgroups 3 
and 4 based on factor 3 scores. 
The profiles of the selected probes demonstrate that subgroup 1 containing the largest number 
of probes (n=146) describes a peak of expression on t0 followed by a decrease in expression 
thereafter. In contrast, the second largest subgroup of probes (n=105) in profile 2 demonstrates 
increasing expression levels from t0 onward. The smaller subgroups 3 and 4 demonstrate lower 
levels of expression with profile 3 (n=49) showing a short-term increase in expression at t1 
followed by decreases thereafter and profile 4 (n= 15) displaying a short-term expression dip 
between t1-t2.  
A total of 83 out of 315 probes could not be annotated and was discarded from further 
analysis. The remaining 232 probes that could be matched to genes (supplementary table 1) 
were used to identify 9 KEGG pathways that were significantly associated with chondrogenic 
differentiation and contained 39 genes. (figure 4). Some genes were present solely in one 
pathway (n= 23), but others were found in 2 (n= 6) or 3 (n= 10) pathways (table 1). Three 
functional groups of genes were recognized: 1) growth factor (GF) and GF-related genes; 2) 
genes associated with the extracellular matrix; and 3) genes associated with signal transduction, 
cell cycle, and cell survival. In supplementary table 2, we have listed the top hits of upregulated 
genes as identified by the microarray analysis at each time point compared to undifferentiated 
hfMSCs. 
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Figure 4 
KEGG signaling pathways significantly associated with chondrogenic differentiation of hfMSCs. For each 
pathway, genes showing the same distinct expression profile during 5 weeks of chondrogenic 
differentiation are depicted as groups. 
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Gene expression fingerprinting for cartilage subtype 
 
Histological and gene expression analyses showed that the differentiating hfMSCs acquire a 
hyaline cartilage phenotype. Two major types of hyaline cartilage can be distinguished, namely 
articular and epiphyseal cartilage. In order to serve as a model for the epiphyseal growth plate, 
differentiating hfMSCs should obtain a growth plate signature. To test this, we compared the 
expression profiles of the differentiating hfMSCs with previously established profiles of human 
articular and growth plate cartilage (AC and GP, respectively, Leijten et al., in preparation). In a 
three-dimensional schematic representation, samples of AC and GP plot in two different groups 
(figure 5). As expected, AC, GP, and undifferentiated hfMSCs (hMSC_t0) plotted as distinct 
entities in a three-dimensional space. As differentiation progressed, the expression profile of the 
hfMSCs changed, and the differentiating chondrocytes gradually acquired a fingerprint 
resembling GP, but not AC. This analysis demonstrated that the hfMSCs differentiating towards 
chondrocytes acquired a GP cartilage-like phenotype.  
 
Figure 5 
Three-dimensional overviews of gene expression data in respect to their correlation (factor score) to 
principal components 1, 2, and 3. Red dots, samples of articular cartilage; Green dots, samples of growth 
plates; Blue dots, differentiation time-range of hfMSCs (t0, undifferentiated hfMSCs; t5, mature 
chondrocytes). Dots indicate the mean factor score for all genes on the Affymetrix chip on the three 
principal components for one cartilage sample. Clouds represent the spread around the mean factor score 
in three dimensions.  
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Discussion 
 
The present study was conducted in order to determine whether fetal bone marrow-derived 
MSCs are a representative human model for studying processes taking place in the epiphyseal 
growth plate and to identify associated signaling pathways. It has been reported that human 
bone marrow-derived MSCs display a better chondrogenic differentiation capacity than those 
derived from other sources, with fetal being superior over adult MSCs (6). Consequently, it 
seems appropriate to use fetal bone marrow-derived MSCs as a model for chondrogenesis. 
However, fetal MSCs are not easily obtained, due to ethical and legal considerations, and as a 
consequence, adult bone marrow-derived MSCs have been used in many previous studies (11-
18).  
Chondrogenic differentiation occurred in our in vitro model, as illustrated by the progressive 
increase in expression of the chondrocyte markers collagen type II and X and the cartilaginous 
matrix constituent glycosaminoglycan over time. Interestingly, hypertrophic differentiation as 
evidenced by an increase in cell size and positive staining for collagen 10 was only observed in a 
discrete zone of the pellet which was surrounded at both sites by chondrocytes positive for 
collagen type 2. 
Further confirmation of chondrogenesis was obtained by analysis of mRNA expression of 
cartilage markers, which, in addition, also validated our microarray results. Similar gene 
expression patterns were obtained during chondrogenic differentiation of fetal MSCs derived 
from other donors. This suggested that the selected 22-weeks old fetal MSC-donor was 
representative for fetal bone marrow in general. 
Matrix mineralization was not observed after 5 weeks of differentiation, suggesting that the 
matrix was not ready for mineralization or that environmental stimuli necessary to induce this 
process were absent. 
Microarray analysis generated a multidimensional dataset of differentially expressed genes for 
each time point. Several methods for analyzing such complex data have been reported, many 
based on presence/absence analysis, which starts with the list of differentially expressed genes 
and applies a strict but arbitrary cut-off for differential expression of individual genes (13;18). 
Misinterpretation of the data can easily occur, since genes are assumed to be independent, 
whereas it is more likely that sets of correlated genes play a role in complex biological processes 
(19). Genes that are not considered differentially expressed, but that do play a role in important 
signaling pathways, may be wrongfully eliminated. Another analysis strategy applied by many 
groups is to report on a priori selected pathway(s) of interest, thereby disregarding the relative 
importance of this pathway in view of other potentially co-regulated or interacting pathways. 
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Alternatively, we have applied PCA with restrictive criteria as a statistical selection method for 
identification of gene expression profiles associated with the acquisition of chondrocyte 
characteristics or the loss of a stem cell phenotype. Since biological replicates were not included 
in this study, such a stringent approach was necessary in order to minimize potentially false-
positive results. 
The gene expression data generated with this analytic approach are consistent with previous 
reports on in vitro cartilage formation by adult mesenchymal stem cells. We therefore conclude 
that PCA is a suitable and unbiased analysis tool for data reduction in multidimensional and 
complex microarray experiments. Using this method, 232 genes were identified to be 
significantly associated with chondrogenic differentiation, 39 of which were present in 9 
significantly enriched KEGG pathways. These 39 genes could be classified in three major 
functional groups that are discussed in the following sections. 
 
Growth factor (GF) and GF-related genes 
 
Growth factors from the transforming growth factor β (TGF-β), Wnt, Hedgehog and VEGF 
families have been recognized as major regulators of endochondral bone formation in embryos 
and postnatally (20;21). Expression of some members of these families changed over time in 
our in vitro model suggesting their involvement in chondrocyte differentiation from fhMSCs.  
BMP2 and its downstream effector ID3 are upregulated early in differentiation consistent with 
previous reports on the importance of BMP signaling in chondrogenesis (22;23). Growth and 
differentiation factor 5 (GDF5), previous reported as stimulator of chondrocyte proliferation 
(24), was highly expressed at the earliest time point observed and downregulated thereafter. A 
similar expression profile was found for the BMP inhibitor follistatine (FST) that was previously 
shown to be expressed by proliferative, but not by hypertrophic chondrocytes (25). 
Previous in vitro studies have demonstrated that BMP2 interacts with Wnt and hedgehog family 
members and their downstream effectors, indicating that functional crosstalk between 
regulatory pathways occurs during chondrogenesis (23;26). Such interactions may have taken 
place in our in vitro model as well, since several genes out of the Wnt and Hedgehog family 
were affected during differentiation, e.g. WNT5a, WNT11, FZD2, WIF1 and IHH. IHH expression 
reached a maximum after 3 weeks of differentiation, a time point at which the first collagen 
type X positive hypertrophic chondrocytes were detected using immunohistochemistry. IHH is 
recognized as an important regulator of hypertrophic chondrocyte differentiation. 
The superfamily of cytokines was another major group of regulatory factors for which 
involvement in chondrogenesis was suggested. Several genes in this group were changing 
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significantly over time, e.g. CXCL12, CCL20, interferon-γ (IFN-γ), IFN-γ receptor IFNGR1, 
interferon-induced transmembrane protein 1 (IFITM1) and the cytokine RANKL (receptor 
activator for nuclear factor κ B ligand). To our knowledge a role for CCL20, IFITM1, IFN-γ and 
its receptor IFNGR1 in chondrogenesis has not been described before.  
Vascular endothelial growth factors (VEGF and VEGFC), originally described to promote 
epiphyseal vascularization prior to endochondral ossification, also regulate in vitro 
chondrogenesis (27-29). Both the expression of VEGF and VEGFC were significantly changing at 
early time points in our model.  
 
Genes associated with the extracellular matrix  
 
Progression of chondrogenic differentiation depends on the coordinated expression of ECM 
components and on cell-matrix interactions (20). Expression of several genes involved in focal 
adhesion, cell-matrix communication, ECM receptor interaction and matrix remodeling changed 
significantly over time in our in vitro model of chondrogenesis. 
The expression of cartilaginous ECM proteins, such as collagens (COL1A1, COL1A2, COL2A1, 
COL5A2, COL11A1), chondroadherin (CHAD), cartilage oligomeric matrix protein (COMP), 
secreted phosphoprotein 1 (osteopontin, SPP1), and fibronectin type III (FNDC1), was 
upregulated. Apart from a structural role in the extracellular matrix, FNDC1, SPP1 and CHAD 
also function as integrin ligands and regulate cell-matrix signaling by binding to the cell surface 
plasma membrane protein integrinT. Aggregation of integrins in focal adhesions is induced by 
activity of myosin light chain kinase (MLCK) (30). Upon ligand-integrin binding, signaling 
complexes are activated that mediate downstream effectors of integrin signaling such as 
phosphoinositide-3-kinase (PI3K) (31), thereby stimulating cell proliferation (32). We observed 
early downregulation of integrin signaling-related proteins such as PI3K and MLCK. 
Members of the complement and coagulation family of proteins were expressed during in vitro 
chondrogenic differentiation. Coagulation factor XIII (F13A1) expression was upregulated, while 
other genes like complement component I (C1R), urokinase-type plasminogen activator (PLAU) 
and bradykinin receptor B2 (BDKRB2) were downregulated during differentiation in our model. 
These proteins are associated with matrix mineralization (33-35) or matrix degradation in the 
growth plate (36-38).  
 
Genes associated with signal transduction, cell cycle, and cell survival 
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Based on differential expression, several genes involved in the regulation of cell survival and 
proliferation and signal transduction were identified in our in vitro model of chondrogenesis. 
Caveolin 1 (CAV1), a multifunctional scaffolding protein located at cell surface caveolae, 
regulates TGF, Wnt, cytokine and VEGF signaling by modulating their downstream signaling 
cascades such as the JAK/STAT, β-catenin/LEF1, MAPK/ERK and PI3K/AKT signaling pathways 
(39-42). The anti-apoptotic baculoviral IAP repeat containing 3 (BIRC3) gene has been shown to 
increase the survival of cultured human chondrocytes (43). Phosphoinositide-3-kinase (PI3K), 
proto-oncogene KIT, transcription factor JUN and FOS are all associated to the regulation of cell 
proliferation  (44;45). Expression of the nuclear envelope protein lamin B2 (LMNB2) was first 
upregulated and later in differentiation downregulated in our model. Constantinescu et al 
suggested a role for LMNB2 in suppressing differentiation of undifferentiated embryonic stem 
cells (46). 
 
Conclusion 
 
Many genes identified in this study were previously reported in association with 
chondrogenesis, validating the robustness of differentiating hfMSC as a model for cartilage 
formation. The implication of bradykinin and IFN-γ signaling, CCL20, and KIT are novel 
findings. Discrepancies between our results and reports by others may rely on differences 
between the source, and chondrogenic capacity of MSCs used, the experimental conditions for 
inducing chondrogenesis, and the gene expression analysis methods (13;14;17). Developmental 
genes essential for chondrogenic differentiation (e.g. SOX genes, IGF-I) were not identified, in 
line with other reports (15). Marginal changes in the expression of these genes may be 
sufficient for inducing major effects, but too subtle to be detected by most gene expression 
analysis methods, including PCA. Alternatively, changes occurring within the first days of 
differentiation may have been unnoticed due to the chosen time interval of analysis.  
This study has demonstrated for the first time that bone marrow-derived hfMSCs acquire an 
epiphyseal GP-, rather than an AC-like gene expression signature during differentiation towards 
chondrocytes. This conclusion is based on comparison of expression profiles of the 
differentiating hfMSCs with human growth plate cartilage and human articular cartilage. These 
findings confirm the growth plate-like nature of the differentiating fhMSCs, indicating its 
validity as an alternative model for the human epiphyseal growth plate. Although a native 
growth plate is present in rodent animal models, these growth plates are not fully 
representative for the human growth plate particularly in puberty. The in vitro model developed 
in this study can potentially be used as an alternative for animal models. It is readily accessible 
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for genetic manipulation and might be used for unraveling the molecular mechanisms 
underlying growth regulation in the human epiphyseal plate during puberty. As such it may find 
its use in the development of novel treatment strategies for various growth disorders aimed at 
intervening in growth plate maturation and fusion  
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Supplementary Table 1. List of genes selected with principal component analysis 
 
Affymetrix ID Gene code Gene title     
205856_at                        SLC14A1  solute carrier family 14 (urea transporter), member 1 (Kidd blood group)  
205911_at                        PTHR1  parathyroid hormone receptor 1  
219148_at                        PBK  PDZ binding kinase  
213182_x_at                      CDKN1C  cyclin-dependent kinase inhibitor 1C (p57, Kip2)  
206737_at                        WNT11  wingless-type MMTV integration site family, member 11  
203868_s_at                      VCAM1  vascular cell adhesion molecule 1  
218730_s_at                      OGN  osteoglycin (osteoinductive factor, mimecan)  
200665_s_at                      SPARC  secreted protein, acidic, cysteine-rich (osteonectin)   
223484_at                        C15orf48  chromosome 15 open reading frame 48   
206315_at                        CRLF1  cytokine receptor-like factor 1  
205497_at                        ZNF175  zinc finger protein 175  
204724_s_at                      COL9A3  collagen, type IX, alpha 3  
219410_at                        TMEM45A  transmembrane protein 45A  
218391_at                        SNF8  SNF8, ESCRT-II complex subunit, homolog (S. cerevisiae)  
210538_s_at                      BIRC3  baculoviral IAP repeat-containing 3  
201487_at                        CTSC  cathepsin C  
219134_at                        ELTD1  EGF, latrophilin and seven transmembrane domain containing 1 
212551_at                        CAP2  CAP, adenylate cyclase-associated protein 2 (yeast) 
206421_s_at                      SERPINB7  serpin peptidase inhibitor, clade B (ovalbumin), member 7  
219837_s_at                      CYTL1  cytokine-like 1  
210220_at                        FZD2  frizzled homolog 2 (Drosophila)  
207064_s_at                      AOC2  amine oxidase, copper containing 2 (retina-specific)  
218542_at                        CEP55   centrosomal protein 55kDa  
206423_at                        ANGPTL7  angiopoietin-like 7  
231227_at                        --- Transcribed locus, strongly similar to WNT-5A protein precursor    
229494_s_at                      CD63   CD63 molecule  
223734_at                        OSAP  ovary-specific acidic protein  
206614_at                        GDF5  growth differentiation factor 5 (cartilage-derived morphogenetic protein-1)  
205713_s_at                      COMP   cartilage oligomeric matrix protein  
230372_at                        --- Transcribed locus, PREDICTED: similar to hyaluronan synthase 2 [Pan troglodytes]  
1563724_at                       SACS  Spastic ataxia of Charlevoix-Saguenay (sacsin)  
203499_at                        EPHA2  EPH receptor A2  
1556499_s_at                     COL1A1   collagen, type I, alpha 1   
219230_at                        TMEM100   transmembrane protein 100  
206790_s_at                      NDUFB1   NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7kDa  
204825_at                        MELK  maternal embryonic leucine zipper kinase  
212565_at                        STK38L  serine/threonine kinase 38 like  
1554997_a_at                     PTGS2  prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase & cyclooxygenase)  
204894_s_at                      AOC3    amine oxidase, copper containing 3 (vascular adhesion protein 1)  
203886_s_at                      FBLN2  fibulin 2  
203153_at                        IFIT1  interferon-induced protein with tetratricopeptide repeats 1   
242517_at                        KISS1R    KISS1 receptor  
1552340_at                       SP7 Sp7 transcription factor  
203963_at                        CA12   carbonic anhydrase XII  
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1554950_at                       AGC1    aggrecan 1 (chondroitin sulfate proteoglycan 1, large aggregating proteoglycan) 
232451_at                        ---     MRNA; cDNA DKFZp564I0816 (from clone DKFZp564I0816)   
227705_at                        TCEAL7   transcription elongation factor A (SII)-like 7   
1570574_at                       GPR177   G protein-coupled receptor 177   
218273_s_at                      PPM2C   protein phosphatase 2C, magnesium-dependent, catalytic subunit       
224735_at                        CYBASC
    
cytochrome b, ascorbate dependent 3              
239787_at                        KCTD4    potassium channel tetramerisation domain containing 4          
226281_at                        DNER  delta-notch-like EGF repeat-containing transmembrane            
218839_at                        HEY1    hairy/enhancer-of-split related with YRPW motif 1      
214710_s_at                      CCNB1  cyclin B1  
231798_at                        NOG    Noggin   
204595_s_at                      STC1    stanniocalcin 1      
209189_at                        FOS   v-fos FBJ murine osteosarcoma viral oncogene homolog        
203297_s_at                      JARID2    Jumonji, AT rich interactive domain 2         
230137_at                        TMEM15
  
transmembrane protein 155                
208078_s_at                      SNF1LK   SNF1-like kinase 
217989_at                        DHRS8  dehydrogenase/reductase (SDR family) member 8     
229125_at                        ANKRD3
  
ankyrin repeat domain 38        
205141_at                        ANG  
 
angiogenin, ribonuclease, RNase A family, 5 
204712_at                       WIF1  WNT inhibitory factor 1   
1552960_at                       LRRC15   leucine rich repeat containing 15      
225155_at                        SNHG5   small nucleolar RNA host gene (non-protein coding) 5     
204351_at                        S100P  S100 calcium binding protein P  
1569372_at                       TUBB2B   Tubulin, beta 2B  
205097_at                        SLC26A2   solute carrier family 26 (sulfate transporter), member 2  
204881_s_at                      UGCG  UDP-glucose ceramide glucosyltransferase     
203434_s_at                      MME  membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase)   
1568574_x_at                     SPP1    Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I)  
206908_s_at                      CLDN11   claudin 11 (oligodendrocyte transmembrane protein)  
1556153_s_at                     NFKBIZ   Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta  
210643_at                        TNFSF11  tumor necrosis factor (ligand) superfamily, member 11, RANKL  
203305_at                        F13A1   coagulation factor XIII, A1 polypeptide   
213791_at                        PENK    proenkephalin  
242324_x_at                      CCBE1    collagen and calcium binding EGF domains 1 
213338_at                        TMEM15
  
transmembrane protein 158  
213139_at                        SNAI2  snail homolog 2 (Drosophila)  
217979_at                        TSPAN13  Tetraspanin 13  
215420_at                        IHH  Indian hedgehog homolog (Drosophila) 
229645_at                        C18orf51  chromosome 18 open reading frame 51   
218717_s_at                      LEPREL1    leprecan-like 1  
238332_at                        ANKRD2
   
ankyrin repeat domain 29   
205828_at                        MMP3  matrix metallopeptidase 3 (stromelysin 1, progelatinase)     
209395_at                        CHI3L1   chitinase 3-like 1 (cartilage glycoprotein-39)  
204337_at                        RGS4  regulator of G-protein signalling 4   
201939_at                        PLK2    polo-like kinase 2 (Drosophila)   
228844_at                        SLC13A5   solute carrier family 13 (sodium-dependent citrate transporter), member 5 
218468_s_at                      GREM1   gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis)  
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201467_s_at                      NQO1    NAD(P)H dehydrogenase, quinone 1   
224482_s_at                      RAB11FIP
   
RAB11 family interacting protein 4 (class II)   
206239_s_at                      SPINK1  serine peptidase inhibitor, Kazal type 1   
213492_at                        COL2A1   collagen, type II, alpha 1    
1552737_s_at                     WWP2   WW domain containing E3 ubiquitin protein ligase 2   
204162_at                        KNTC2   kinetochore associated 2  
213622_at                        COL9A2   collagen, type IX, alpha 2  
202497_x_at                      SLC2A3  solute carrier family 2 (facilitated glucose transporter), member 3   
206309_at                        LECT1  leukocyte cell derived chemotaxin 1   
1556427_s_at                     LOC2210
  
similar to hypothetical protein   
201762_s_at                      PSME2      proteasome (prosome, macropain) activator subunit 2 (PA28 beta)  
201795_at                        LBR    lamin B receptor   
209946_at                        VEGFC     vascular endothelial growth factor C   
210432_s_at                      SCN3A   sodium channel, voltage-gated, type III, alpha    
206439_at                        DSPG3    dermatan sulfate proteoglycan 3    
203498_at                        DSCR1L1   Down syndrome critical region gene 1-like 1  
202912_at                        ADM  adrenomedullin    
221729_at                        COL5A2    collagen, type V, alpha 2  
1555345_at                       SLC38A4   solute carrier family 38, member 4   
210095_s_at                      IGFBP3   insulin-like growth factor binding protein 3   
201601_x_at                      IFITM1    interferon induced transmembrane protein 1 (9-27)  
205483_s_at                      ISG15    ISG15 ubiquitin-like modifier   
1554685_a_at                     KIAA119
    
KIAA1199      
221019_s_at                      COLEC12    collectin sub-family member 12 
240448_at                        KIAA080
   
KIAA0802  
200790_at                        ODC1   ornithine decarboxylase 1  
206932_at                        CH25H   cholesterol 25-hydroxylase  
205352_at                        SERPINI1    serpin peptidase inhibitor, clade I (neuroserpin), member 1  
228640_at                        ---  CDNA clone IMAGE:4800096   
205051_s_at                      KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog    
204731_at                        TGFBR3  transforming growth factor, beta receptor III (betaglycan, 300kDa) 
221823_at                        C5orf30  chromosome 5 open reading frame 30  
1554736_at                       ARHGAP
  
Rho GTPase activating protein 29   
217997_at                        PHLDA1    pleckstrin homology-like domain, family A, member 1  
226907_at                        PPP1R14
  
protein phosphatase 1, regulatory (inhibitor) subunit 14C  
223235_s_at                      SMOC2  SPARC related modular calcium binding 2 
202403_s_at                      COL1A2   collagen, type I, alpha 2    
204469_at                        PTPRZ1  protein tyrosine phosphatase, receptor-type, Z polypeptide 1 
223614_at                        C8orf57   chromosome 8 open reading frame 57  
212850_s_at                      LRP4   low density lipoprotein receptor-related protein 4  
202965_s_at                      CAPN6   calpain 6   
223316_at                        CCDC3   coiled-coil domain containing 3 
200974_at                        ACTA2   actin, alpha 2, smooth muscle, aorta  
213293_s_at                      TRIM22  tripartite motif-containing 22  
222020_s_at                      HNT  neurotrimin   
210609_s_at                      TP53I3  tumor protein p53 inducible protein 3    
201739_at                        SGK  serum/glucocorticoid regulated kinase   
MSCs as a model for the growth plate 
 
163 
 
217995_at                        SQRDL   sulfide quinone reductase-like (yeast)   
204682_at                        LTBP2   latent transforming growth factor beta binding protein 2  
201195_s_at                      SLC7A5   solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 
206764_x_at                      MPPE1    metallophosphoesterase 1   
213060_s_at                      CHI3L2  chitinase 3-like 2  
205334_at                        S100A1  S100 calcium binding protein A1   
209955_s_at                      FAP fibroblast activation protein, alpha    
204035_at                        SCG2  secretogranin II (chromogranin C)   
217875_s_at                      TMEPAI  transmembrane, prostate androgen induced RNA      
203879_at                        PIK3CD  phosphoinositide-3-kinase, catalytic, delta polypeptide   
202709_at                        FMOD   fibromodulin   
1554737_at                       FBN2   fibrillin 2 (congenital contractural arachnodactyly)   
205941_s_at                      COL10A
   
collagen, type X, alpha 1(Schmid metaphyseal chondrodysplasia) 
202727_s_at                   IFNGR1  interferon gamma receptor 1   
226930_at                        FNDC1  fibronectin type III domain containing 1    
207001_x_at                      TSC22D3  TSC22 domain family, member 3     
206960_at                        GPR23   G protein-coupled receptor 23    
203666_at                        CXCL12  chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 
204320_at                        COL11A
  
collagen, type XI, alpha 1  
203058_s_at                    PAPSS2  3'-phosphoadenosine 5'-phosphosulfate synthase 2   
205870_at                        BDKRB2    bradykinin receptor B2     
201464_x_at                      JUN  v-jun sarcoma virus 17 oncogene homolog (avian)   
226989_at                        RGMB   RGM domain family, member B      
229740_at                        LOC6430
 
PP12104      
203304_at                        BAMBI   BMP and activin membrane-bound inhibitor homolog (Xenopus laevis)  
218899_s_at                      BAALC  brain and acute leukemia, cytoplasmic  
224348_s_at                      H19   H19, imprinted maternally expressed untranslated mRNA   
209560_s_at                      DLK1  delta-like 1 homolog (Drosophila)  
222162_s_at                      ADAMTS
  
ADAM metallopeptidase with thrombospondin type 1 motif, 1  
206115_at                        EGR3   early growth response 3  
1562094_at                       MGC269
  
Hypothetical protein MGC26963   
216952_s_at                    LMNB2  lamin B2   
210948_s_at                      LEF1 lymphoid enhancer-binding factor 1   
1563466_at                       MYLK    Myosin, light polypeptide kinase   
212689_s_at                      JMJD1A  jumonji domain containing 1A  
205347_s_at                      TMSL8    thymosin-like 8  
204967_at                        SHROOM
  
shroom family member 2   
218009_s_at                    PRC1   protein regulator of cytokinesis 1  
212067_s_at                      C1R 
  
complement component 1, r subcomponent      
1560259_at                       RORA  RAR-related orphan receptor A      
206432_at                        HAS2  hyaluronan synthase 2   
1561065_at                       ANKRD6  Ankyrin repeat domain 6     
1555800_at                       ZNF533  zinc finger protein 533   
219747_at                        C4orf31  chromosome 4 open reading frame 31      
1558636_s_at                     ADAMTS
 
ADAM metallopeptidase with thrombospondin type 1 motif, 5 (aggrecanase-2)  
227497_at                        --- CDNA FLJ11723 fis, clone HEMBA1005314   
1555527_at                       COL9A1   collagen, type IX, alpha 1    
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202768_at                        FOSB    FBJ murine osteosarcoma viral oncogene homolog B   
204221_x_at                      GLIPR1     GLI pathogenesis-related 1 (glioma)   
204774_at                        EVI2A    ecotropic viral integration site 2A    
206157_at                        PTX3     pentraxin-related gene, rapidly induced by IL-1 beta   
202643_s_at                      TNFAIP3     tumor necrosis factor, alpha-induced protein 3     
234994_at                        KIAA191
   
KIAA1913   
227475_at                        FOXQ1  forkhead box Q1  
219334_s_at                      OBFC2A   oligonucleotide/oligosaccharide-binding fold containing 2A 
218986_s_at                      FLJ20035   hypothetical protein FLJ20035  
228382_at                        FAM105
  
family with sequence similarity 105, member B   
205523_at                        HAPLN1   hyaluronan and proteoglycan link protein 1   
224967_at                        UGCG   UDP-glucose ceramide glucosyltransferase   
213817_at                        ---     CDNA FLJ13601 fis, clone PLACE1010069      
212900_at                        SEC24A  SEC24 related gene family, member A (S. cerevisiae) 
1552619_a_at                     ANLN  anillin, actin binding protein      
224609_at                        SLC44A2  solute carrier family 44, member 2   
203755_at                        BUB1B  BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) 
1555724_s_at                     TAGLN  transgelin  
202450_s_at                      CTSK   cathepsin K (pycnodysostosis)     
213861_s_at                      FAM119
  
family with sequence similarity 119, member B     
213248_at                        LOC2213
  
hypothetical protein LOC221362    
203570_at                        LOXL1   lysyl oxidase-like 1       
230407_at                        --- Transcribed locus, strongly similar to strawberry notch homolog 1; MOP-3  
209567_at                        RRS1   RRS1 ribosome biogenesis regulator homolog (S. cerevisiae) 
210512_s_at                      VEGF    vascular endothelial growth factor  
205289_at                        BMP2   bone morphogenetic protein 2  
203065_s_at                      CAV1   caveolin 1, caveolae protein, 22kDa  
203758_at                        CTSO   cathepsin O   
205476_at                        CCL20   chemokine (C-C motif) ligand 20   
207826_s_at                      ID3   inhibitor of DNA binding 3, dominant negative helix-loop-helix protein   
205479_s_at                      PLAU    plasminogen activator, urokinase     
201136_at                        PLP2    proteolipid protein 2 (colonic epithelium-enriched)   
203764_at                        DLG7    discs, large homolog 7 (Drosophila)    
209160_at                        AKR1C3   aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II) 
207977_s_at                      DPT  dermatopontin   
205125_at                        PLCD1   phospholipase C, delta 1    
207980_s_at                      CITED2  Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2   
204475_at                        MMP1  matrix metallopeptidase 1 (interstitial collagenase)   
1556209_at                       CLEC2B  C-type lectin domain family 2, member B  
205830_at                        CLGN    calmegin   
219295_s_at                      PCOLCE2  procollagen C-endopeptidase enhancer 2 
205907_s_at                      OMD  osteomodulin    
206869_at                        CHAD   chondroadherin    
223836_at                        KSP37  Ksp37 protein    
204948_s_at                      FST   follistatin      
240955_at                        PANX3   pannexin 3               
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Supplementary Table 2. List of top hits of upregulated genes at each time point with their fold change 
in expression compared to undifferentiated hfMSCs 
 
TOP upregulated genes of pellets isolated at 1 week of differentiation compared to 
undifferentiated hfMSCs 
Symbol Gene title   Fold change 
COL2A1 collagen, type II, alpha 1  48,69295 
COMP cartilage oligomeric matrix protein 29,52449 
SPP1 Secreted phosphoprotein 1 (osteopontin) 29,24743 
COL10A1 collagen, type X, alpha 1 26,33897 
S100P S100 calcium binding protein P 23,64239 
ANKRD38 ankyrin repeat domain 38 21,03949 
H19 H19, imprinted maternally expressed untranslated mRNA  20,74613 
COL9A3 collagen, type IX, alpha 3 17,44117 
OMD osteomodulin 14,81684 
CCL20 chemokine (C-C motif) ligand 20 14,58234 
PANX3 pannexin 3 14,0997 
SP7 Sp7 transcription factor 10,99764 
WIF1 WNT inhibitory factor 1 7,854743 
FNDC1 fibronectin type III domain containing 1 7,754044 
MMP3 matrix metallopeptidase 3  7,723496 
 
 
TOP upregulated genes of pellets isolated at 2 weeks of differentiation compared to 
undifferentiated hfMSCs 
Symbol Gene title Fold change 
COL2A1 collagen, type II, alpha 1  127,526 
COMP cartilage oligomeric matrix protein 63,39943 
COL9A3 collagen, type IX, alpha 3 56,65738 
COL10A1 collagen, type X, alpha 1 43,11545 
S100P S100 calcium binding protein P 39,35336 
SPP1 Secreted phosphoprotein 1 (osteopontin) 38,08394 
H19 H19, imprinted maternally expressed untranslated mRNA  37,46208 
PANX3 pannexin 3 35,24063 
OMD osteomodulin 26,66117 
ANGPTL7 angiopoietin-like 7 20,79869 
AGC1 aggrecan 1 (chondroitin sulfate proteoglycan 1) 17,50114 
FMOD fibromodulin 16,41947 
ANKRD38 ankyrin repeat domain 38 14,97306 
FNDC1 fibronectin type III domain containing 1 14,939 
SP7 Sp7 transcription factor 12,00436 
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TOP upregulated genes of pellets isolated at 3 weeks of differentiation compared to 
undifferentiated hfMSCs 
Symbol Gene title Fold change 
COL2A1 collagen, type II, alpha 1 124,5769 
PANX3 pannexin 3 56,73114 
COMP cartilage oligomeric matrix protein 55,02747 
COL9A3 collagen, type IX, alpha 3 52,95049 
S100P S100 calcium binding protein P 47,56261 
COL10A1 collagen, type X, alpha 1 42,84764 
H19 H19, imprinted maternally expressed untranslated mRNA  37,78425 
SPP1 Secreted phosphoprotein 1 (osteopontin) 29,09326 
OMD osteomodulin 28,90007 
ANGPTL7 angiopoietin-like 7 24,41976 
AGC1 aggrecan 1 (chondroitin sulfate proteoglycan 1) 21,56025 
FMOD fibromodulin 19,79998 
SMOC2 SPARC related modular calcium binding 2 18,17641 
SLC13A5 solute carrier family 13 (sodium-dependent citrate transporter), member 5 16,55767 
SP7 Sp7 transcription factor 14,70519 
 
 
TOP upregulated genes of pellets isolated at 4 weeks of differentiation compared to 
undifferentiated hfMSCs 
Symbol Gene title Fold change 
COL2A1 collagen, type II, alpha 1  86,82906 
COL10A1 collagen. type X, alpha 1 43,4907 
COL9A3 collagen, type IX, alpha 3 31,28265 
SPP1 Secreted phosphoprotein 1 (osteopontin) 30,3413 
S100P S100 calcium binding protein P 25,19413 
PANX3 pannexin 3 17,31646 
COMP cartilage oligomeric matrix protein 16,64807 
ANGPTL7 angiopoietin-like 7 14,37924 
H19 H19, imprinted maternally expressed untranslated mRNA  13,72816 
FMOD fibromodulin 10,87799 
OMD osteomodulin 10,24159 
AGC1 aggrecan 1 (chondroitin sulfate proteoglycan 1) 9,153789 
CAPN6 calpain 6 8,080906 
SMOC2 SPARC related modular calcium binding 2 7,830802 
SLC13A5 solute carrier family 13 (sodium-dependent citrate transporter), member 5 7,085708 
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TOP upregulated genes of pellets isolated at 5 weeks of differentiation compared to 
undifferentiated hfMSCs 
Symbol Gene title Fold change 
COL2A1 collagen, type II, alpha 1  118,4129 
COL10A1 collagen, type X, alpha 1 43,15333 
COL9A3 collagen, type IX, alpha 3 64,24298 
SPP1 Secreted phosphoprotein 1 (osteopontin) 36,69967 
S100P S100 calcium binding protein P 45,26042 
PANX3 pannexin 3 36,55029 
COMP cartilage oligomeric matrix protein 49,01692 
ANGPTL7 angiopoietin-like 7 24,0925 
H19 H19, imprinted maternally expressed untranslated mRNA  27,29474 
FMOD fibromodulin 22,08534 
OMD osteomodulin 22,77907 
AGC1 aggrecan 1 (chondroitin sulfate proteoglycan 1) 19,0998 
CAPN6 calpain 6 9,836288 
SMOC2 SPARC related modular calcium binding 2 16,58001 
SLC13A5 solute carrier family 13 (sodium-dependent citrate transporter), member 5 13,48765 
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General discussion 
 
The aim of this thesis was to investigate the long-term results of two novel treatment modalities 
in children with ISS (part A), to study the effect of the administration of aromatase inhibitors in 
the rat (part B), and to assess whether mesenchymal stem cells can differentiate into 
chondrocytes with a phenotype resembling the epiphyseal growth plate. In this chapter, the 
results of our findings are discussed in the perspective of current knowledge. Considerations 
with regard to clinical practice will be presented, the role of model systems in growth studies 
will be debated, and recommendations for future research will be given. 
 
A. What are the long-term results of two novel treatment modalities in 
children with ISS? 
 
Despite almost three decades of clinical trials with GH treatment in ISS, many questions have 
remained with respect to the optimal treatment regimen. The two clinical trials reported in this 
thesis have contributed to the discussion about optimizing GH treatment strategies in children 
with ISS. The first trial was designed to study the effect of high dose GH treatment restricted to 
the prepubertal period in young children with ISS. In the second trial, GH was combined with 
GnRHa treatment in adolescents with ISS and a relatively early-timed pubertal onset. In both of 
our studies, subjects were randomly allocated to receive treatment or to participate in a non-
treated control group. Non-treated controls did not only serve for comparison with GH-treated 
subjects, but also illustrated the natural history of ISS. We have reported both interim data (1-3) 
and adult height data (this thesis) of both trials. 
As mentioned in Chapter 2, at the time this study was designed, there were three important 
unresolved issues with respect to GH treatment of children with ISS. First, it was unknown what 
the effect would be of a high GH dosage on growth velocity, bone maturation, puberty and 
adult height. Second, the relative contribution of GH treatment before and during puberty was 
unclear. Third, there was a need to gain more insight into the factors affecting the growth 
response, as only a modest part of the inter-individual variation can be explained (4) 
Besides these questions on GH monotherapy, there was an additional question that was 
approached in Chapter 3: what would be the effect of combined treatment with GH and 
GnRHa on adult height? 
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Relationship between GH dose and growth response.  
 
Most clinical trials with GH in ISS have used a GH dosage of 40-50 µg/kg/day, or the equivalent 
dosage corrected for body surface (1.2-1.4 mg/m2/day). As reviewed in chapter 1, adult height 
gain on such a dosage is close to 7 cm (5-7). While there is little doubt that lower dosages are 
less efficacious, leading to an adult height gain of 3-4 cm (8;9), the effect of higher dosages is 
unclear.  
Results of two trials in which high dose GH treatment was applied have been reported. In the 
first trial (10) there were three study arms: 1) a conventional dose of 40 µg/kg/day; 2) a titration 
arm in which GH dose was titrated to achieve an IGF-I SDS at the mean level of the normal 
range; and 3) a titration arm in which GH dose was titrated to achieve an IGF-I SDS level 2 SD 
above the mean of the normal range. In the last group the growth response was best, but 
required on average a 2.5 times higher dosage than used in the second group. In the other 
study (11) two doses were compared: 33 and 67 µg/kg/day. These doses led to a change in 
height SDS of 1.0 and 1.4, respectively, in comparison to 0.2 SDS in untreated controls. Thus, in 
both studies a high GH dose had a positive effect on adult height gain.  
In contrast, we showed in Chapter 2 that high dose GH treatment restricted to the prepubertal 
period, and administered to young children, increased height gain during treatment, but also 
accelerated bone maturation and ultimately did not lead to an increased adult height. Cohen 
and co-workers did not observe bone age advancement after treatment with a high GH dose 
(median 98 µg/kg/d, range 20-346 µg/kg/d) titrated on circulating IGF-I levels of 2 SDS (10). 
However, the dose range in that study was large, and the children who needed high GH doses 
to reach the aimed IGF-I level may have been more resistant to GH. Also in the study of 
Albertsson-Wikland no advance of skeletal maturation was observed (11).  
We speculate that the difference between our results and those of Cohen et al. and Albertsson-
Wikland et al. can be explained by a difference in age at start of GH therapy. The mean age at 
start of GH treatment in our study was 8.7 years, considerably younger than the mean age of 
approximately 11 years in the other studies. The observation in retrospective studies of an 
inverse association of age at start of GH treatment and height gain (4) is not necessarily in 
contradiction with our hypothesis, as the average age in those retrospective studies is also 
around 11 years.  
The discrepancy between the negative effect of high dose GH treatment in our trial and positive 
effects on height gain in other studies may rely on an increased sensitivity of the epiphyseal 
growth plates of younger children in comparison with those of older children to high doses of 
GH and/or IGF-I. In favor of the hypothesis of age-dependent sensitivity to GH was our finding 
that a younger age was associated with a lower height gain. Cruickshank and co-workers have 
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described that GH administration to rats was found to have no effect on GHR expression and to 
decrease IGF1R expression in the epiphyseal growth plates of prepubertal rats, whereas 
expression of both receptors was found to be upregulated at the age of sexual maturation, a 
phase associated with fast growth (12). They hypothesized that the dissociation between GHR 
expression and exogenous GH at a young age may reflect an inherent mechanism to prevent 
excessive proliferation and prevent overgrowth of the bone (12).  
The combined results of our and other studies in young children imply that at such a young age 
GH dose may be positively associated with adult height gain in the range of 25-50 µg/kg/d, but 
that higher doses may decrease adult height gain due to accelerated epiphyseal maturation, 
while at the same time the effect on growth reaches a plateau after a certain dose.  
 
The relative contribution of GH treatment before and during puberty 
 
An alternative explanation for the attenuated adult height outcome after high dose GH in our 
study may be the discontinuation of treatment at the onset of puberty, which theoretically may 
have abolished therapy-induced height gain. Such a catch-down phenomenon has been 
described in children with persistent short stature born SGA when GH treatment was 
discontinued 1-3 years before the onset of puberty (13). Those children showed a marked 
reduction in height velocity and height SDS in the post-treatment follow-up period and a 
decrease in adult height prediction, suggesting that GH treatment should at least be continued 
until pubertal onset.  
At the time our study was initiated, there were several arguments in favor of the hypothesis 
that growth enhancing strategies should be designed to improve prepubertal growth. One of 
these arguments was that height at onset of puberty is positively correlated with adult height in 
GHD or short SGA children (14-16). Another argument was that prolonged GH treatment 
during puberty might not be needed, since height gain during the pubertal growth spurt is 
primarily determined by sex steroid signaling, possibly in combination with an increased 
secretion of GH and IGF-I. Since children with ISS by definition have a normal GH secretion, one 
could argue that GH levels should be sufficient at the time of increased sex steroids. A third 
argument was that Rekers-Mombarg et al. demonstrated in previous studies that pubertal 
height gain was not different between GH-treated and non-treated GHD children (17).  
In our study described in Chapter 2, GH treatment was discontinued at the onset of pubertal 
development. Already at that time, predicted adult height of the GH-treated group was found 
to be similar to that of the non-treated controls, arguing against the catch-down growth 
hypothesis as an explanation for the absence of enhanced adult height.  
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Another topic, that is related to the question whether GH should be continued or not during 
puberty, is whether GH influences the timing of pubertal onset and the tempo of pubertal 
development. On regular dosages most studies have not been able to document that GH 
advances pubertal onset and tempo, but in our study (chapter 2), using a higher dosage, there 
are at least reasons to suspect such an effect. We believe that this may be related to age as 
well. In the final analysis on 26 children using a novel technique for expressing pubertal stage in 
SDS (correcting for age and gender) (18), we found a trend (p=0.2) towards a younger age at 
Tanner stage 2 in the GH-treated groups compared to controls. While this technique enables 
appropriate correction for the (statistically significant) age difference between the groups at 
start of the trial, the inability to reach statistical significance may well be related to the limited 
number of subjects that could be studied at follow up.  
In the larger group of 35 subjects studied 5 years after inclusion, the age difference at start did 
not reach significance, some patients had not yet entered puberty at the moment of analysis, 
and another method (cumulative proportions of patients having entered puberty, and 
calculation of relative risk) was used. In that analysis the relative risk for early puberty, adjusted 
for age and sex, was 4.7 (1.4-15.8, p=0.012) (2).  
There are two other observations that can serve as indirect evidence for an effect on pubertal 
onset. First, the observation that none of the 12 males in the GH treatment group entered 
puberty late, compared to 2 out of 8 controls. Second, at follow-up the GH-treated subjects 
had a significantly shorter leg length than controls and a higher SH/H SDS, suggesting earlier 
exposure to sex steroids. Unfortunately, the study design during follow-up did not allow for the 
collection of sufficient data on the progression of puberty.  
The higher SH/H ratio may also explain the increase in BMI SDS observed in the GH-treated 
children, as shown previously in GH deficient children (19). Up to early adolescence, height SDS 
remained stable at -2.6, but adult height was 0.7 SD higher than height SDS at start, 
presumably due to a rather delayed and possibly protracted pubertal development. A similar 
pattern was seen for SH and LL SDS.  
In conclusion, high-dose GH treatment limited to the prepubertal period in young children with 
ISS has no effect on adult height, probably caused by concomitant advance of bone 
maturation, and may advance pubertal onset.  
 
Factors affecting the growth response 
 
The study described in Chapter 2 has not contributed to the identification of factors that can 
predict growth response to GH therapy. In our study only age was a (positive) predictor of 
treatment effect. In the first part of the study, it was shown that plasma IGF-I during treatment 
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was positively associated with growth response in the first year (2), but in the final analysis we 
have demonstrated that short-term growth is not necessarily predictive for long-term success.  
In the last decades several other studies have investigated the possible predictors of growth 
response, either on first year height velocity or adult height gain. These were recently reviewed 
(20). Data from the large KIGS cohort have shown that positive predictors for adult height after 
GH treatment include midparental height and the first year growth response (expressed as 
studentized residual), while age is a negative predictor (4). 
 
The effect of a combined treatment with GH and GnRHa on adult height 
 
In Chapter 3 we have shown that 3 years of treatment with GH and a GnRH agonist in short 
children with a relatively early puberty increases adult height, with a mean gain of 5 cm. This 
result confirms the results of previous less well controlled clinical trials. However, this positive 
effect apparently has a price. Postponing puberty in adolescents has some negative impact on 
psychosocial status (21), and in boys there are indications that it decreases bone mineral density 
of the lumbar spine.  
 
Conclusions 
 
We conclude that a regimen of high dose GH started at an early age in children with ISS, and 
restricted to the prepubertal phase, is not effective, and therefore not to be advised. The 
combination of GH and GnRHa in young teenagers with short stature and relatively early 
puberty can be considered in selected cases, but its effect is modest and bone mineral density 
may be at risk  in males. 
 
B. The effect of the administration of aromatase inhibitors in the rat 
 
The main reason to perform the studies described in Chapters 4 and 5 was that aromatase 
inhibitors (AIs) would be a logical class of drugs for growth enhancement in boys who are short 
at the onset of puberty. Clinical trials had already been planned, whereas at the same time 
there was uncertainty about the short- and long-term adverse effects of these drugs, as locally 
produced estrogens are important in many tissues. With our studies we hoped to gain more 
insight into the effect of aromatase inhibition on growth, as well as on potential adverse results 
of such treatment in several tissues. 
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An unexpected outcome of our studies was that the effect on growth was strongly dependent 
on gender. Female rats became larger after treatment, while male rats became shorter. The 
growth attenuation observed in male rats was not consistent with the growth phenotype of 
male aromatase-deficient or estrogen-resistant patients. However, the negative effects of 
exemestane treatment on growth and BMD in male rats are in line with similar findings in male 
6 weeks old rats treated with the nonsteroidal aromatase inhibitor vorozole (22) and in 4 weeks 
old male rats treated with the selective estrogen receptor modulator tamoxifen (22;23). Growth 
attenuation was also observed in male aromatase knockout (ArKO) mice and estrogen receptor 
alpha (ERα) and ERαβ knockout mice (24-26). We must therefore conclude that the male rat is 
not a suitable model to study the effect of AIs on growth.  
With respect to side effects, in both genders a negative effect on bone quality was observed, 
which was not unexpected based on the pivotal role of estrogens in bone metabolism (27;28). 
In female rats there was a negative effect on the ovaries, leading to abnormalities similar to 
those observed in girls and women with the polycystic ovary syndrome (PCO). Such a 
phenotype has also been reported in female aromatase-deficient patients. These adverse effects 
argue against the use of aromatase inhibitors in girls with ISS, at least until additional research 
has proven beyond doubt that the observed ovarian changes are reversible and do not 
negatively affect fertility later in life. The development of the male genital tract was not 
impaired by aromatase inhibitor treatment, and no adverse effects were seen on brain 
morphology in both genders. 
In the meantime, more data have become available about the long-term effect of AIs in 
adolescent boys with short stature. In children with GH deficiency, the addition of AIs 
(anastrozole) to GH treatment had a modest positive effect on predicted adult height (29). In 
children with ISS, AIs alone (letrozole) for 2 years increased adult height by 5.9 cm (30). Initial 
worries that letrozole would lead to abnormalities of the thoracic vertebrae (31), have recently 
been confirmed (32). MRI-analysis of the vertebral spine demonstrated that letrozole-treated 
boys with ISS developed vertebral deformities, whereas no such findings were reported in the 
non-treated control group (32).  
Although the clinical trial with letrozole in boys with ISS showed a modest positive result on 
predicted adult height (30), the Finnish investigators emphasized that aromatase inhibition 
should be considered an experimental form of treatment, and that more studies had to be 
performed before AIs could be applied in clinical practice on a routine basis (33). The recent 
identification of vertebral body deformities potentially induced by estrogen depletion further 
justifies a reluctant attitude towards this type of treatment. 
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C. Development of an in vitro model for growth plate physiology: do 
mesenchymal stem cells differentiating into chondrocytes show a phenotype 
resembling the epiphyseal growth plate? 
 
In Chapter 6 we have shown that human fetal MSCs can indeed differentiate into 
chondrocytes, and that the gene expression profile resembles more the profile of epiphyseal 
chondrocytes than that of articular chondrocytes. We have therefore concluded that this model 
is suitable to further study the role of the numerous genes that are associated with the 
transition from immature chondrocytes in the resting zone, towards actively replicating 
chondrocytes in the proliferative zone, and finally to hypertrophic chondrocytes.  
We believe that this model can serve for various purposes. First, the model can be used to study 
the effect of various growth factors and hormones on chondrocyte differentiation and may 
assist in increasing the understanding of the interplay between those various factors. This may 
result in the identification of new drug targets and the development of new drugs. Second, the 
model can be used to assess whether genes that seem to be associated with growth, for 
example the genes encountered in genome-wide association studies (GWAS) on height (34-36) 
are indeed expressed during chondrocyte differentiation. Similarly, SNP-array studies in children 
with short or tall stature have shown deletions and duplications in various chromosomal 
regions, disabling various genes associated with growth regulation. The search for candidate 
genes, as detected in these studies, can be facilitated by checking the role of the essential 
genes that orchestrate chondrocyte differentiation.  
 
D. Conclusion and suggestions for future studies 
 
The results of the two clinical trials included in this thesis have shown that a high GH dosage in 
young children with ISS restricted to the prepubertal phase is not efficacious, and we believe 
that even if GH had been continued during puberty, the result would not have been better. The 
treatment course of 3 years of GH plus GnRHa is more effective (5 cm height gain), but may 
have undesirable side effects. This indicates that for the treatment of ISS, in countries where GH 
is registered for this indication, a dosage of 40-50 µg/kg/day or 1.2-1.4 mg/m2/day may still be 
the best option. However, the pros and cons of GH treatment in ISS are still heavily debated 
among pediatric endocrinologists and legislators, since the modest gain in adult height is 
counterbalanced by a very long and intensive treatment (daily injections for 4-8 years), high 
costs, and little effect on psychosocial status. Future studies in this area could focus on better 
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tools to assess psychosocial consequences of short stature, and on developing psychological 
counselling programs for short children who seem to suffer from their shortness. 
The results of the animal studies on AIs show that for the analysis of drugs that intervene with 
sex steroid signaling, rodents are not an optimal model. The role of sex steroids in rodent 
growth appears very different from that in the human. Still, such studies can serve to collect 
information about possible side effects of steroids and their antagonists. As it is uncertain which 
other animal models are better suited, well-controlled clinical trials on AIs in children and 
adolescents are needed before their use in clinical practice can be propagated. 
The in vitro model of MSCs differentiating into epiphyseal chondrocytes can be used in future 
studies aimed at a better understanding of the physiology of the epiphysis, and to assess the 
influence of various growth factors and growth-modifying drugs. 
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Summary  
 
Postnatal growth in humans is programmed by a person’s individual genetic blueprint and fine-
tuned by hormonal, environmental, psychosocial and nutritional factors. For decades, scientists 
have been determined to identify regulatory mechanisms associated with growth and to unravel 
the pathophysiological processes underlying growth disorders. Increased insight into those 
mechanisms and processes is fundamental for the development of novel treatment strategies 
for enhancing growth in children with idiopathic short stature. This thesis consists of three 
parts, in which several aspects of growth modulation and regulation are investigated.  
 
Part A describes the long-term results of two randomized controlled clinical trials in which 
novel treatment modalities for children with ISS were analyzed. At the time these clinical trials 
were initiated, there were several unresolved issues with respect to the optimal growth 
hormone treatment strategy for children with ISS:  
 
(1) What is the effect of a high GH dosage on growth velocity, bone maturation, puberty 
and adult height? 
(2)  What is the relative contribution of GH treatment before and during puberty? 
(3)  Which factors can predict the individual growth response to GH treatment? 
(4)  Can height gain be optimized by co-treatment with a GnRH agonist? 
 
Chapter 2 describes that high dose GH treatment restricted to the prepubertal period, and 
administered to young children, increased height gain during treatment, but simultaneously 
accelerated bone maturation and ultimately did not lead to an increased adult height. 
Moreover, there were indications that high dose GH treatment may have led to an advanced 
pubertal onset. Our results are in contrast with data from other groups that have reported a 
positive effect of high dose GH treatment on adult height in older children. We speculate that 
the discrepancy between our and other trials may rely on an increased sensitivity of the 
epiphyseal growth plates of younger children in comparison with those of older children to high 
doses of GH (and/or IGF-I). The finding of a similar predicted adult height in treated and 
untreated groups at the time of discontinuation of treatment (at pubertal onset) makes it 
unlikely that prolonged GH treatment during pubertal development would have led to better 
adult height results. Age at onset of treatment was found to show a positive correlation with 
height outcome, which is in contrast with data from other trials that have identified a negative 
correlation between age at onset and adult height. Again, an explanation for this difference 
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may reside in the considerably younger age at onset of treatment in our trial. Apart from age at 
onset, our study did not identify other predictive factors for growth response to GH therapy. 
We concluded that a regimen of high dose GH started at an early age in children with ISS, and 
restricted to the prepubertal phase, was not effective and therefore not to be advised. 
Chapter 3 demonstrates that the addition of a GnRHa to GH treatment in children with ISS and 
a relatively early onset of puberty increased adult height, especially in girls. However, 
postponing pubertal development may have a negative impact on psychosocial development in 
young children, and there were also indications of a lower bone mineral density of the lumbar 
spine in treated boys. These aspects require additional investigation. In the meantime, 
combined GH and GnRHa treatment should not be routinely prescribed for growth stimulation 
in children with ISS, but it may be considered in strictly selected individual cases, especially in 
girls with an extremely low predicted adult height, an early onset of puberty, and considerable 
psychosocial problems associated with being short. 
 
Part B assesses the effect on growth and the potential side effects of estrogen depletion by 
treatment with an aromatase inhibitor (exemestane) on growth in an experimental animal 
model. Aromatase inhibition resulted in a sexual dimorphic response in young rats. In female 
rats, exemestane treatment resulted in augmented length and weight gain, longer femurs and 
an increased growth plate width, as illustrated in Chapter 4. However, adverse effects on 
genital development were found, including uterus atrophy and polycystic ovaries. The observed 
effects on growth and genital development are consistent with the phenotype of female 
aromatase-deficient patients. As long as it is uncertain whether the genital abnormalities are 
reversible or whether long term effects on fertility and reproduction are to be expected, 
aromatase inhibitors should not be considered in the treatment of girls with ISS.  
In male rats, a decreased weight gain was found, without effects on axial and appendicular 
growth and genital development (Chapter 5). In contrast, the growth phenotype of male 
estrogen-deficient or estrogen-resistant patients is characterized by the absence of a pubertal 
growth spurt and ongoing growth into adulthood resulting in a tall stature. Also, clinical trials 
with aromatase inhibitors in boys with ISS or short stature due to constitutional delay of growth 
and puberty have demonstrated a positive effect of estrogen depletion on adult height. The 
difference between these data and our results may rely on species differences. It suggests that 
the rat, at least the male rat, is not a suitable animal model for studying the effect of aromatase 
inhibition on growth. 
In both male and female rats, we found evidence of osteopenic changes of the bone due to 
aromatase inhibitor treatment, which may precede the development of osteoporosis. In 
aromatase-deficient patients, osteoporosis has also been described. Recently, MRI-analysis of 
Chapter 8 
 
188 
 
the spine in boys treated with an aromatase inhibitor revealed the occurrence of vertebral body 
deformities. These collective data urge for a reluctant attitude towards the application of 
aromatase inhibitors in growth-enhancing treatment strategies in children with ISS. Additional 
research is necessary to identify the pathological mechanisms underlying the observed changes 
in bone quality. 
 
In part C the role of mesenchymal stem cells differentiating towards the chondrogenic lineage 
as a potential new in vitro model for growth plate physiology is evaluated. Development of 
alternative model systems is required, as the available animal models for growth studies are all 
hampered in the sense that they do not fully represent the human growth pattern, and species 
differences sometimes hamper the interpretation of results from animal experiments. In 
Chapter 6 it is shown that human fetal MSCs can indeed differentiate into chondrocytes, and 
that the gene expression profile bears more resemblance to the profile of epiphyseal than to 
that of articular chondrocytes. This model is suitable to further study the role of the numerous 
genes that are associated with growth plate maturation and fusion. This may aid in the 
identification of new angles for the development of novel treatment strategies as alternatives to 
regular GH therapy for enhancing growth in children with ISS. 
 
In Chapter 7 the major findings of this thesis are summarized and critically reviewed in the 
perspective of current literature. It is discussed that high dose GH or combined GH and GnRHa 
treatment are no routine alternatives to standard GH treatment schedules. Results from rat 
studies also do not support the use of aromatase inhibitors in growth enhancement strategies. 
Future studies may need to ameliorate the tools to assess psychosocial consequences of short 
stature and to develop better methods for counselling short children who suffer from being 
short.  
Finally, the limited role of animal models for the analysis of human growth regulation and 
modulation has urged the development of an alternative human model system. Using a model 
of human fetal mesenchymal stem cells differentiating towards the chondrogenic lineage may 
render new insights into human growth regulation and may aid the development of new 
methods for growth modulation. 
  
Summary 
 
189 
 
  
Chapter 8 
 
 
 
  
  
Chapter 9  
Samenvatting
Chapter 9 
 
192 
 
Samenvatting (summary in Dutch) 
 
De blauwdruk voor de lengtegroei van de mens wordt gedefinieerd de genetische achtergrond 
van het individu, maar wordt eveneens beïnvloed door hormonale, psychosociale, omgevings- 
en voedingsfactoren. Wetenschappers proberen al geruime tijd de regulatiemechanismen die 
betrokken zijn bij lengtegroei te identificeren. Er gaat ook veel aandacht uit naar het ontrafelen 
van de pathofysiologische processen die leiden tot groeistoornissen. Een beter begrip van deze 
mechanismen en processen is essentieel en kan een eerste stap zijn naar de ontwikkeling van 
nieuwe vormen van behandeling voor groeibevordering bij kinderen met onbegrepen kleine 
gestalte, ook wel ‘idiopathic short stature’ (ISS) genoemd. In de drie delen van dit proefschrift 
worden verschillende aspecten van groeimodulatie en groeiregulatie bestudeerd. 
 
In Deel A worden de resultaten gepresenteerd van twee gerandomiseerde klinische studies 
waarin het effect van nieuwe, potentieel groeibevorderende behandelvormen voor kinderen 
met ISS is bestudeerd. In de tijd dat deze studies werden opgestart, waren er enkele 
onopgeloste kwesties met betrekking tot de optimale behandelstrategie met groeihormoon 
(GH) voor deze categorie patiënten: 
 
(1) Wat is het effect van een hoge dosis groeihormoon op de groeisnelheid, botrijping en 
volwassen eindlengte? 
(2) Wat is de relatieve bijdrage van GH behandeling voor en tijdens de puberteit? 
(3) Welke factoren kunnen de individuele groeirespons op behandeling voorspellen? 
(4) Kan de lengtewinst worden verbeterd door toevoeging van een puberteitsremmer, 
een ‘gonadotropin releasing hormone agonist’ (GnRHa), aan de standaard GH 
behandeling? 
 
In Hoofdstuk 2 wordt beschreven dat behandeling van jonge kinderen met ISS met een hoge 
dosis GH in de periode voorafgaand aan de puberteit resulteerde in een toename van de 
voorspelde lengtewinst gedurende de behandelfase, maar ook in een versnelde botrijping, 
waardoor de uiteindelijke volwassen eindlengte niet groter was dan bij onbehandelde 
patiënten. Er waren tevens aanwijzingen dat een hoge dosis GH een vervroegde start van de 
puberteit veroorzaakte. Onze resultaten komen niet overeen met die van andere studies waarin 
oudere kinderen werden behandeld met een hoge dosis GH en een positief effect op de 
eindlengte werd gevonden. Wij speculeren dat deze verschillende bevindingen mogelijk 
berusten op een verhoogde gevoeligheid voor GH (en/of ‘insulin-like growth factor I’ (IGF-I)) van 
de groeischijven van jonge kinderen vergeleken met die van oudere kinderen. Er werd geen 
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verschil gevonden tussen de GH-behandelde en de onbehandelde controlegroep in de 
voorspelde volwassen eindlengte ten tijde van het afronden van de behandelfase (bij aanvang 
van de puberteit). Om deze reden denken wij dat het voortzetten van GH behandeling 
gedurende de puberteit niet zal leiden tot een grotere lengtewinst. In onze studie vonden we 
dat de lengtewinst bij jongere kinderen minder groot was dan bij oudere kinderen. Andere 
studies vermelden een tegenovergesteld effect, namelijk een afname van de lengtewinst met 
toename van de leeftijd bij aanvang van GH behandeling. De verklaring voor deze discrepantie 
tussen onze en andere studies ligt misschien wederom in het feit dat de gemiddelde leeftijd in 
onze studie aanmerkelijk lager was dan in de andere bekende studies. In onze studie konden er 
geen andere voorspellende factoren voor lengtewinst worden geïdentificeerd. We concluderen 
dat behandeling van jonge kinderen met ISS met een hoge dosis GH in de periode voorafgaand 
aan de puberteit niet effectief is en adviseren daarom om deze behandeling niet te 
implementeren in de kliniek. 
Hoofdstuk 3 vermeldt dat behandeling met een combinatie van GH en een GnRHa bij 
kinderen met ISS en een relatief vroege puberteit resulteerde in een toegenomen volwassen 
eindlengte, met name bij meisjes. Echter, het uitstellen van de puberteitsontwikkeling zou een 
negatieve invloed kunnen hebben op de psychosociale ontwikkeling van kinderen in deze 
leeftijdscategorie. Daarnaast werden er aanwijzingen gevonden voor een afgenomen 
botdichtheid van de lumbale wervelkolom bij behandelde jongens. Aanvullende studies zijn 
nodig om dergelijke ongewenste effecten nader te bestuderen. Gecombineerde behandeling 
met GH en GnRHa zou niet standaard toegepast moeten worden in de dagelijkse praktijk, maar 
kan wel overwogen worden in individuele gevallen, met name bij meisjes met een extreem 
kleine voorspelde eindlengte, een vroege puberteit en zwaarwegende psychosociale 
problematiek gerelateerd aan het klein zijn. 
 
Deel B bestudeert het effect op groei en de mogelijke bijwerkingen van oestrogeendepletie ten 
gevolge van behandeling met een aromataseremmer (exemestane) in de rat. Er werd een 
geslachtsafhankelijk effect van aromataseremming gevonden. In vrouwtjesratten leidde 
behandeling met exemestane tot een toename van lengte- en gewichtsgroei, langere femora en 
een toegenomen dikte van de groeischijf, zoals beschreven in Hoofdstuk 4. Er werden echter 
tevens atrofie van de uterus en polycysteuze ovaria gezien. Zolang onduidelijk is of deze 
effecten reversibel zijn en of deze leiden tot vruchtbaarheidsproblematiek, is het onverstandig 
om aromataseremmers toe te passen in de behandeling van meisjes met ISS. De gevonden 
effecten van exemestane-behandeling in vrouwtjesratten zijn vergelijkbaar met het fenotype 
van vrouwelijke aromatase-deficiënte patiënten. 
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In mannetjesratten werd geen toename gezien van de lengtegroei, maar wel een verminderde 
gewichtsgroei (Hoofdstuk 5). Er waren geen nadelige effecten op de genitale ontwikkeling. Dit 
groeipatroon is duidelijk anders dan dat van mannelijke oestrogeenresistente of -deficiënte 
patiënten, dat wordt gekenmerkt door het ontbreken van de groeispurt in de puberteit, een 
ook op de volwassen leeftijd continu doorgaande groei en daaruit volgende grote lengte. 
Eveneens zijn onze resultaten in tegenspraak met het groeibevorderende effect van 
aromataseremming bij jongens met onbegrepen kleine gestalte of jongens met constitutionele 
vertraging van de groei en ontwikkeling. Speciesverschillen liggen mogelijk ten grondslag aan 
deze contrasterende resultaten. Dit suggereert dat de rat, en in het bijzonder de mannelijke rat, 
niet een optimaal model is voor het bestuderen van het effect van aromataseremming op de 
lengtegroei. 
Bij zowel mannetjes- als vrouwtjesratten werd als gevolg van de behandeling met exemestane 
een afname van de botkwaliteit gevonden, passend bij osteopenie, een voorloperstadium van 
osteoporose. Bij aromatasedeficiënte patiënten is osteoporose eveneens beschreven. Onlangs 
zijn de resultaten verschenen van een MRI-studie waarin werd gekeken naar de wervelkolom 
van jongens met een kleine gestalte die waren behandeld met aromataseremming. Deze studie 
toonde aan dat aromataseremming resulteerde in afwijkingen van de wervellichamen. Meer 
onderzoek is geïndiceerd om het precieze pathologische mechanisme hierachter te 
identificeren. Op basis van momenteel beschikbare gegevens adviseren wij dat men 
terughoudend dient te zijn met  aromataseremming voor de behandeling van kinderen met een 
kleine gestalte. 
 
In deel C wordt de rol van een nieuw in vitro model voor het bestuderen van de fysiologie van 
de groeischijf beschouwd. De ontwikkeling van alternatieve modellen voor het bestuderen van 
groeigerelateerde processen is essentieel, aangezien de huidige beschikbare (dier)modellen 
geen perfecte weergave van het humane groeipatroon geven en speciesverschillen de 
interpretatie van proefdierstudies kunnen bemoeilijken. In Hoofdstuk 6 wordt beschreven hoe 
mesenchymale stamcellen (hMSCs) werden gestimuleerd tot differentiatie in de chondrogene 
richting. De aldus verkregen kraakbeencellen bleken een genexpressiepatroon te vertonen dat 
meer gelijkenis vertoonde met dat van groeischijfkraakbeen dan dat van gewrichtskraakbeen. 
Dit model is geschikt voor het bestuderen van talloze genen die betrokken zijn bij de rijping en 
sluiting van de groeischijf en dergelijk onderzoek kan leiden tot het vinden van nieuwe 
invalshoeken voor de ontwikkeling van groeibevorderende behandelingen als alternatief voor 
GH behandeling bij kinderen met ISS. 
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Tenslotte zijn in Hoofdstuk 7 de belangrijkste bevindingen van dit proefschrift samengevat en 
besproken in de context van de bestaande literatuur. Behandeling met een hoge dosis GH of 
GH gecombineerd met een GnRHa zijn geen alternatieven voor standaard GH behandeling. 
Dierexperimentele studies in de rat pleiten ook tegen een rol voor aromataseremmers in 
behandelingen gericht op groeibevordering. Toekomstig onderzoek zou zich kunnen richten op 
het verbeteren van methoden voor het objectiveren van de psychosociale gevolgen van klein 
zijn en op een betere psychosociale begeleiding van kinderen die lijden onder hun kleine 
gestalte. 
Tot slot wordt besproken dat de beperkte waarde van diermodellen voor het bestuderen van 
humane groeiregulatie en -modulatie heeft benadrukt dat alternatieve humane modellen 
ontwikkeld moeten worden. Studies met het model van humane foetale mesenchymale 
stamcellen die zich differentiëren tot chondrocyten kunnen nieuwe inzichten opleveren op het 
gebied van humane groeiregulatie, hetgeen de ontwikkeling van groeibevorderende 
behandelvormen zou kunnen bevorderen.  
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AH   Adult height 
AI   Aromatase inhibitor 
ALS   Acid-labile subunit 
ANOVA   Analysis of variance 
AR(KO)   Androgen receptor (knockout mouse) 
ArKO   Aromatase knockout mouse 
BA   Bone age 
BM(A)D   Bone mineral (apparent) density 
BMI   Body mass index  
BMP   Bone morphogenetic protein 
CA   Chronological age 
CAH   Congenital adrenal hyperplasia 
CPP   Central precocious puberty 
DHT   Dihydrotestosterone 
DSD   Disorder of sex development 
DXA   Dual energy x-ray absorptiometry 
E   Exemestane 
ECM   Extracellular matrix 
ER(α/β/αβ KO)  Estrogen receptor (alpha/beta/alpha+beta knockout mouse) 
FH   Final height 
FSS   Familial short stature 
GF   Growth factor 
(h)GH   (human) Growth hormone 
GHR   Growth hormone receptor 
GHRH   Growth hormone releasing hormone 
GHD   Growth hormone deficiency 
GnRHa   Gonadotropin releasing hormone agonist 
GWAS   Genome-wide association studies 
H   Height 
H&E   Haematoxylin and Eosin 
IGF-I   Insulin-like growth factor I 
IGF1R   Insulin-like growth factor receptor 
IGFBP3   IGF binding protein 3 
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ISS   Idiopathic short stature 
KEGG   Kyoto encyclopedia of genes and genomes 
LL   Leg length 
MAS   McCune-Albright syndrome 
micro-CT  X-ray microtomography 
(hf)MSC(s)  (human fetal) Mesenchymal stem cell(s) 
NFSS   Non-familial short stature 
NHANES   National health and nutrition examination survey 
ORCHX   Orchidectomy 
OVX   Ovariectomy 
PAH   Predicted adult height 
PBI   Pediatric bone index 
PCA   Principal component analysis 
PCO   Polycystic ovaries syndrome 
qPCR   Real-time quantitative polymerase chain reaction 
P/H   Proliferative zone/hypertrophic zone ratio 
PICP   Procollagen type IC propeptide 
PIIINP   Procollagen type III N propeptide 
PI3K   Phosphoinositide-3-kinase 
PLC   Placebo 
PTHrP   Parathyroid hormone related protein 
RCT   Randomized controlled clinical trial 
SD(S)   Standard deviation (score) 
SERM   Selective estrogen receptor modulator 
SGA   Short for gestational age 
SH   Sitting height 
SNP   Single nucleotide polymorphism 
TBW   Total body weight 
TGF   Transforming growth factor 
(c)TH   (conditional) Target height 
Wnt   Wingless-type MMTV integration site family 
  
 
 
